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1 | General introduction
Huntington’s disease (HD) is a progressive autosomal dominant inherited neuro-
degenerative disorder, with an estimated prevalence of 5 – 10 per 100,000 in the 
Caucasian population.1,2 In the Netherlands, there are approximately 1,700 individuals 
with genetically confirmed HD and 6,000 to 9,000 individuals that potentially have the 
disease but have not been tested. 
In 1993, it was discovered that HD is caused by a cytosine-adenine-guanine (CAG) 
trinucleotide repeat expansion located on the short arm of chromosome 4p16.3 in 
the Huntingtin gene, which encodes the huntingtin protein.3 Expanded repeat lengths 
above 36 units cause a mutation in the Huntingtin gene, which inevitably leads to 
clinical signs of HD, whereas in the normal population the repeat length ranges from 
6 to 35 units.2 When the disease progresses, the mutant huntingtin aggregates within 
different compartments of nerve cells (e.g., in the nucleus, cytoplasm and axons), 
resulting in cell toxicity and neuronal dysfunction.2,4 
There is currently no effective treatment available to delay or prevent disease 
progression. As a result, physicians are focused on improving daily functioning by 
reducing symptom severity to maintain a good quality of life for the patient and their 
caregivers.5
CLINICAL FEATURES 
HD is characterized by progressive motor dysfunction, cognitive decline and behavioral 
changes,1,2 and is often accompanied by weight loss and sleep disturbances.6,7 Still, the 
presence and severity of symptoms is very heterogeneous among individuals. Disease 
onset varies between the ages of 30 and 50 years with a mean disease duration of 17 
to 20 years, although the disease can also occur in early childhood (juvenile HD) or 
later in life (late onset HD).1,8 Longer CAG repeat lengths are associated with early 
clinical disease onset and more rapid progression.1,2 Clinical disease onset is typically 
defined by the manifestation of characteristic motor signs, which are divided into 
involuntary movements such as chorea, dystonia, and tics, and impaired voluntary 
movements resulting in hypokinesia and apraxia.1,9 Chorea is the most recognized sign 
and can be described as unwanted, irregular movements of the extremities and facial 
jerking.9 The occurrence and severity of choreiform movements can vary from subtle 
movements of the eyebrows or upper face to more generalized contractions of the 
trunk and limbs.9 Dystonia is often present in more advanced stages of the disease and 
is defined as intermittent muscle contractions leading to abnormal posture of the trunk 
and extremities.10 Ultimately, motor symptoms will interfere with speech, swallowing, 
and gait stability.1 
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In general, HD gene carriers are considered to be clinically manifest based on the 
presence of motor signs that are related to HD, whereas premanifest HD gene 
carriers are defined as individuals with a confirmed expanded CAG repeat before the 
occurrence of substantial motor signs.11 Still, cognitive deterioration can already be 
present before the onset of motor symptoms, which progresses throughout the course 
of the disease and eventually results in dementia.11 Frequently reported early cognitive 
deficits include impairments in executive functioning (i.e., difficulties with planned 
behavior, attentional deficits and disinhibition), psychomotor speed, and emotion 
recognition.2,11,12 The majority of HD gene carriers additionally experience behavioral 
changes during their lifetime.13 Depression, irritability, aggression, obsessive-
compulsive behavior, and apathy are the most frequently reported neuropsychiatric 
symptoms in HD.13 
Patients become increasingly dependent in daily life, which interferes with social 
activities. Eventually, severe motor disturbances and behavioral changes are often the 
main reasons for nursing home placement.14
NEUROPATHOLOGY
 
Progressive neurodegeneration bilateral in the striatum, i.e., caudate nucleus, 
putamen, and nucleus accumbens, is the main neuropathological feature of HD.15 
Striatal degeneration is caused by an extensive loss of medium spiny projection 
neurons that form the main efferent output of the striatum towards cortical brain 
regions.4,15 The presence of neuronal loss and reactive astrogliosis is, therefore, often 
suggested as an explanation for the clinical signs in HD.15,16 Neuronal loss progresses 
along a dorsal-ventral and medial-lateral gradient, with the most early microscopic 
changes occurring in the body and tail of the caudate nucleus.4,15 In addition to striatal 
atrophy, post-mortem studies have shown severe widespread cortical atrophy.4,17–20 In 
advanced disease stages, brain weight is often reduced to 1,000 – 1,100 grams while 
the average normal brain weight is 1,300 to 1,500 grams.20
Still, it remains uncertain if cortical degeneration precedes or is secondary to striatal 
neuronal loss in HD and how this relates to the clinical features of HD. 
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BRAIN STRUCTURE AND FUNCTION 
Magnetic Resonance Imaging (MRI) is a non-invasive and objective approach to 
quantify in vivo alterations in brain structure and function. In general, structural imaging 
modalities such as T1-weighted images and diffusion tensor imaging (DTI), measure 
global and regional brain volume and the microstructure of white matter fiber tracts, 
while functional imaging modalities assess neural activity and cell (dys-)function by 
detecting changes in cerebral blood flow in rest or when performing tasks. 
For the diagnosis of HD, genetic testing is the gold standard. Therefore, MRI is not 
of diagnostic value in clinical practice. Occasionally, MRI is used to exclude other 
disorders in case of an atypical presentation or absent family history of HD.21 
In HD research, MRI is primarily used as a tool to evaluate the natural progression of 
the disease and to find biomarkers that can be used as an outcome measure in clinical 
trials.21,22 Structural imaging studies have mainly focused on changes in striatal volume 
and consistently observed atrophy of both caudate nucleus and putamen.22,23 Striatal 
atrophy is even found a decade before predicted disease onset in premanifest HD 
gene carriers,24 with a relatively linear rate of decline throughout the course of the 
disease.25 As a result, striatal volume is now frequently used as a marker for disease 
severity, to predict time to diagnosis, or as an outcome measure in clinical intervention 
trials. 
In addition to striatal atrophy, volumes of other subcortical and cortical brain regions 
are also vulnerable for degeneration early in the disease,11,26,27 but have been studied 
less extensively. In clinical manifest disease stages, early cortical atrophy is thought to 
originate in the superior and posterior cerebral cortex, primarily in the parietal and 
occipital lobes, and spreads throughout the entire cortex in more advanced stages.11,26 
Atrophy of the pallidum and nucleus accumbens is found in premanifest stages of the 
disease,27 but there is some controversy regarding cortical involvement in this stage. 
Several studies report cortical volume loss in premanifest HD gene carriers which is 
primarily localized in the posterior frontal, parietal and occipital brain regions,11,28 
whereas other studies report no changes, or even an increase of cortical grey matter 
volume in premanifest HD compared to controls.29,30 
There is additional evidence that besides brain atrophy, the clinical manifestation of 
HD also results from neuronal dysfunction, tissue repair, and circuitry reorganization 
that can be measured using task-based or resting-state functional MRI.31 Here, 
changes in the blood-oxygen-level-dependent (BOLD) signal are used to discriminate 
between brain regions with altered activations. In HD, functional imaging studies 
13
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showed reduced brain activity (e.g., cellular dysfunction) in heterogeneous cortical 
and subcortical areas after cognitive task performance (such as working memory and 
attentional tasks) and at rest.31–33 Changes in functional brain networks can even be 
found independent of brain atrophy, implying that cellular dysfunction precedes cell 
death in HD.31 However, the pattern of cortical dysfunction, the influence of structural 
and functional cortical degeneration on the clinical signs of HD, and associations with 
striatal atrophy are not yet identified.
AIMS OF THIS THESIS
The primary aim of this thesis is to examine alterations in the cerebral cortex in HD 
gene carriers. Different image modalities and approaches will be used to extent the 
knowledge on both structural and functional cortical brain changes in early disease 
stages and their relation to the clinical features of HD. 
First, to examine the influence of brain changes on the motor phenotype in HD, we 
aimed to identify associations between grey matter loss and motor symptoms in early 
stage HD patients (chapter 2). To further explore the cortical coherence, we aimed 
to investigate alterations in grey matter brain regions using a novel technique to 
identify structural covariance networks in controls, premanifest and manifest HD gene 
carriers (chapter 3). In chapter 4, we wanted to investigate corticostriatal circuitry in 
HD by assessing the pattern of cortical degeneration and the relationship with striatal 
degeneration in early manifest disease stages. 
An overview of the current literature regarding brain structure and function of the visual 
cortex and visual cognitive impairment in HD is presented in chapter 5. Here, the 
aim was to summarize the findings on clinical visual cognitive deficits and underlying 
structural and functional changes in the posterior cerebral cortex in HD. 
Based on the findings reported in chapter 5, we conducted a cross-sectional study in 
a cohort of controls, premanifest HD gene carriers and manifest HD gene carriers. The 
aim was to investigate changes in structure and function of the posterior cerebral cortex 
in different disease stages and examine the relation with visual cognitive impairments. 
The findings of this study are described in chapters 6 and 7. Conclusions, final remarks 
on the findings of this thesis, and future perspectives are presented in chapter 8.
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ABSTRACT 
Background: Motor disturbances are clinical hallmarks of HD and involve chorea, 
dystonia, hypokinesia and visuomotor dysfunction. Investigating the association 
between specific motor signs and different regional volumes is important to understand 
the heterogeneity of HD.
Objectives: To investigate the motor phenotype of Huntington’s disease (HD) and 
associations with subcortical and cortical grey matter volume loss.
Methods: Structural T1-weighted MRI scans of 79 HD patients and 30 healthy controls 
were used to calculate volumes of seven subcortical structures including the nucleus 
accumbens, hippocampus, thalamus, caudate nucleus, putamen, pallidum and 
amygdala. Multiple linear regression analyses, corrected for age, gender, CAG, MRI 
scan protocol and normalized brain volume, were performed to assess the relationship 
between subcortical volumes and different motor subdomains (i.e., eye movements, 
chorea, dystonia, hypokinesia/rigidity and gait/balance). Voxel-based morphometry 
analysis was used to investigate the relationship between cortical volume changes and 
motor signs.
Results: Subcortical volume loss of the accumbens nucleus, caudate nucleus, putamen, 
and pallidum were associated with higher chorea scores. No other subcortical region 
was significantly associated with motor symptoms after correction for multiple 
comparisons. Voxel-based cortical grey matter volume reductions in occipital regions 
were related with an increase in eye movement scores. 
Conclusion: In HD, chorea is mainly associated with subcortical volume loss, while 
eye movements are more related to cortical volume loss. Both subcortical and cortical 
degeneration has an impact on motor impairment in HD. This implies that there is 
a widespread contribution of different brain regions resulting in the clinical motor 




Huntington’s disease (HD) is an autosomal-dominant, neurodegenerative disorder 
characterized by progressive motor disturbances, cognitive impairment and psychiatric 
symptoms. The clinical diagnosis of HD is based on the presence of motor signs, and 
can involve chorea, dystonia and/or hypokinesia.1 Oculomotor dysfunction, such as 
saccadic eye movements or gaze paralysis, can also be prominent in premanifest and 
early HD.2 The clinical HD phenotype is heterogeneous and different motor signs can 
also co-exist.3 Longitudinal analysis of motor signs showed that choreatic movements 
decrease over time, whereas hypokinetic-rigid signs slightly increase.4 This suggests 
that different motor symptoms can be more pronounced during different disease 
stages. The Unified HD Rating Scale Total Motor Score (UHDRS-TMS)5 is the gold 
standard to evaluate motor functioning in HD and establish the clinical diagnosis. Here, 
several motor domains including chorea, dystonia, gait, rigidity, and eye movements 
are examined, with higher total scores indicating more motor dysfunction.
Although striatal atrophy is the main neuropathological finding in HD, neuronal loss has 
been identified in many other extrastriatal brain regions.6 In these regions, it has been 
shown that grey matter volume reductions may also be associated with decreased 
global motor and functional scores.7–11 
Instead of focusing on global motor functioning, we aimed to investigate associations 
between separate motor domains and grey matter volume changes. To monitor HD 
signs in clinical practice and intervention trials, it is important to further understand the 
pathophysiology underlying the HD phenotype, because this can vary among patients. 
2. METHODS
2.1 Participants
A total of 79 patients with manifest HD and 30 healthy controls who visited the 
outpatient clinic at the department of Neurology of the Leiden University Medical 
Center (LUMC) between January 2008 and June 2016 were included. All manifest HD 
had a genetically confirmed CAG repeat length of ≥39 and an UHDRS-TMS of more 
than 5, confirming the diagnosis and clinical motor presence of HD. The local ethical 
committee approved this study and written informed consent was obtained from all 
participants. 
Distinctive items of the UHDRS motor scale were added for each participant to establish 
total scores per motor subdomain based on previous studies,4,12,13 representing five 
domains of motor functioning. For further details, see supplementary Table S1.   
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2.2 MRI image acquisition
All participants underwent MRI scanning on a 3 Tesla MRI scanner (Philips Achieva, Best, 
the Netherlands). For each participant, a structural three-dimensional T1-weighted 
image was acquired. Imaging parameters of the scan protocols were: TR = 7.7 ms, TE 
= 3.5 ms, flip angle = 8 °, FOV 24 cm, matrix size 224 x 224 cm and 164 sagittal slices to 
cover the entire brain with a slice thickness of 1.0 mm with no gap between slices. This 
resulted in a voxel size of 1,07 mm x 1,07 mm x 1,0 mm.
2.3 Image post-processing
Functional Magnetic Resonance Imaging of the Brain (FMRIB) Software Library (FSL, 
version 5.0.8, Oxford, United Kingdom) was used for data analysis of all structural 
T1-weighted images.14 Brain tissue volume, normalized for individual head size, 
was estimated with SIENAX.15 Using SIENAX, brain and skull images were extracted 
from the single whole-head input data. Then, the brain image is affine-registered to 
Montreal Neurological Institute (MNI) 152-space standard image,16 using the skull 
image to determine the registration scaling. This volumetric scaling factor was used to 
normalize for head size. Next, tissue-type segmentation with partial volume estimation 
was performed in order to calculate the total volume of normalized brain tissue, 
including separate estimates of volumes of grey matter, white matter, peripheral grey 
matter and ventricular CSF for each HD patient. Visual inspection of the registration 
and segmentation was performed for each brain-extracted image. 
2.4 Subcortical volumes
Absolute volumes of seven subcortical structures (i.e., nucleus accumbens, hippo-
campus, thalamus, caudate nucleus, putamen, pallidum and amygdala) were measured 
using FMRIB’s integrated registration and segmentation tool (FIRST).17 Here, all non-
brain tissue was removed from the T1-weighted images using a semi-automated brain 
extraction tool that is implemented in FSL.18 After registration of the images to the MNI 
152-standard space image, using linear registration with 12° of freedom, segmentation 
of the subcortical regions was carried out using mesh models that were constructed 
from manually segmented images provided by the Center for Morphometric Analysis 
(CMA), Massachusetts General Hospital, Boston. Then, the volume for each structure 
was separately estimated. Visual inspection was performed for each output image 




To investigate voxel-wise differences in grey matter volume between HD patients and 
controls, voxel-based morphometry (VBM) analysis was performed as implemented in 
FSL.19 
First, brain extracted T1-weighted images were segmented into different tissue types 
(i.e., grey matter, white matter or cerebrospinal fluid). Each segmented image has 
values that indicate the probability of a given tissue type. Then, the grey matter images 
were aligned to the 2 mm MNI-152 standard space image using non-linear registration. 
The resulting images were averaged to create a study-specific grey matter template. 
Subsequently, all native grey matter images were non-linearly registered to this study-
specific template and ‘modulated’ to correct for local enlargements and contractions 
due to the non-linear component of the spatial transformation.20 The modulated grey 
matter images were finally smoothed with an isotropic Gaussian kernel with a sigma of 
3 mm and analyzed using a general linear model in FSL for statistical inference. 
Brain structures that showed a significant difference between groups were identified 
using the Harvard-Oxford atlas integrated in FSL. 
2.6 Statistical analyses
Group differences between HD patients and controls were analyzed using parametric 
(independent sample t-test) and non-parametric tests (χ2-test) when applicable. To 
analyze group differences in the VBM output, a general linear model was constructed 
in FSL to compare controls with manifest HD using two-tailed t-statistics with age, 
gender, normalized brain volume and MRI scan protocol as covariates. Voxel-wise 
non-parametric permutation testing with 5000 permutations was performed using FSL 
randomise.21 The Threshold-Free Cluster Enhancement (TFCE) technique was used 
to correct for multiple comparisons with family wise error,22 with a p-value < 0.05 as 
significant threshold. The regions that showed significant differences between HD 
patients and controls were selected for further analyses in the HD group only.
The following analyses, investigating the relationship between separate motor 
subdomains, subcortical and cortical brain volumes, were performed in HD patients 
only. Multiple linear regression analyses were used to investigate the relationship 
between the separate motor subdomains and subcortical brain volumes. Analyses 
were accounted for age, gender, CAG repeat length, normalized brain volume, and 
MRI scan protocol. To correct for multiple comparisons the p-value for statistical 
significance was set at p < 0.008 (0.05/6) for analyses of subcortical volumes. To assess 
the relationship between clinical motor scores and cortical grey matter changes in HD 
patients, a general linear model was constructed using a design matrix in FSL with 
24
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each clinical motor domain separately, correcting for age, gender, CAG repeat length, 
normalized brain volume, and MRI scan protocol. FSL-Randomise was used for voxel-
wise non-permutation testing,21 using the regions that showed significant grey matter 
changes between controls and HD patients as a grey matter mask. Again, the TFCE 
technique was used to correct for multiple comparisons with family wise error,22 with a 
p-value < 0.05 as significant threshold. Statistical analyses were performed using IBM 
SPSS 23.0 for Windows.
3. RESULTS
Group characteristics and comparisons between HD patients and controls are report-
ed in Table 1. There were no significant differences in age and gender between both 
groups. HD patients had a significantly higher mean UHDRS-TMS compared to the 
control group.
3.1 Subcortical volumes
The mean volumes of the accumbens nucleus, caudate nucleus, putamen, pallidum, 
thalamus and hippocampus were significantly lower in manifest HD compared to 
controls (Table 1). Since the mean volume of the amygdala did not differ between HD 
patients and controls, this structure was not included in further analyses in HD patients 
only. 
After correction for multiple comparisons, there was a significant association between 
the UHDRS chorea score and UHDRS-TMS with the accumbens nucleus, caudate 
nucleus, putamen and pallidum in HD patients (Table 2). Thalamus and hippocampus 
volumes did not show any association with UHDRS motor subdomains. 
3.2 Cortical grey matter volume
To assess differences in cortical grey matter volume between HD patients and controls, 
regional volumetric VBM analysis was performed. Significant grey matter volume 
reduction in HD patients was found in the motor cortex, visual cortex, and in the frontal 
and temporal lobes (Figure 1 and supplementary Table S2). 
In HD patients, VBM analysis showed that after correction for covariates and multiple 
comparisons, higher eye movement scores and UHDRS-TMS were associated with 
cortical volume loss of occipital regions (Figure 2 and supplementary Table S3). 
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TABLE 1  Clinical and volumetric group differences between HD patients and controls
HD (n= 79) Controls (n=30) p-value
Clinical characteristics
Age 46.5 (9.7; 28 – 65) 48.9 (8.4; 35 – 65) 0.229
Gender m/f (%m) 30/49 (38.0%) 14/16 (46.7%) 0.409
CAG 44.1 (2.4; 40 – 51) NA NA
Disease duration 3.3 (3.0; 0 – 13) NA NA
Disease burden 382.1 (77.8; 234 – 551) NA NA
UHDRS-TMS 17.8 (10.8; 6 – 45) 2.6 (2.4; 0 – 7) <0.001
UHDRS chorea 5.2 (4.8; 0 – 18) NA NA
UHDRS hypokinetic-rigid 4.6 (3.2; 0 – 12) NA NA
UHDRS dystonia 0.2 (0.6; 0 – 3) NA NA
UHDRS eye movements 4.9 (3.2; 0 – 13) NA NA
UHDRS gait/balance 1.8 (1.4; 0 – 6) NA NA
Subcortical structures
Accumbens nucleus 732.0 (188.0) 930.5 (207.0) <0.001
Caudate nucleus 4942.2 (997.5) 6695.4 (839.0) <0.001
Amygdala 2208.0 (528.5) 2163.4 (379.4) 0.673
Putamen 7093.0 (1229.1) 9280.0 (1289.7) <0.001
Pallidum 2749.8 (555.8) 3338.5 (471.4) <0.001
Thalamus 13958.0 (1551.3) 14844.2 (1383.7) <0.005
Hippocampus 7195.4 (1016.0) 7682.1 (818.3) 0.021
Data are mean (SD; range) or number (%) for gender. Volumes of subcortical structures are
expressed in mm3. Mean disease duration is based on a smaller sample size (n=65) due to missing 
data. Independent sample t-test was used to compare groups, except for gender (χ2-test). 
Statistically signifi cant p-values are highlighted in bold (p<0.05). NA = Not applicable; CAG = 
Cytosine-Adenine-Guanine; HD = Huntington’s Disease; UHDRS = Unifi ed Huntington’s Disease 
Rating Scale; TMS = Total Motor Score.
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Putamen Pallidum Thalamus Hippocampus
UHDRS-TMS  -0.283  -0.316 -0.279 -0.312 -0.096 -0.265
UHDRS chorea -0.260 -0.346 -0.275 -0.273 -0.045 -0.172
UHDRS hypokinetic-
rigid
-0.180 -0.118 -0.175 -0.156 -0.052 -0.179
UHDRS dystonia -0.075 -0.033 -0.012 0.076 0.056 0.047
UHDRS eye 
movements
-0.188 -0.212 -0.171 -0.239 -0.169 -0.240
UHDRS gait/balance -0.097 -0.056 -0.112 -0.214 -0.057 -0.245
Reported data are standardized coeffi cients (standardized beta) from the multiple linear regression analysis. 
Analyses were accounted for age, gender, CAG, MRI scan protocol, and normalized brain volume. Statistically 
signifi cant values are printed in bold (corrected for multiple comparisons, p < 0.008). UHDRS = Unifi ed Huntington’s 
Disease Rating Scale; TMS = Total Motor Score
Brain regions that showed significant differences in grey matter volume in manifest HD compared to 
controls by means of voxel-based morphometry (VBM) are presented. Age, gender, MRI study protocol and 
normalized brain volume were included as covariates in the statistical model. Identified grey matter regions 
are overlaid on sagittal, transversal and coronal slices of Montreal Neurological Institute (MNI)-152 standard 
space T1-weighted images. Corresponding MNI x-, y-, z- coordinates are displayed. A threshold of p < 0.05 
(corrected with TFCE family wise error) is used. 
FIGURE 1  Voxel based morphometry analysis between manifest HD and controls
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4. DISCUSSION
Our study showed that specific clinical motor signs in manifest HD are related to 
volume loss in different grey matter brain regions. Higher UHDRS chorea scores were 
particularly related to volume loss of subcortical structures, especially the accumbens 
nucleus, caudate nucleus, putamen and pallidum, whereas cortical brain regions did 
not. These findings suggest that volume loss in the subcortical regions are more 
involved in the development of chorea than cortical atrophy. It is well known that the 
medium-sized spiny neurons located in the striatum, that comprises of the caudate 
nucleus and putamen, are the most affected cells in HD.23 As these neurons are 
involved in motor control, this might explain the association we found between striatal 
volume loss and the UHDRS chorea score. 
In premanifest HD, general motor functioning is related to volume loss of the putamen, 
caudate nucleus and pallidum.7,10,11 Increased choreatic movements have been 
associated with striatal atrophy in premanifest HD.24 However, to our knowledge, no 
studies have been performed that examined motor domains separately in relation with 
both subcortical and cortical changes. In addition to striatal volume loss, we observed 
a correlation between volume loss of the pallidum and higher UHDRS chorea scores. 
It is suggested that changes in the pallidum might be due to the loss of striato-pallidal 
fibers projecting from striatal medium spiny neurons, implying that volume loss of the 
pallidum is not due to cell loss within the pallidum.11 
Besides subcortical grey matter volume changes, we also investigated the association 
with cortical regions in patients with HD. Here, cortical grey matter volume loss was 
particularly associated with oculomotor dysfunction, but not with choreatic signs. Our 
findings are in contrast with results reported in a previous study where no correlations 
were found between cortical grey matter and motor functioning in premanifest HD.11 
A possible explanation might be that this previous study calculated lobular cortical 
volumes instead of investigating relationships with cortical volumes using a voxel-based 
technique. Another explanation could be that the HD patients included in our study 
were in a more advanced disease stage with more motor impairments, suggesting that 
involvement of cortical regions is more pronounced later in the disease. Still, UHDRS 
dystonia and hypokinetic-rigid scores did not show any significant correlations with 
subcortical volumes in our study.
The motor cortex, visual cortex, and cortical regions in the frontal and temporal lobes 
showed significant decrease in grey matter volume in manifest HD compared to controls 
by means of voxel-based morphometry. These identified regions are consistent with 
28
2 | Grey matter volume loss is associated with specific clinical motor signs in HD
FIGURE 2   Correlations between clinical motor scores and grey matter loss in manifest HD
VBM analyses showing significant correlations between increased motor scores and reduction in grey matter 
volume. A threshold of p < 0.05 is used. Brain regions in blue are uncorrected for multiple testing and red-
yellow brain regions are corrected with TFCE family wise error. Results are overlaid on sagittal, transversal 
and coronal slices of Montreal Neurological Institute (MNI)-152 standard space T1-weighted images. 
Corresponding MNI x-, y-, z- coordinates are displayed. UHDRS – TMS = Unified Huntington’s Disease Rating 
Scale – Total Motor Score.
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FIGURE 2   Correlations between clinical motor scores and grey matter loss in manifest HD findings in previous voxel-based studies.11,25–28 Additionally, we observed volume loss 
in visual cortical regions, which were associated with higher eye movement scores in 
HD gene carriers. It is known that fronto-striatal and occipital regions are important for 
oculomotor control and visual processing,29,30 providing a possible explanation for the 
observed correlations in these specific motor domains. These results are comparable 
to other studies observing associations between volume changes and quantitative 
motor functioning.27,28
It has also been reported that more prominent bradykinesia and dystonia are related 
to cortical thinning of the anterior frontal regions, including the premotor and 
supplementary motor cortex.9,28 In addition, finger tapping has been related to striatal 
and cortical atrophy.24,28 Although we investigated changes in subcortical and cortical 
regions separately, there is a known interplay between the basal ganglia and cerebral 
cortex. Especially changes of the basal ganglia-thalamo-frontal circuits are known to 
contribute to hyperkinetic movements such as chorea.11,23 
We did not find an association between some of the motor domains and grey matter 
regions, such as the cingulate gyrus. Since we aimed to focus on the clinical hallmark 
of HD, which is the presence of motor signs, this absent association might be caused 
by the fact that these brain regions are also involved in other domains than motor 
control. It has been reported that cortical brain atrophy, specifically in frontal, parietal 
and occipital lobes is related to a decline in cognitive functioning.9,27,30 Future studies 
investigating the relationship between cognitive and psychiatric symptoms of HD and 
volume reductions of the brain are necessary to further understand the pathogenesis 
of HD. 
The lack of a relationship between dystonia and subcortical volumes in our study might 
also be caused by the relatively low scores on this item in our cohort of early stage HD 
patients. A further limitation of this study is the relatively smaller sample size of the 
control group, which could potentially influence the results. A larger sample size of the 
control group is preferred in future studies.
In conclusion, patients with HD can present with a heterogeneous motor phenotype, 
consisting of chorea, dystonia, hypokinesia and/or balance disturbances. Our results 
demonstrate that chorea, which is the clinical hallmark of HD, is strongly associated 
with subcortical volume loss of the striatum and pallidum and not with cortical atrophy. 
Oculomotor dysfunction, however, seems to be more related to cortical volume 
changes, especially in occipital regions. Thus, there is a widespread contribution of 
different brain regions resulting in the overall clinical motor presentation seen in HD 
patients. We showed that not only subcortical volume loss is involved in the expression 
of motor disturbances, but also, although to a much lesser extent, cortical degeneration. 
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TABLE S1   Subscales of fi ve motor domains based on the Unifi ed Huntington’s Disease 
Rating Scale (UHDRS)
Motor sum scores Description Items from 
UHDRS
Range
Chorea Chorea 12 0 – 28
Dystonia Dystonia 11 0 – 20
Eye movements Ocular, saccades 1, 2, 3 0 – 24
Hypokinesia/rigidity Finger tapping, pronate/supinate, 
bradykinesia, rigidity
6, 7, 9, 10 0 – 28 
Gait/balance Gait, tandem walking, retropulsion 13, 14, 15 0 – 12
Motor domains are based on previous studies.5, 14, 15 Scores of each individual item of the UHDRS 
were summed to create the specifi c motor domains. 




TABLE S2  Grey matter differences in manifest HD compared to controls
MNI coordinates (mm) t-value p-value
x y z
Frontal lobe
Precentral gyrus 14 -14 76 6.65 <0.001
Supplementary motor cortex 10 -22 66 6.17 <0.001
Frontal orbital cortex 24 42 -8 3.21 0.043
Frontal pole 36 44 -6 3.10 0.044
Temporal lobe
Inferior temporal gyrus 48 -36 -14 6.37 <0.001
Middle temporal gyrus -46 -58 6 6.06 <0.001
Parietal lobe
Postcentral gyrus -20 -34 72 3.16 <0.001
Supramarginal gyrus 66 -22 42 3.37 0.045
Cingulate gyrus -8 -38 2 3.51 0.043
Occipital lobe
Occipital pole 26 -92 0 7.34 <0.001
Occipital fusiform gyrus 22 -80 -10 7.11 <0.001
Lateral occipital cortex -30 -94 4 6.91 <0.001
Anatomical regions that showed a signifi cant difference in grey matter volume between manifest 
HD and controls using voxel-based morphometry. All anatomical regions were identifi ed using the 
Harvard-Oxford Subcortical and Cortical atlases and the cluster tool implemented in FSL. T-statistics 
and corresponding p-values are presented (with a family wise corrected p-value of p<0.05)
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UHDRS-TMS Left occipital 
pole
403 -16 -100 -2 1.05 0.019
Right putamen 33 22 4 6 1.47 0.024





172 20 -92 -28 0.92 0.036
Occipital fusiform 
gyrus
141 32 -84 -16 0.95 0.036
Right putamen 41 22 2 8 1.65 0.016
Voxel-wise identifi ed anatomical regions that showed a negative correlation with clinical scores in 
HD patients, i.e. an increase in clinical score is correlated with a decrease in grey matter volume. 
All anatomical regions were identifi ed using the Harvard-Oxford Subcortical and Cortical atlases 
and the cluster tool implemented in FSL. T-statistics and corresponding p-values are presented
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ABSTRACT 
Background: Progressive subcortical changes are known to occur in Huntington’s 
disease (HD), a hereditary neurodegenerative disorder. Less is known about the 
occurrence and cohesion of whole brain grey matter changes in HD. 
Objectives: We aimed to detect network integrity changes in grey matter structural 
covariance networks and examined relationships with clinical assessments.
Methods: Structural magnetic resonance imaging data of premanifest HD (n = 30), HD 
patients (n = 30) and controls (n = 30) was used to identify ten structural covariance 
networks based on a novel technique using the co-variation of grey matter with 
independent component analysis in FSL. Group differences were studied controlling 
for age and gender. To explore whether our approach is effective in examining grey 
matter changes, regional voxel-based analysis was additionally performed.
Results: Premanifest HD and HD patients showed decreased network integrity in 
two networks compared to controls. One network included the caudate nucleus, 
precuneous and anterior cingulate cortex (in HD p < 0.001, in pre-HD p = 0.003). 
One other network contained the hippocampus, premotor, sensorimotor, and insular 
cortices (in HD p < 0.001, in pre-HD p = 0.023). Additionally, in HD patients only, 
decreased network integrity was observed in a network including the lingual gyrus, 
intracalcarine, cuneal, and lateral occipital cortices (p = 0.032). Changes in network 
integrity were significantly associated with scores of motor and neuropsychological 
assessments. In premanifest HD, voxel-based analyses showed pronounced volume 
loss in the basal ganglia, but less prominent in cortical regions.
Conclusion: Our results suggest that structural covariance might be a sensitive 




Huntington’s disease (HD) is an autosomal dominant inherited neurodegenerative 
disorder, caused by a cytosine-adenine-guanine (CAG) trinucleotide repeat expansion 
on chromosome four in the Huntingtin (HTT) gene.1 The clinically manifest phase of 
the disease is characterized by motor disturbances, cognitive decline and psychiatric 
symptoms (such as apathy, depression, irritability, and obsessive-compulsive behavior), 
with a mean age at onset of 30 to 50 years.2 
HD gene carriers that have been tested positive for the CAG expansion are diagnosed 
as manifest HD based on the presence of typical motor disturbances that mainly 
involve chorea, dystonia, bradykinesia and rigidity.2 
Recent neuroimaging studies revealed pronounced neuropathological changes in 
subcortical structures, which primarily involve atrophy of the caudate nucleus and 
putamen.3 This decline in striatal volume is already detectable in premanifest gene 
carriers, years before onset of motor disturbances.4–6 Local subcortical grey matter 
volume changes in HD are commonly examined using a voxel-based approach,7–13 but 
only few neuroimaging studies have investigated the occurrence of volume changes 
in the cerebral cortex. Still, neuropathological studies on HD report the presence 
of widespread cortical atrophy in addition to striatal atrophy.14 Reported voxel-wise 
subcortical volume changes in HD are, however, more prominent than cortical changes 
and the amount of cortical changes varies across voxel-based studies.15,16
As voxel-based methods, such as voxel-based morphometry (VBM) analysis, provide 
whole-brain results for individual regions by studying voxels separately, a multivariate 
network-based analysis might give more information about inter-regional dependencies 
between grey matter voxels. As neurodegeneration is probably a network-based 
process involving several brain regions and is not regional specific,17 examining 
such approach might be particularly interesting in HD. Recently, a novel technique 
is developed to study disease-specific inter-regional network changes in grey matter 
by using structural covariance networks independent of a-priori defined regions.18,19 
Structural covariance networks are based on the observation that grey matter regions 
in the brain co-vary in morphometric characteristics. Therefore, structural covariance 
networks might be a valuable tool in investigating the topological organization of the 
brain.18 
Previous studies in premanifest HD showed that cognitive impairment and psychiatric 
symptoms can present prior to motor disturbances.5,20 Additionally, subcortical changes 
are already detectable in this stage of the disease.21,22 Whether or not abnormal grey 
matter changes are present in premanifest HD, we hypothesize that we may be able 
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to reveal morphological characteristics that vary reciprocally between cortices or 
between the cortex and the subcortical grey matter regions using structural covariance 
networks. Such changes in a given patient population address for abnormality in the 
reciprocal relationship that is due to disturbance in normal development or aging. 
Using structural covariance networks in such an unrestricted exploratory way can give 
more insight into the pathophysiological processes underlying HD.
Network integrity scores can be defined as the strength of an individuals’ expression 
in each identified anatomical network and can therefore indirectly provide information 
about grey matter changes. Network integrity scores can change as covariance can 
diminish when the existing correlation drops due to the variation within a normal range. 
Therefore, network integrity can change regardless of atrophy and might provide a 
more sensitive biomarker for tracking disease progression than direct measurement of 
volume changes in HD.
Thus, the aim of this study is to investigate network integrity changes in grey matter 
structural covariance networks in HD and examine the relationship between the 
identified networks and clinical assessments. Furthermore, we compared our inter-
regional findings with regional volumetric voxel-based analysis on the same data, as 
this approach is most often used to examine volume loss in HD.16
2. METHODS
2.1 Participants
Thirty premanifest gene carriers (pre-HD), 30 HD patients and 30 healthy controls who 
participated in the TRACK-HD study at the Leiden University Medical Center study 
site, were included. Both pre-HD and HD patients required a positive genetic test with 
40 CAG repeats or more. Participants were considered pre-HD with a total motor score 
(TMS) of 5 or less on the motor assessment of the Unified Huntington’s Disease Rating 
Scale (UHDRS)23 and a disease burden score (age x [CAG repeat length – 35.5]) of > 
250.24 HD patients were included with an UHDRS-TMS score > 5 and a Total Functional 
Capacity (TFC) score greater than or equal to 7 points. Partners and gene-negative 
relatives were recruited as healthy controls. The control group was age and gender 
matched to the combined pre-HD and HD patients. The Medical Ethical Committee 
of the Leiden University Medical Center approved this study and written informed 
consent was obtained from all participants. For additional details about the study 




The UHDRS-TMS was used to measure the degree of motor disturbances, ranging 
from 0 to 124, with higher scores indicating more increased motor impairment. The 
TFC assesses global impairments in daily functioning, ranging from 0 to 13, with lower 
scores indicating more impaired function. Cognitive scores included the total scores 
of the Mini Mental State Examination (MMSE), Symbol Digit Modality Test (SDMT), 
Stroop word reading test and Trail-Making Test (TMT) A and B. The TMT score was 
derived by subtracting the completion time of TMT-A from TMT-B, thus minimizing 
the potential effect of motor speed and disturbances. For more details on all clinical 
assessments.4
2.3. MRI image acquisition 
From January until August 2008, all participants underwent structural magnetic 
resonance imaging (MRI) scanning. Quality control of all images was performed by 
IXICO, London, United Kingdom. Imaging was performed on a 3 Tesla MRI scanner 
(Philips Achieva, Best, the Netherlands) using a standard 8-channel whole-head coil. 
Three-dimensional T1-weighted images were acquired with the following parameters: 
TR = 7.7 ms, TE = 3.5 ms, flip angle = 8 °, FOV 24 cm, matrix size 224 x 224 cm and 
164 sagittal slices to cover the entire brain with a slice thickness of 1.0 mm with no gap 
between slices. This resulted in a voxel size of 1,07 mm x 1,07 mm x 1,0 mm. 
2.4. Data analysis
2.4.1. Image post-processing
All T1-weighted images were analyzed using the software provided by FMRIB’s 
software library (FSL, version 5.0.8, Oxford, United Kingdom).25
First, all non-brain tissue was removed from structural T1-weighted images using a 
semi-automated brain extraction tool implemented in FSL.26 Before being aligned to 
the 2 mm MNI (Montreal Neurological Institute)-152 standard space image27 using 
non-linear registration,28 voxel-based morphometry (VBM) analysis was used as 
implemented in FSL.29 First, tissue-type segmentation was performed. The segmented 
images have values that indicate the probability of a given tissue type (i.e. grey matter, 
white matter or cerebrospinal fluid). To correct for the partial volume effect (i.e. voxels 
containing more than one tissue type), the tissue type segmentation was carried out 
with partial volume estimation. The segmented images have values that indicate the 
probability of a given tissue type. The resulting grey matter segmented images were 
averaged to create a study-specific grey matter template and ‘modulated’ to correct 
for local enlargements and contractions due to the non-linear component of the 
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spatial transformation.30 During the modulation step, each voxel of every registered 
grey matter image was multiplied by the Jacobian of the warp field. This defines the 
direction (larger or smaller) and the amount of modulation. The modulated grey matter 
images were finally smoothed with an isotropic Gaussian kernel with a sigma of 3 mm. 
For the network-based data-driven analysis, Multivariate Exploratory Linear Optimized 
Decomposition into Independent Components (MELODIC)31,32 was used with the 
modulated grey matter images of all participants as a four-dimensional dataset. 
This statistical technique with independent component analysis (ICA) defines fully 
automated spatial component maps of maximal statistical independence, which is 
commonly used to study functional network integrity. When applied on structural grey 
matter images, this method defines spatial components based on the co-variation 
of grey matter patterns among all participants.18,19,33 Then, ICA provides for each 
participant a score (‘network integrity score’), which can be negative or positive, 
describing the strength of the individual expression in each network,31,33 with high scores 
indicating strong individual expression of the identified network. In general, there is no 
consensus on the optimal number of components, which may be depending on the 
data size and the research question.34 In our study, choosing less than ten components 
caused loss of spatial information due to merging of components, whereas selecting 
more components created additional components consisting of considerable noise. 
Therefore, we choose to set the number of independent components in our study to 
ten components. This number is consistent with previous studies of brain networks, in 
which eight to ten components are most often applied.18,34 A standard threshold level 
of 0.5 was used to describe significance of individual voxels within a spatial map. This 
indicates that the probability of a voxel being a signal component is greater than the 
probability of a voxel being noise. 
To investigate voxel-wise group differences in grey matter volume, VBM analysis was 
performed. Here, the modulated grey matter images were analyzed using a general 
linear model in FSL for statistical inference. 
Voxel-wise non-parametric permutation testing with 5000 permutations was performed 
using FSL randomise.35 Further, the Threshold-Free Cluster Enhancement (TFCE) 
technique was used,36 to correct for multiple comparisons with a p-value < 0.05 as 
significant threshold.
Brain structures were identified using the Harvard-Oxford atlas integrated in FSL.
For each participant, the mean voxels’ grey matter density value was calculated using 





Statistical analyses were performed using the Statistical Package for Social Sciences 
(SPSS for Mac, version 23, SPSS Inc.). Differences in demographic and clinical variables 
between groups were assessed using analysis of variance (ANOVA), χ2 and Kruskall-
Wallis tests for continuous, categorical and skewed data respectively. 
For group comparisons, separate linear regression analysis was performed in each 
network with correction for age and gender using the network integrity scores as 
dependent variable. The analysis was performed to compare controls with gene 
carriers (i.e. pre-HD and HD patients separately). All independent variables were 
entered in one block. Furthermore, correlations between clinical assessments and 
genetic markers (i.e. CAG repeat length and disease burden) with the anatomical 
networks were assessed using linear regression analysis in pre-HD and HD patients. 
For the VBM analysis, a design matrix for a general linear model was constructed in 
FSL to compare grey matter differences between controls and pre-HD and HD patients 
separately using two-tailed t-statistics, with age and gender as covariates to correct for 
confounding effects. To correct for multiple comparisons with family wise error, the 
Threshold-Free Cluster Enhancement (TFCE) technique was used,36 with a p-value < 
0.05 as significant threshold.
Linear regression analysis in HD gene carriers was performed to assess the relationship 
between clinical assessments and genetic markers with grey matter density values 
based on the mean value of the significant voxels of the VBM analysis.
In this observational study, the identified anatomical networks, grey matter density 
values, and cognitive tasks that were assessed share a mutual dependency. Considering 
it is not clear for which dependency to correct, we therefore present our correlational 
findings with clinical assessments uncorrected for multiple comparisons. As a result, 
to prevent type 2 errors, the interpretation of slight significant findings will be with 
caution. The significance threshold was set at a p value < 0.05.
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3. RESULTS
3.1. Demographic characteristics
Demographic and clinical data of all participants are shown in Table 1. There was a 
significant difference between groups for all clinical measures. Age, gender, handedness 
and education level did not differ between groups. There was no difference in CAG 
repeat length in both pre-HD and HD patients. 
TABLE 1  Clinical and volumetric group differences between HD patients and controls
HD (n= 79) Controls (n=30) p-value
Clinical characteristics
Age 46.5 (9.7; 28 – 65) 48.9 (8.4; 35 – 65) 0.229
Gender m/f (%m) 30/49 (38.0%) 14/16 (46.7%) 0.409
CAG 44.1 (2.4; 40 – 51) NA NA
Disease duration 3.3 (3.0; 0 – 13) NA NA
Disease burden 382.1 (77.8; 234 – 551) NA NA
UHDRS-TMS 17.8 (10.8; 6 – 45) 2.6 (2.4; 0 – 7) <0.001
UHDRS chorea 5.2 (4.8; 0 – 18) NA NA
UHDRS hypokinetic-rigid 4.6 (3.2; 0 – 12) NA NA
UHDRS dystonia 0.2 (0.6; 0 – 3) NA NA
UHDRS eye movements 4.9 (3.2; 0 – 13) NA NA
UHDRS gait/balance 1.8 (1.4; 0 – 6) NA NA
Subcortical structures
Accumbens nucleus 732.0 (188.0) 930.5 (207.0) <0.001
Caudate nucleus 4942.2 (997.5) 6695.4 (839.0) <0.001
Amygdala 2208.0 (528.5) 2163.4 (379.4) 0.673
Putamen 7093.0 (1229.1) 9280.0 (1289.7) <0.001
Pallidum 2749.8 (555.8) 3338.5 (471.4) <0.001
Thalamus 13958.0 (1551.3) 14844.2 (1383.7) <0.005
Hippocampus 7195.4 (1016.0) 7682.1 (818.3) 0.021
Data are mean (SD; range) or number (%) for gender. Volumes of subcortical structures are
expressed in mm3. Mean disease duration is based on a smaller sample size (n=65) due to missing 
data. Independent sample t-test was used to compare groups, except for gender (χ2-test). 
Statistically signifi cant p-values are highlighted in bold (p<0.05). NA = Not applicable; CAG = 
Cytosine-Adenine-Guanine; HD = Huntington’s Disease; UHDRS = Unifi ed Huntington’s Disease 
Rating Scale; TMS = Total Motor Score.
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Voxel-based morphometric analysis showed regional grey matter volume changes in premanifest gene 
carriers (A) and Huntington’s disease patients (B) compared to controls. The grey matter changes are overlaid 
on sagittal, transversal and coronal slices of MNI-152 standard T1-weigthed images. Corresponding MNI x-, 
y- and z- coordinates are displayed. The threshold for display is p < 0.05 (corrected using familywise error). 
The color scale bar represents T-scores.
FIGURE 1  Regional grey matter volume changes in HD
3.2. Voxel-based morphometry analysis
Regional volumetric voxel-based analysis was performed to assess voxel-wise 
differences between HD gene carriers and controls. In pre-HD, significant local 
grey matter volume reductions in the basal ganglia, mainly in the putamen, nucleus 
accumbens and caudate nucleus (Figure 1A and Table 2) was found compared to 
controls. Cortical volume changes in pre-HD were limited to the insular cortex (p = 
0.018) and a small region containing the planum temporale, parietal operculum cortex 
and posterior supramarginal gyrus (p = 0.045).  
In HD patients, grey matter volume reductions were more distributed across the brain 
(Figure 1B and Table 2). VBM analysis showed subcortical volume loss in the caudate 
nucleus, putamen and pallidum. Significant cortical grey matter changes were primarily 
located in the pre- and postcentral gyrus, the supplementary motor cortex and the 
lateral occipital cortex. 
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3.3. Anatomical networks and group comparisons
Ten grey matter anatomical networks were identified in all participants (Figure 2 and 
Table 3). Two structural covariance networks, the caudate nucleus network (network B) 
and the hippocampal network (network D), revealed a significant association in both 
pre-HD and HD patients compared to controls, meaning network integrity is reduced 
in both gene carrier groups compared to controls (Figure 2B, 2D and Table 4). The 
TABLE 2  Results of voxel-based morphometry analysis





1126 Left putamen -32 -16 -6 5.39 0.005
Left caudate nucleus -20 14 8 4.25 0.013
Left accumbens -6 12 2 4.14 0.015
Insular cortex -28 6 10 4.49 0.018
1018 Right caudate nucleus 14 8 6 5.78 0.001
Right thalamus 14 -8 18 4.92 0.003
Right putamen, right pallidum 28 -16 8 3.99 0.025
10 Planum temporale 
-46 -36 16 4.47 0.045Parietal operculum cortex
Posterior supramarginal gyrus
HD patients
61398 Caudate nucleus 16 10 8 12.29 0.001
Putamen, pallidum 24 -4 8 5.17 0.001
Postcentral gyrus -18 -36 70 3.28 0.001
Precentral gyrus -14 -22 60 2.98 0.001
Supplementary motor cortex 10 -22 58 3.22 0.001
Lateral occipital cortex -46 -72 4 3.96 0.001
11 Frontal pole 22 44 18 4.24 0.041
Anatomical regions that showed signifi cant grey matter volume changes in Huntington’s disease 
compared to controls using voxel-based morphometry analysis. Regions were identifi ed using 
the cluster tool and the Harvard-Oxford Subcortical and Cortical Structural Atlases in FSL. 
The most signifi cant local maxima are presented with T-statistics and a Threshold-Free Cluster 
Enhancement (TFCE) family-wise error corrected p-value.
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FIGURE 2  Overview of structural covariance networks
The ten identified anatomical networks are based on the structural covariance of grey matter among all 
participants. The networks are overlaid on sagittal, transversal and coronal slices of MNI-152 standard T1-
weigthed images.
caudate nucleus network includes the nucleus accumbens, pallidum, putamen, and 
precuneous. The hippocampal network is further comprised of the parahippocampal 
gyrus, cerebellum, pallidum, and planum polare. One other network, the intracalcarine 
network (network E), showed only a significant change in network integrity in HD 
patients compared to controls, but not in pre-HD (Figure 2E and Table 4). 
This network includes the precuneous, cuneal and lateral occipital cortices and lingual 
gyrus. There were no significant group differences in network integrity in the 7 other 
identified networks (Figure 2A,C, F-J and Table 4). These networks include: anterior 
cingulate gyrus (network C), temporal gyrus (network F), lateral occipital cortex 
(network H), precuneous (network I), lingual gyrus (network J) and two cerebellar 
networks (networks A and G).
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3.4. Correlations of structural changes with clinical assessments
The caudate nucleus network, hippocampal network and intracalcarine network were 
selected to further assess the relationship with clinical scores, as these anatomical 
networks showed significant differences between controls and HD gene carriers. Six 
clinical assessments were analyzed in the HD gene carrier group and consisted of 
motor, functional and cognitive scores. CAG repeat length and disease burden score 
were used as a measurement of genetic burden in HD gene carriers. The caudate 
nucleus network showed a significant correlation with the TFC score and the UHDRS 
total motor score (Table 5). This means that a higher motor score is associated with a 
reduction in network integrity for this specific network. Significant correlations were 
also found with the caudate nucleus network and both CAG repeat length and disease 
burden score, meaning that a larger CAG repeat length and higher disease burden 
score are associated with a reduction in network integrity scores. Furthermore, all 
cognitive assessments showed a significant correlation with this network, i.e. the SDMT 
score, Stroop word reading test, TMT score and MMSE. The hippocampal network 
revealed no significant correlations with any of the clinical assessments or the measures 
of genetic burden. Two clinical assessments showed significant correlations with the 
intracalcarine network, the TFC score and the TMT score (Table 5). Furthermore, the 
disease burden score also showed a significant correlation with this network. The 
identified voxel-based anatomical regions of grey matter volume changes in HD were 
additionally used to assess relationships with clinical assessments in HD gene carriers. 
Overall, grey matter density values were significantly lower in manifest HD compared 
to controls and pre-HD (F(2,87) = 24.1, p < 0.001). For all clinical motor, functional 
and cognitive assessments, there was a significant correlation with grey matter density 
values in HD gene carriers (Table 5).
52
3 | Early grey matter changes in structural covariance networks in HD














β p-value β p-value β p-value β p-value
UHDRS-TMS -0.519 < 0.001 0.057 ns -0.160 ns -0.525 < 0.001
TFC 0.329 0.002 0.019 ns 0.272 0.037 0.437 < 0.001
SDMT 0.544 < 0.001 0.152 ns 0.151 ns -0.520 < 0.001
Stroop word 
reading 
0.410 0.001 0.171 ns 0.047 ns 0.330 0.003
TMT -0.420 0.001 -0.109 ns -0.258 0.049 -0.520 < 0.001
MMSE 0.341 0.008 0.036 ns -0.025 ns 0.348 0.002
CAG repeat 
length
-0.578 < 0.001 -0.012 ns -0.294 ns -0.564 < 0.001
Disease 
burden
-0.474 < 0.001 -0.034 ns -0.263 0.046 -0.452 < 0.001
Signifi cant correlations of motor, functional and cognitive assessments and genetic burden with 
structural covariance networks and voxel-based grey matter volume changes in HD gene carriers are
presented. ns = not signifi cant; β  = standardized Beta coeffi cient; UHDRS-TMS = Unifi ed Huntington’s 
Disease Rating Scale – Total Motor Score; TFC = Total Functional Capacity score; SDMT = Symbol Digit 
Modality Test; TMT = Trail Making Test; MMSE = Mini Mental State Examination; CAG = cytosine, 




In this study, we showed that identification of structural covariance networks revealed 
early grey matter changes in premanifest gene carriers and HD patients. In total, ten 
anatomical networks were identified in all participants. The regions of grey matter 
changes were located in two specific structural covariance networks, in which we found 
network integrity changes in both pre-HD and HD patients. One of these networks 
contained the basal ganglia, precuneous and anterior cingulate cortex, whereas the 
other network comprised of the hippocampus, parahippocampal gyrus, cingulate, 
insular, and sensorimotor cortices, superior parietal lobule, angular gyrus and frontal 
orbital cortex. One other network, the intracalcarine network, only showed a significant 
change in network integrity in HD patients, not in pre-HD, compared to controls. The 
other seven networks involving the cerebellum, temporal and frontal lobes showed 
no significant differences in network integrity between controls and pre-HD or HD 
patients.
The mean network integrity score describes the strength of group expression in 
each network with higher scores indicating strong group expression of the identified 
network. 
Our findings suggest that there is a progressive increasing change of network integrity 
in grey matter structures from the premanifest phase, when motor symptoms are not 
yet present, to the manifest stage of the disease.
Network integrity changes found in both pre-HD and HD patients were located in a 
network containing the precuneous and anterior cingulate cortex. These structures 
are involved in motor planning, visuospatial processing, and cognitive attention and 
control.37,38 As these motor and cognitive functions are known to be affected in HD,20,22 
this can explain the strong associations we found in HD gene carriers between this 
network and performances on motor and cognitive tasks. The identified hippocampal 
network comprised of cortical structures involved in working memory performance, 
emotion processing and motor control. Although we showed evidence for change in 
network integrity in this network in pre-HD and HD patients, there were no significant 
correlations with clinical assessments. One possible explanation might be that we 
assessed cognitive tasks that are not designed to measure the domains of working 
memory and emotion processing. Another possible explanation could be that changes 
in network integrity precede the clinical decline. 
In HD, network-based analysis has been applied in one other recent study that 
investigated structural covariance networks in brain regions that are functionally 
related.39 Here, in all pre-specified motor, working memory, cognitive flexibility, and 
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social-affective networks there were no differences between controls and pre-HD 
observed.39 In our study, however, we found evidence for early grey matter volume 
changes in two structural covariance networks in pre-HD compared to controls. This 
difference might be explained by the fact that we used patterns of co-variation in 
whole brain grey matter of the participants and were not restricted to pre-defined 
brain regions.
Further, we assessed correlations with our identified anatomical networks and genetic 
markers, such as CAG repeat length and disease burden. We found that a larger CAG 
repeat length and higher disease burden score in HD gene carriers were associated 
with a reduction in network integrity scores of the caudate nucleus network, suggesting 
that genetic markers might have an effect on the rate of disease progression. This is 
consistent with previous studies showing a larger CAG repeat length is associated 
more widespread atrophy.10,12,24
In general, grey matter structural covariance networks showed to spatially overlap with 
resting-state functional connectivity networks.33,40 It is suggested that the topological 
organization of anatomical networks reflect the pattern of functional organization of 
different networks, thus, regions that co-vary in grey matter volume may also be part of 
the same functional network.40,41 The identified anatomical networks in our study also 
show similarity with resting state functional connectivity networks found in early HD 
patients in previous studies.42–44
Visual comparison of our identified networks with results from previous functional 
neuroimaging studies in HD show spatial overlap between the caudate nucleus network 
(B) and the functional striatal network, the anterior cingulate cortex network (C) and 
the executive control network, the hippocampal network (D) and the frontoparietal 
network, the intracalcarine network (E) and the functional visuomotor network, the 
temporal gyrus network and the functional medial temporal network, the lateral 
occipital network (H) and the default mode network, the precuneous network (I) and 
the sensorimotor network, the lingual gyrus network (J) and the auditory network, and 
the structural cerebellar networks (A and G) and the functional cerebellar network. Yet, 
more studies are needed to gain more knowledge about the relationship between 
structural networks and functional connectivity in HD.
To investigate whether identifying structural covariance networks is an effective 
approach to examine grey matter changes in HD, regional voxel-based analysis was 
additionally performed on the same data. 
In pre-HD, previous voxel-based analysis studies revealed volume loss in the prefrontal 
cortex,11 insular cortex and parietal lobe.12 This is consistent with our regional analysis 
that showed limited cortical volume loss in pre-HD, located in the insular cortex, 
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planum temporale, parietal operculum cortex and posterior supramarginal gyrus. 
However, our network-based analysis revealed that changes were also located in 
other brain regions like the precuneous, cingulate and sensorimotor cortices, and the 
parahippocampal gyrus. These results are consistent with previous studies on cortical 
thinning in early clinical disease stages.45,46 For the voxel-based regions that showed 
volume loss in HD gene carriers, mean grey matter density values were calculated 
and correlated with scores of clinical assessments. We found significant correlations 
between grey matter density values and motor, functional and cognitive assessments, 
as well as CAG repeat length and disease burden. Comparable significant correlations 
with these clinical assessments were also found in the caudate nucleus network, 
suggesting that network-based analysis is also sensitive in detecting correlations 
with clinical measures. Using univariate VBM, however, these correlations are based 
on voxel-wise differences in grey matter density. Therefore, it is difficult to directly 
compare the sensitivity of the univariate VBM approach with a multivariate network 
approach, based on the correlation with clinical assessments. 
Nevertheless, based on the current results and previous reports, network-based 
analyses using structural covariance network with spatially independent regions 
might be a sensitive method in detecting early grey matter changes in HD as network 
integrity can change regardless of atrophy. Also, cognitive dysfunctions might not only 
be caused by localized brain damage, but of a impaired brain network as well.47
Still, more studies are needed to determine if structural covariance networks are 
reliable to be used as a standardized method for grey matter changes in HD.
4.1. Strengths and limitations
The strength of this current study lies in detecting whole brain networks by using the 
anatomical relationship between spatially distributed brain regions as covariance 
networks without using pre-defined regions of interest or analyzing voxels separately. 
However, this study has a cross-sectional design, so a longitudinal follow-up study 
is preferred to further assess the relationship with disease progression. Additionally, 
larger sample sizes might provide more information about associations with clinical 
assessments. Another limitation of this study is the number of components or networks 
used in our analysis, which was chosen arbitrary.34 When choosing the number of 
components it is important to take into account that the sensitivity to detect regional 
effects can be affected and thus might influence outcomes.18
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5. CONCLUSIONS
This study identified spatially independent grey matter regions that form different 
structural networks based on the co-variance of grey matter in healthy controls, 
pre-HD and HD patients. Our findings suggest that changes in grey matter volume 
are widespread, involve several brain regions, and are already detectable in the 
premanifest stage of the disease. Potentially, structural covariance networks might 
develop into an early biomarker for identifying grey matter changes in HD that could 
be used in future clinical trials. Additionally, it is important to understand large-scale 
anatomical networks in a neurodegenerative disorder like HD, as this might provide 
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ABSTRACT 
Background: Progressive striatal atrophy is the neuropathological hallmark of 
Huntington’s disease (HD), a hereditary neurodegenerative disorder. Cortical atrophy 
is additionally present in HD, but it is unknown if striatal degeneration is related with 
cortical atrophy or if these are independent neurodegenerative processes.
Objective: To investigate the extent of corticostriatal degeneration in early manifest 
disease stages and examine the relationship between cortical thinning and striatal 
volume loss.
Methods: Ninety-two participants (18 healthy controls, 31 HD stage 1, and 43 HD 
stage 2) underwent structural MRI scanning. Thickness and surface area of cortical 
brain regions and striatal volumes were calculated using FreeSurfer. Based on 
independent corticostriatal circuits (motor, oculomotor, prefrontal, limbic, and visual 
loops), associations between cortical thickness and striatal volumes (caudate nucleus, 
putamen, and accumbens nucleus) in HD gene carriers were assessed using multiple 
linear regression analyses adjusted for age and gender, and corrected for multiple 
comparisons (p < 0.003).
Results: Atrophy of the striatum, especially the caudate nucleus, was more extensive 
than thinning of the cerebral cortex in HD gene carriers. In HD stage 2, cortical thinning 
was mainly located in parietal and occipital cortices. Although both striatal volume loss 
and cortical thinning was observed, no significant associations were found between 
cortical thickness and striatal volumes. 
Conclusion: In early stage HD, cortical atrophy is mainly located in parietal and 
occipital brain regions. Since no relationship was observed in the degree of atrophy 
within corticostriatal circuits, our findings imply that cortical degeneration might be 




Progressive striatal degeneration is the neuropathological hallmark of Huntington’s 
disease (HD), an autosomal dominant inherited neurodegenerative disorder caused 
by an elongated cytosine-adenosine-guanine (CAG) repeat length on chromosome 
four.1,2 The gradual loss of medium spiny projection neurons in the striatum are 
thought to explain the clinical signs of HD, such as choreiform movements, oculomotor 
dysfunction, and even cognitive and psychiatric symptoms.3–5 Early microscopic 
changes in the striatum usually begins in the body and tail of the caudate nucleus, 
and further deterioration occurs in a dorsal to ventral direction.4 In addition to striatal 
atrophy, widespread neuronal cell loss in different regions of the cerebral cortex have 
been found in advanced HD patients, resulting in an overall brain weight loss of more 
than 40%.6–8 Regional cortical atrophy can also be detected in early disease stages, 
although to a lesser extent than striatal atrophy.9–14 
Currently, it is suggested that cortical atrophy in HD originates in posterior brain regions 
and progresses to the anterior cerebral cortex,15 but it is unknown if the degree of 
regional cortical degeneration is related to striatal volume loss. It is hypothesized that 
either the striatum is the primary site of degeneration in HD and other subcortical and 
cortical brain regions are subsequently affected, or that striatal atrophy is secondary 
to degeneration in the cerebral cortex.1 However, it is also possible that striatal and 
cortical degeneration occur relatively independent of each other.16
In general, different cortical regions have projections to different striatal regions (i.e., 
the putamen, caudate nucleus, or accumbens nucleus) that subsequently project 
to the pallidum, thalamus, and finally back to the cortex. Five major independent 
corticostriatal circuits have been identified: the motor, oculomotor, prefrontal, limbic, 
and visual loops (Figure 1).5,17–19 Dysfunction of the corticostriatal pathways may lead to 
neurodegeneration of both cortical and striatal neurons.6
Identifying the pathways of corticostriatal neurodegeneration in HD is important 
because this can provide more insight into the debate to which extent the striatum 
plays a causal or modulatory role in the onset of clinical signs. To date, striatal atrophy 
is often used as a marker to track disease progression or to measure the effect of a 
pharmacological treatment in clinical trials. When cortical degeneration indeed occurs 
independent from striatal atrophy, this could have consequences for future clinical 
trial designs and therapeutic interventions, especially since cognitive, affective and 
behavioral disturbances in HD patients have been linked to cortical atrophy.9,13
Therefore, with this study, we aimed to identify the degree of corticostriatal degeneration 
in early manifest HD disease stages and examine the relationship between cortical 
thinning and striatal volume loss.
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2. METHODS
2.1. Participants
A total of 92 individuals (18 healthy controls and 31 manifest HD gene carriers stage 
1 (HD1) and 43 manifest HD gene carriers stage 2 (HD2)) were included in this study. 
Participants were recruited from the outpatient clinic of our Neurology department. 
Spouses and gene-negative relatives without neurological or psychiatric disorders 
were included as healthy controls. All HD gene carriers had a genetically confirmed 
CAG repeat length of ≥ 36 and scored above 5 points on the Total Motor Score of 
FIGURE 1  Corticostriatal circuits
Schematic overview of the main corticostriatal circuits in the human brain, adapted from Alexander et al.17 
and Lawrence et al.18 Each circuit is a closed loop projecting from the cerebral cortex to specific regions of 
the striatum, pallidum, and thalamus, which project back to the cerebral cortex. The sensorimotor cortex 
mainly connects to the putamen, the orbitofrontal, parietal, and occipital cortices with the caudate nucleus, 
whereas the limbic structures and prefrontal cortex are involved with the nucleus accumbens. Note that the 
connections between striatal regions (i.e., the indirect and direct pathways), and to the pallidum and thalamus 
are not displayed in this figure. 
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the Unified Huntington’s Disease Rating Scale (UHDRS), a scale to evaluate motor 
functioning in HD, ranging from 0 to 124.20 Usually, a score above 5 points on the 
UHDRS-TMS refers to clinical presence of typical HD-related motor signs.10 Based 
on the UHDRS Total Functional Capacity (TFC) score, which assesses global daily 
functioning, manifest HD gene carriers were divided into diseases stages21 The TFC 
score ranges from 0 to 13, with lower scores indicating more impaired function. This 
resulted in 31 patients in the earliest disease stage (HD1) with TFC score between 11 
and 13, and 43 patients in the second disease stage (HD2), with TFC score between 
7 and 10. The disease burden score was calculated as indicator of disease pathology, 
based on the following formula: age x (CAG – 25.5).22
The local medical ethical committee approved this study and written informed consent 
was obtained from all participants. 
2.2. MRI acquisition 
All participants underwent structural Magnetic Resonance Imaging (MRI) scanning 
between January 2016 and December 2017 on a 3 Tesla MRI scanner (Philips Achieva, 
Best, the Netherlands). Anatomical T1-weighted images were acquired using a 
standard 32-channel whole head coil. The following image parameters were used: TE 
= 3.3, TR = 7.2 ms, flip angle = 9°, FOV = 256 x 240 x 176 mm and 176 slices with a slice 
thickness of 1 mm and no gap between slices, resulting in a voxel size of 1.00 x 1.00 x 
1.00 mm, and scan duration of approximately 9 minutes.
2.3. Image processing
FreeSurfer (version 5.3.0) was used to calculate the cortical thickness and surface area of 
the cortical brain regions.23 Automated parcellation and segmentation was performed 
by the FreeSurfer algorithm, which assigns a neuroanatomical label to each location on 
a cortical surface model, based on probabilistic information. Frontal, medial and lateral 
temporal, parietal, occipital and cingulate regions in each hemisphere were identified 
based on the Desikan-Killiany atlas, resulting in 34 cortical regions.24 Thickness and 
surface area measures were averaged across the two hemispheres. Then, average 
thickness values per region (comprising of the frontal, parietal, temporal, and occipital 
lobes and the cingulate cortex) were calculated based on a weighted sum of mean 
thickness which accounted for surface area that has been described previously.13,25 
In addition, volumetric measures of striatal structures, i.e., caudate nucleus, putamen, 
and nucleus accumbens were obtained automatically using FreeSurfer’s subcortical 
segmentation pipeline.26 
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2.4. Statistical analysis
Group differences in demographic variables were analyzed using analysis of variance 
(ANOVA) or χ2 for continuous and categorical data respectively. Differences between 
HD1 and HD2 for clinical outcome measures (CAG, disease burden score, disease 
duration and UHDRS-TMS) were analyzed using independent samples t-tests. 
Differences between HD1, HD2, and controls in striatal volumes and average cortical 
thickness for each lobe were analyzed using ANOVA, with Bonferroni correction. 
Based on the corticostriatal circuits presented in Figure 1, we used multiple linear 
regression analyses in all HD gene carriers (i.e., HD1 and HD2 combined) to assess 
associations between cortical thickness of specific brain regions within each circuit and 
the corresponding striatal volumes (i.e., caudate nucleus, putamen, and accumbens 
nucleus). Each specific cortical region’s thickness was entered as dependent variable 
with the corresponding striatal volume as independent variable, adjusted for age and 
gender. All independent variables were entered in one block. 
An alpha-level of p < 0.05 was used as significant threshold and, if applicable, an 
adjusted p-value was set to account for multiple comparisons. Statistical analyses were 




Demographic data are presented in Table 1. There were no significant group 
differences in age and gender. CAG repeat length and disease burden score were 
not different between the HD disease stages. The HD2 group had a significant longer 
disease duration and higher score on the UHDRS-TMS compared to HD1. 
3.2. Striatal volume and cortical thickness
Significant reduced volumes of all striatal structures were found for both HD1 and HD2 
compared to controls (Table 2 and Figure 2). 
The caudate nucleus showed the largest volume loss in HD gene carriers compared to 
controls with 31.1% and 31.4% volume loss in HD1 and HD2 respectively. There were 
no significant differences in striatal volumes between HD1 and HD2. After correction 
for multiple comparisons, each lobe showed reduced average cortical thickness in 
HD2 compared to controls, with largest volume reductions in the parietal and occipital 
brain regions, while no significant reductions in HD1 compared to controls were found. 
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TABLE 1  Demographic characteristics of study population
Controls HD1 HD2 p-value
N 18 31 43







Gender (M/F) 7/11 17/14 22/21 0.548





Disease duration (years) NA 3.5 ± 2.6 5.3 ± 2.9 0.005










Data are presented with mean ± SD (range), except for gender (male/female) in numbers. 
UHDRS: Unifi ed Huntington’s Disease Rating Scale – Total Motor score. NA: not applicable. 
Signifi cant group differences are displayed in bold. 
TABLE 2  Structural brain data 







Average subcortical volumes (mm3)
Caudate 3580 ± 426 2467 ± 584 2449 ± 662 < 0.001 < 0.001
Putamen 4863 ± 586 3392 ± 644 3333 ± 643 < 0.001 < 0.001
Accumbens 472 ± 112 378 ± 115 362 ± 102 0.014 0.002
Average cortical thickness per brain region (mm)
Frontal cortex 2.55 ± 0.11 2.49 ± 0.09 2.43 ± 0.12 0.227 < 0.001
Medial temporal cortex 2.86 ± 0.17 2.81 ± 0.14 2.71 ± 0.16 0.997 0.003
Lateral temporal cortex 2.75 ± 0.12 2.68 ± 0.12 2.60 ± 0.14 0.262 < 0.001
Parietal cortex 2.34 ± 0.11 2.22 ± 0.11 2.17 ± 0.14 0.006 < 0.001
Occipital cortex 2.03 ± 0.12 1.92 ± 0.13 1.88 ± 0.14 0.016 < 0.001
Cingulate cortex 2.56 ± 0.14 2.50 ± 0.09 2.43 ± 0.11 0.209 < 0.001
Mean ± SD of subcortical volumes (mm3) and cortical thickness per brain region (mm) are presented. 
The average cortical thickness for each brain region was calculated using a weighted sum of 
thickness values accounted for surface area using the following formula described previously by 
Johnson et al., 2015 13, and Segura et al., 2014 25: Average thickness of region A and B = ((Thickness 
region A * Surface area region A) + (Thickness region B * Surface area region B)) / (Surface area region 
A + Surface area region B). One-way ANOVA was used to analyze group differences, with post-hoc 
comparisons using Bonferonni correction. Signifi cant differences compared to controls after correction 
for multiple comparisons (p < 0.006) are displayed in bold. 
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3.3. Relationship between cortical and striatal atrophy
In the whole HD gene carriers group (HD1 and HD2 combined), the relationship 
between striatal volume and cortical thickness was examined adjusted for age and 
gender for each corticostriatal loop described in Figure 1. Multiple linear regression 
analyses after correction for multiple comparisons showed no significant associations 
between any cortical region and corresponding striatal volume within a corticostriatal 
loop (Table 3 and Figure 3).
FIGURE 2  Striatal volume and cortical thickness in HD gene carriers
Boxplots of striatal volumes and cortical thickness per region in HD gene carriers compared to controls 
(100%). Using analysis of variance (ANVOA), significant reductions in caudate nucleus and putamen volumes 
were observed for both HD1 and HD2 patients compared to controls. Furthermore, significant cortical 
thinning for all brain regions was present in HD2 patients compared to controls. 
* Significant different compared to controls, p < 0.006 (corrected for multiple comparisons, 0.05/8)
71
4
TABLE 3  Associations between regional cortical thickness and striatal volumes 


















































































Data are standardized Beta coeffi cients using linear regression corrected for age and gender. Unadjusted signifi cant p-values (p < 0.05) are 
displayed in bold. After correction for multiple comparisons (p < 0.003), no signifi cant associations were observed between regional cortical
thickness and striatal regions.
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FIGURE 3  Relationship within striatum and in corticostriatal circuits
A:  Scatter plots of relationships between striatal structures (i.e., caudate nucleus, putamen, and accumbens 
nucleus). The most pronounced association was present between the putamen and caudate nucleus. 
B:  Scatter plots of relationships between cortical thickness and striatal volume in HD gene carriers. For each 
corticostriatal circuit, an example is presented. However, after correction for multiple comparisons, there 




This study showed striatal atrophy and cortical thinning, primarily in parietal and 
occipital regions in the earliest manifest HD disease stage, but we found no association 
between cortical thinning and striatal volume loss. This suggests that striatal 
degeneration in early HD gene carriers might be independent of cortical degeneration 
and can therefore be seen as two separate neurodegenerative processes that occur 
simultaneously. 
Furthermore, it is surprising that the frontal lobe is relatively unaffected in early disease 
stages, since the striatum predominantly projects to frontal cortical regions, such 
as the primary motor cortex and dorsolateral prefrontal cortex.17,18 Still, the parietal 
and occipital cortices, brain regions that seem to be mainly affected in HD, are also 
connected to the striatum.19 More specifically, orbitofrontal, parietal, and occipital 
brain regions are connected to the caudate nucleus, whereas the sensorimotor cortex 
in the fronto-parietal cortices are mainly connected with the putamen.17–19 The limbic 
structures and the prefrontal cortex have projections to the nucleus accumbens, 
the ventral part of the striatum.17–19 Our findings showed a trend towards a possible 
association between the volume of the caudate nucleus and the thickness of cortical 
regions of the oculomotor loop and visual loop. However, these associations were not 
significant after correction for multiple comparisons. 
Early manifest HD gene carriers can be divided in disease stage 1 (HD1) and stage 2 (HD2) 
based on the patients’ capacity of daily functioning.21 In our study, extensive atrophy of 
the caudate nucleus, putamen, and nucleus accumbens was present in similar degrees 
in both disease stages. Cortical thinning, however, was found throughout the entire 
brain in HD2 patients. In HD1 patients, our data showed a trend towards thinning of 
parietal and occipital cortices compared to controls, however, this was not significant 
due to correction for multiple comparisons. These results suggest that the degree of 
striatal atrophy seems to stabilize after disease onset whereas the degree of cortical 
atrophy increases, beginning in the posterior brain regions with relative sparing of 
the frontal, parietal, and cingulate cortices. Our findings are consistent with previous 
studies in manifest HD that showed thinning of the superior and posterior cortical 
brain regions with minimal involvement of the anterior frontal and lateral temporal 
lobes.9,10 Other studies additionally showed that cortical involvement contributes to 
behavioral, cognitive and motor symptoms in HD patients.6,9,13,14 For instance, worse 
performance on attentional and executive tasks was correlated with thinning in the 
primary motor cortex, and parietal and occipital regions.9,13 In addition, cell loss in the 
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anterior cingulate cortex was found in HD patients with prominent mood symptoms,6 
whereas oculomotor abnormalities have been related with volume reductions in 
occipital regions.14 
Our findings support the hypothesis that cortical and striatal degeneration might be 
independent neurodegenerative processes in HD. This could explain the fact that 
affective, behavioral and cognitive symptoms of HD have been linked to cortical 
atrophy instead of striatal atrophy.6,9,13
Only few studies have previously assessed cortical thinning in early manifest HD gene 
carriers and most studies consisted of small sample sizes without subdividing manifest 
HD gene carriers in different disease stages.9,27–30 The strength of our study lies in 
the fact that we can confirm a distinct pattern of cortical thinning in a relatively large 
sample of early manifest HD gene carriers, considering HD is a rare neurodegenerative 
disorder.
A limitation of this study is that we used automated global volumetric segmentations of 
striatal structures using relatively large structural models. In the early disease stages of 
HD, striatal atrophy mainly involves the body and tail of the caudate nucleus.4 However, 
our structural models did not allow us to subdivide the caudate nucleus. Furthermore, 
although we assessed patterns of neurodegeneration in different disease stages to 
better understand the structural changes during disease progression, longitudinal 
studies are still necessary to validate our findings. 
Many longitudinal studies have previously focused on evaluating the rate of decline in 
striatal volume in different disease stages, even in HD gene carriers close to disease 
onset but without motor symptoms.10,31,32 Striatal atrophy has also been linked to 
clinical signs in HD, such as motor symptoms,11,14 and executive dysfunction,33,34 thus 
making striatal volume an interesting outcome measure in clinical intervention trials. 
Nevertheless, given the relationship of cortical atrophy with other specific HD related 
signs and our suggestion that cortical degeneration occurs independent from striatal 
atrophy, cortical thickness measurements might also be valuable for future clinical trial 
designs.
In conclusion, cortical degeneration in the earliest manifest HD disease stage primarily 
begins in parietal and occipital brain regions, while the frontal lobe remains less 
affected in this stage. This is interesting, since the striatum mainly projects to the frontal 
lobe. Still, thinning of parietal and occipital cortices is not related with striatal atrophy, 
suggesting that cortical and striatal degeneration are independent neurodegenerative 
processes in HD. This is important for future clinical trial designs that target cognitive, 
affective or behavioral symptoms in HD patients, as these symptoms have been linked 




  1.  Rüb U, Seidel K, Heinsen H, Vonsattel JP, den Dunnen WF, Korf HW. Huntington’s disease (HD): 
the neuropathology of a multisystem neurodegenerative disorder of the human brain. Brain 
Pathol. 2016;26:726-740.
  2.  The Huntington’s Disease Collaborative Research Group. A novel gene containing a 
trinucleotide repeat that is expanded and unstable on Huntington’s disease chromosomes. 
Cell. 1993;72(6):971-983.
  3.  Reiner A, Albin RL, Anderson KD, D’Amato CJ, Penney JB, Young AB. Differential loss of 
striatal projection neurons in Huntington disease. Proc Natl Acad Sci U S A. 1988;85(15):5733-
5737.
  4.  Vonsattel JP, Myers RH, Stevens TJ, Ferrante RJ, Bird ED, Richardson EP. Neuropathological 
classification of Huntington’s disease. J Neuropathol Exp Neurol. 1985;44(6):559-577.
  5.  O’Callaghan C, Bertoux M, Hornberger M. Beyond and below the cortex: the contribution 
of striatal dysfunction to cognition and behaviour in neurodegeneration. J Neurol Neurosurg 
Psychiatry. 2014;85(4):371-378.
  6.  Thu DCV, Oorschot DE, Tippett LJ, et al. Cell loss in the motor and cingulate cortex correlates 
with symptomatology in Huntington’s disease. Brain. 2010;133(4):1094-1110. 
  7.  Nana AL, Kim EH, Thu DCV, et al. Widespread heterogeneous neuronal loss across the 
cerebral cortex in Huntington’s disease. J Huntingtons Dis. 2014;3:45-64.
  8.  Waldvogel HJ, Kim EH, Thu DCV, Tippett LJ, Faull RLM. New perspectives on the 
neuropathology in Huntington’s disease in the human brain and its relation to symptom 
variation. J Huntingtons Dis. 2012;1:143-153.
  9.  Rosas HD, Salat DH, Lee SY, et al. Cerebral cortex and the clinical expression of Huntington’s 
disease: complexity and heterogeneity. Brain. 2008;131(4):1057-1068.
10.  Tabrizi SJ, Langbehn DR, Leavitt BR, et al. Biological and clinical manifestations of Huntington’s 
disease in the longitudinal TRACK-HD study: cross-sectional analysis of baseline data. Lancet 
Neurol. 2009;8(9):791-801.
11.  Scahill RI, Hobbs NZ, Say MJ, et al. Clinical impairment in premanifest and early Huntington’s 
disease is associated with regionally specific atrophy. Hum Brain Mapp. 2013;34(3):519-529.
12.  Harrington DL, Liu D, Smith MM, et al. Neuroanatomical correlates of cognitive functioning in 
prodromal Huntington disease. Brain Behav. 2014;4(1):29-40.
13.  Johnson EB, Rees EM, Labuschagne I, et al. The impact of occipital lobe cortical thickness 
on cognitive task performance: An investigation in Huntington’s Disease. Neuropsychologia. 
2015;79:138-146. 
76
4 | Patterns of corticostriatal degeneration in early HD patients
14.  Coppen EM, Jacobs M, van den Berg-huysmans AA, van der Grond J, Roos RAC. Grey matter 
volume loss is associated with specific clinical motor signs in Huntington’s disease. Park Relat 
Disord. 2018;46:56-61.
15.  Coppen EM, van der Grond J, Hart EP, Lakke EAJF, Roos RAC. The visual cortex and visual 
cognition in Huntington’s disease: An overview of current literature. Behav Brain Res. 
2018;351:63-74. 
16.  Younes L, Ratnanather JT, Brown T, et al. Regionally selective atrophy of subcortical structures 
in prodromal HD as revealed by statistical shape analysis. Hum Brain Mapp. 2014;35(3):792-
809. 
17.  Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits 
linking basal ganglia and cortex. Annu Rev Neurosci. 1986;9:357-381. 
18.  Lawrence AD, Sahakian BJ, Robbins TW. Cognitive functions and corticostriatal circuits: 
Insights from Huntington’s disease. Trends Cogn Sci. 1998;2(10):379-388. 
19.  Seger CA. The visual corticostriatal loop through the tail of the caudate: circuitry and function. 
Front Syst Neurosci. 2013;7:1-15. 
20.  Huntington Study Group. Unified Huntington’s disease rating scale: reliability and consistency. 
Mov Disord. 1996;11(2):136-142.
21.  Shoulson I, Fahn S. Huntington disease: Clinical care and evaluation. Neurology. 1979;(29):1-3.
22.  Penney J, Vonsattel JP, MacDonald ME, Gusella JF, Myers RH. CAG repeat number governs 
the development rate of pathology in Huntington’s disease. Ann Neurol. 1997;41(5):689-692.
23.  Fischl B, Dale AM. Measuring the thickness of the human cerebral cortex from magnetic 
resonance images. Proc Natl Acad Sci U S A. 2000;97(20):11050-11055.
24.  Desikan RS, Segonne F, Fischl B, et al. An automated labeling system for subdividing the 
human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage. 
2006;31:968-980.
25.  Segura B, Baggio HC, Marti MJ, et al. Cortical thinning associated with mild cognitive 
impairment in Parkinson’s disease. Mov Disord. 2014;29(12):1495-1503.
26.  Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: Automated labeling of 
neuroanatomical structures in the human brain. Neuron. 2002;33:341-355. 
27.  Rosas HD, Liu AK, Hersch S, et al. Regional and progressive thinning of the cortical ribbon in 
Huntington’s disease. Neurology. 2002;58(5):695-701. 
28.  Nopoulos PC, Aylward EH, Ross CA, et al. Cerebral cortex structure in prodromal Huntington 
disease. Neurobiol Dis. 2010;40(3):544-554.
29.  Rupp J, Dzemidzic M, Blekher T, et al. Comparison of vertical and horizontal saccade measures 




30.  Nanetti L, Contarino VE, Castaldo A, et al. Cortical thickness, stance control, and arithmetic 
skill: An exploratory study in premanifest Huntington disease. Park Relat Disord. 2018;51:17-
23. 
31.  Aylward EH, Liu D, Nopoulos PC, et al. Striatal volume contributes to the prediction of onset 
of Huntington disease in incident cases. Biol Psychiatry. 2012;71(9):822-828. 
32.  Paulsen JS, Long JD, Ross CA, et al. Prediction of manifest Huntington’s disease with clinical 
and imaging measures: A prospective observational study. Lancet Neurol. 2014;13(12):1193-
1201. 
33.  Peinemann A, Schuller S, Pohl C, Jahn T, Weindl A, Kassubek J. Executive dysfunction in 
early stages of Huntington’s disease is associated with striatal and insular atrophy: A 
neuropsychological and voxel-based morphometric study. J Neurol Sci. 2005;239:11-19.
34.  Wolf RC, Thomann PA, Thomann AK, et al. Brain structure in preclinical huntington’s disease: 
A multi-method approach. Neurodegener Dis. 2013;12(1):13-22.
5
The visual cortex and 
visual cognition in 
Huntington’s disease: 
an overview of 
current literature
Emma M. Coppen, Jeroen van der Grond, Ellen P. Hart, 
Egbert A.J.F. Lakke, Raymund A.C. Roos
Behavioural Brain Research. 2018 May;351:63-74
80
5 | The visual cortex and visual cognition in HD: an overview of current literature
ABSTRACT 
The processing of visual stimuli from retina to higher cortical areas has been 
extensively studied in the human brain. In Huntington’s disease (HD), an inherited 
neurodegenerative disorder, it is suggested that visual processing deficits are present in 
addition to more characteristic signs such as motor disturbances, cognitive dysfunction, 
and behavioral changes. Visual deficits are clinically important because they influence 
overall cognitive performance and have implications for daily functioning.
The aim of this review is to summarize current literature on clinical visual deficits, 
visual cognitive impairment, and underlying visual cortical changes in HD patients. A 
literature search was conducted using the electronic database of PubMed/Medline. 
This review shows that changes of the visual system in patients with HD were not the 
primary focus of currently published studies. Still, early atrophy and alterations of the 
posterior cerebral cortex was frequently observed, primarily in the associative visual 
cortical areas such as the lingual and fusiform gyri, and lateral occipital cortex. Changes 
were even present in the premanifest phase, before clinical onset of motor symptoms, 
suggesting a primary region for cortical degeneration in HD. Although impairments in 
visuospatial processing and visual perception were reported in early disease stages, 
heterogeneous cognitive batteries were used, making a direct comparison between 
studies difficult. The use of a standardized battery of visual cognitive tasks might 
therefore provide more detailed information regarding the extent of impairments 
in specific visual domains. Further research could provide more insight into clinical, 




Many regions of the human brain are involved in processing visual stimuli, from the 
retina to cortical brain areas. The organization and function of the visual cortex has 
been extensively studied in primates, both in macaques and healthy human adults.1,2 
Visual field mapping using functional Magnetic Resonance Imaging (fMRI) showed that 
approximately 20-30% of the human brain is directly or indirectly involved in visual 
processing.3,4 Incoming visual stimuli are transmitted from the retina through the 
afferent visual pathway via the optic nerve and optic tract, to the lateral geniculate 
nucleus in the thalamus.5 Then, via the optic radiation, signals reach the primary visual 
cortex in the occipital lobe and eventually the associative (secondary and tertiary) 
visual cortices for further processing.5 
FIGURE 1  Visual cortex in human brain
Schematic lateral and medial overview of cortical regions involved in the processing of visual stimuli in the 
human brain. Stimuli pass the retina via the optic tract to the primary visual cortex (V1) and secondary visual 
cortex (V2) for basic processing (i.e. shape and contrast). Although there are no clear demarcations among the 
regions of the posterior cortex, it is clear that higher-level visual processing occurs in the regions surrounding 
the primary visual cortex, which are divided into visual areas V3, V4 and V5. The ventral pathway runs through 
the medial part of Brodmann area 19, located in the anterior medial occipito-temporal gyrus, towards 
Brodmann area 37 (or V4) which is located in the caudal two-thirds of the lateral occipito-temporal gyrus (e.g. 
fusiform gyrus). V4 projects to Brodmann area 20, located in the inferior temporal gyrus, to Brodmann area 
38, located in the anterior temporal pole, and to the limbic system. The dorsal pathway (V3 and V5) conveys 
visual information to the posterior parietal cortex (Brodmann area 7) and the premotor cortex (Brodmann 
area 6). In general, the ventral pathway in the temporal-occipital region is involved in object recognition and 
color processing, whereas the dorsal pathway processes depth and movement perception. Numbers in each 
cortical region depict corresponding Brodmann areas.
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The primary visual cortex (also known as V1, striate cortex or Brodmann area 17) is 
located around the edges of the calcarine fissures on the medial and dorsolateral 
surface of the occipital lobe.3,6 The visual association areas (also known as the extra-
striate cortices) are responsible for the interpretation of the visual input, such as 
color discrimination, motion perception, depth, and contrast. 3 The secondary visual 
cortex (V2 or Brodmann area 18) processes basic visual characteristics such as color 
perception and orientation.2,7 On the medial occipital lobe surface, V2 is located in the 
cuneus above V1 and in the medial occipito-temporal gyrus (e.g. lingual gyrus) below 
V1, whereas on the lateral surface, V2 is located in the occipital gyrus anterior to V1.2 
From V2 onwards, visual processing proceeds along two parallel pathways, the ventral 
(occipito-temporal) pathway, and the dorsal (occipito-parietal) pathway.8 The ventral 
stream is also known as the ‘what’ visual pathway, and is involved in the recognition 
of objects, faces and shapes and color processing.2,7 The dorsal stream is known as 
the ‘where’ visual pathway and it is suggested that this area is necessary for depth 
(three-dimensional vision) and movement perception in relation to objects in space in 
the frontal eye fields.1,2,9,10 A summary of the visual cortical areas and their function is 
presented in Table 1 and Figure 1.
TABLE 1  Visual cortex and higher visual function
Visual 
area















Ventral ‘what’ pathway: 
Object recognition
V3 19 Lateral part of cuneus
Dorsal ‘where’ pathway: 
Movement and spatial 





Any alteration in the visual pathway may result in clinical visual deficits and changes in 
cognitive performance. In Huntington’s disease (HD), a hereditary neurodegenerative 
disorder, cortical degeneration of visual brain regions is suggested to be present in 
early disease stages, in addition to striatal atrophy.11–13 HD is autosomal dominantly 
inherited and caused by a cytosine-adenine-guanine (CAG) repeat mutation of the 
Huntingtin (HTT) gene on chromosome 4.14 The estimated prevalence of the disease 
is 5-10 per 100.000 in the Caucasian population.15 The manifest phase of the disease 
is generally characterized by progressive motor disturbances, cognitive decline, and 
behavioral changes.15 However, clinical signs can vary considerably among patients 
during the course of the disease as well as time of disease onset. Typically, the mean 
age of disease onset is between 30 and 50 years (range from 2 to 85 years) and the 
mean disease duration is between 17 to 20 years.15 
Most reported behavioral and psychiatric symptoms in HD include apathy, depression, 
irritability, and obsessive-compulsive behavior.16 Visual hallucinations or other psychotic 
symptoms are rarely seen in HD patients. In a study of 1,993 HD gene mutation carriers, 
mild psychosis was only observed in 2.9% of the study population and only 1.2% scored 
moderate to severe psychosis, but no visual hallucinations were reported.16
Early cognitive deficits in HD mainly involve impairments in executive functioning, 
such as attention and planning difficulties, and cognitive inflexibility, which gradually 
progresses over time and eventually results in dementia.15,17 Executive dysfunction 
can already be present in the premanifest phase, before motor symptoms occur.17,18 
Although deficits in visual acuity or visual dysfunction are not typical clinical features of 
HD, visuospatial deficits are reported in HD patients. Such visuospatial deficits are of 
clinical importance because they can influence overall cognitive performance and may 
have major functional implications, for example the impact on driving a car or using 
electronic devices such as mobile phones and computers. Also, visual deficits should 
be taken into account when conceptualizing cognitive assessments for measuring 
drug efficacy in clinical trials. By providing an overview regarding the brain structure 
and function of the visual cortex in patients with HD, we propose to provide novel 
information on disease progression and cortical degeneration. Therefore, the aim of 
this review is to summarize the current literature regarding visual cognitive impairment 
and identify the posterior cortical changes that occur in HD patients. 
84
5 | The visual cortex and visual cognition in HD: an overview of current literature
2. METHODS
A review of the existing literature on visual impairment in HD was conducted using the 
electronic database of PubMed/Medline. All literature published before August 2017 
was critically reviewed. The following search terms were used in several combinations 
to identify the available literature: “Huntington”, “Huntington’s disease”, “visual”, 
“visual cognition”, “visual processing”, “visuospatial”, “atrophy”, “occipital cortex”, 
“cerebral blood flow”, “visual pathway”, and “visual system”. In addition, potential 
eligible studies were also screened using the reference lists of the studies found. Only 
original research papers and review articles written in English were considered for 
further review. Animal model studies, letters to editors and editorial comments were 
excluded. Articles that examined the visual cortex and/or assessed visual cognition in 
manifest and premanifest HD gene carriers were included for further evaluation. 
3. RESULTS
3.1. Search results
Of the 1,406 articles that were identified by the initial database search, 85 articles were 
selected for further review based on the abstract. Twenty-two studies were included 
for this review as these studies specifically investigated visual function in HD. Of these 
22 studies, one post-mortem brain study and six neuroimaging studies addressed 
changes of the visual cortex in HD gene carriers, and 15 neuropsychological studies 
assessed visual cognitive functioning in HD. We will first focus on the structural and 
functional changes of the visual cortex reported in manifest and premanifest HD 
gene carriers in paragraphs 3.2.1 and 3.2.2. An overview of the literature regarding 
changes of the visual cortex is also provided in Table 2. In paragraph 3.2.3, we will 
discuss the findings of studies investigating visual cognition in HD using the following 
cognitive domains: visual perception, visuospatial processing, visual working memory, 
visuoconstruction and visuomotor function. These visual cognitive domains and 
their associated neuropsychological tasks are summarized in Table 3. Furthermore, 
a summary of the current literature on visual cognition in HD is given in Table 4. 
Besides the 22 studies that investigated visual function in HD, another 26 articles were 
additionally reviewed, of which 24 articles assessing whole brain changes in HD, and 
two articles examining an extensive neuropsychological assessment battery in HD. 
These studies did not specifically aim to focus on the visual system, but did report 




3.2. The visual cortex in Huntington’s disease
Neuropathological alterations in HD are primarily found in the striatum, especially in 
the caudate nucleus and putamen, due to loss of striatal medium-sized spiny neurons.19 
Although striatal atrophy is considered to be the origin of choreiform movements 
seen in HD patients, it is suggested that other symptoms of HD are related to cortical 
degeneration, as extensive neuronal loss is seen throughout the cerebral cortex when 
the disease progresses.20–22 
3.2.1. Structure of the cerebral cortex
A post-mortem brain study showed a 32% reduction of nerve cells in the primary visual 
area (Brodmann area 17) in brains of 7 HD patients in advanced disease stages compared 
to 7 controls.23 The authors conclude that damage to the primary visual area contributes 
to the pathogenesis of visual dysfunction.23 This study, however, only examined nerve 
cells in Brodmann area 17 in the occipital lobe and did not assess other brain regions, 
which is contrary to another study that examined the patterns of neuronal cell loss in 
the frontal, parietal, temporal, and occipital lobes in post-mortem brains of 14 end 
stage HD patients.21 Compared to controls, HD patients showed the highest difference 
in pyramidal neuron cells in the secondary visual cortex (42% decrease), whereas no 
significant pyramidal cell differences was observed in the primary visual cortex (3% 
decrease).21 In comparison, a 27-34% reduction in pyramidal cell number was found in 
HD patients compared to controls for the superior frontal, middle temporal, superior 
parietal, and primary sensory cortices.21 Between HD patients, there was additionally 
more neuronal loss in the secondary visual cortex (36% loss) than in the primary visual 
cortex (12% loss), suggesting that mainly associative visual regions are impaired in 
HD.21 These latter findings were confirmed by a MRI study that observed reduced 
cortical thickness of the lingual gyrus and lateral occipital cortex in premanifest gene 
carriers close to disease onset (n=58) and early stage HD patients (n=40) that was 
associated with worse visuospatial task and visual working memory performance 
measured with the Map Search task, Spot the change task and the Trail Making Test 
part A.13 No associations were found between cognitive performance and thickness 
of the cuneus. This implies a distinct association between higher-level cognitive 
performance and cortical occipital degeneration.13 An additional MRI study examined 
structural posterior brain changes in relation to visuospatial attention in premanifest 
(n=119) and early stage manifest HD (n=104), and found associations between poorer 
visuospatial performance (measured using the Map Search and mental rotation tasks) 
and volume loss in the cuneus, lingual, fusiform gyri, and motor regions in manifest 
HD compared to controls.24 Another study focused on the link between visuomotor 
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performance and prefrontal cortex atrophy, but additionally found focal volume loss in 
the occipital cortex and associations between this volume loss and poorer visuomotor 
performance (measured using the 15-Object test, a visuomotor integration task).25 
Yet, another study examining visuomotor function using the Circle Tracing task and 
cortical volume loss did not find any significant association between visuomotor task 
performance and the visual and motor cortices,26 but this might be explained by 
the fact that in these studies different cognitive assessments were used to evaluate 
visuomotor function.
In studies focusing on whole brain cortical changes and associations with clinical 
impairments, reduced cortical thickness of the cuneus,12,27 and volume loss of the 
occipital lobe,11,28–31 and parietal lobe 12 were observed in both premanifest and early 
manifest disease stages compared to controls.
In conclusion, volumetric changes of posterior cortical regions can already be detected 
in early stages of the disease, even in the premanifest phase, while frontal and temporal 
regions remain largely unaffected. 
3.2.2. Cortical brain function
It is thought that clinical manifestations of HD not only depend on brain atrophy, but 
are also influenced by neuronal dysfunction and loss in neuronal network structure.32 
Functional MRI (fMRI) can be used to study neural function. Several fMRI studies in 
HD gene carriers showed changes in multiple functional brain networks before brain 
atrophy or clinical symptoms were present.32,33
Only one functional imaging study focused on the visual system in 20 early HD patients 
using resting-state fMRI.34 Resting-state fMRI assesses overall brain connectivity that 
is not related to task performance. Reduced fusiform cortex activity in HD patients 
was found after correcting for whole brain atrophy compared to controls.34 The 
authors therefore conclude that activation differences in the occipital cortex could not 
sufficiently be explained by regional brain volume loss alone. Another study reported 
reduced brain connectivity using whole brain resting-state fMRI in the occipital cortices 
in both premanifest and manifest HD gene carriers compared to controls.35 However, 
decline in brain connectivity over time in the occipital region was not confirmed in 
longitudinal resting-state fMRI studies.36,37
It is suggested that visual stimulation results in an increase in glucose uptake in the 
brain and cerebral blood flow.38 Therefore, a 31phosphorus nuclear magnetic resonance 
(NMR) spectroscopy study used a basic visual stimulation task to activate the occipital 
cortex and measure metabolite concentrations for the assessment of brain energy 
deficits in manifest HD (n=15) compared to controls (n=15).39 An increase in metabolite 
87
5
concentrations was observed in controls, whereas HD patients did not show any 
response to brain activation, indicating impaired mitochondrial function in the visual 
cortex.39 In addition, two small task-based fMRI studies demonstrated reduced neural 
activity of the occipital cortex, during a Porteus Maze task in 3 premanifest individuals,40 
and during a serial reaction time task in early and premanifest HD patients (n=8).41 
These studies also showed reduced activation in the caudate, parietal and 
sensorimotor cortices,40 and in the middle frontal gyri and precuneus.41 As these tasks 
were examined in small patient groups and involve a combination of basic and higher 
visual processing, motor speed, and spatial functioning, a direct conclusion cannot be 
drawn regarding neural dysfunction of the occipital cortex alone. 
3.2.3. Cerebral metabolism
With positron emission tomography (PET) imaging, functional or metabolic changes 
in HD can be studied using a radioactive labeled tracer that binds to specific 
structures within the brain. Several reviews have recently discussed the developments 
of PET imaging in HD.42–44 Overall, there is increasing evidence of reduced glucose 
metabolism in the striatum, and frontal and temporal cortices, which seem to be 
reliable predictors of disease progression in HD.42–44 There have been no PET studies 
performed to date that specifically focused on the glucose metabolism of the visual 
cortex in HD patients. However, an interesting finding was observed by a study 
group that examined spatial covariance patterns between different networks of 
regions with altered glucose metabolism using PET imaging.45,46 A relative increase 
in glucose metabolism was found in thalamic, motor, occipital and cerebellar regions, 
in association with a decrease in striatal metabolism in HD patients compared to 
healthy controls.45,46 A recent study reports similar findings of striatal hypometabolism 
in combination with hypermetabolism in the cerebellum, thalamus, and occipital 
cortex.47 Here, hypermetabolism in the cuneus and lingual gyrus was negatively 
correlated with hypokinetic motor scores. These findings suggest that a decrease in 
glucose metabolism might be linked to clinical disease onset, whereas an increase in 
glucose metabolism indicates a compensatory mechanism for neuronal loss and/or 
motor disturbances.46,47 As neuronal loss is indirectly measured using functional MRI, 
the reduced brain activity in the occipital cortex of HD patients found in previous fMRI 
studies might indeed explain the hypermetabolism found in these PET studies. 
Another approach to assess alterations in metabolism is by measuring cerebral 
blood flow (CBF) or cerebral blood volume (CBV) using transcranial Doppler (TCD) 
ultrasonography, PET imaging or arterial spin labeling MRI.48
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Reductions in cerebral blood flow and elevations in cerebral blood volume were 
primarily observed in frontal cortical regions in premanifest HD gene carriers.49,50 In 
manifest HD, hypoperfusion was additionally observed in the fronto-parietal regions 
and anterior cingulate cortex during a word generation task,51 motor task,52 and 
executive functioning tasks,53,54 but no alterations in cerebral perfusion were detected 
in the posterior cortex during task performance. One study reported heterogeneous 
regional CBF reductions in rest in 17 early manifest HD extending to the sensorimotor, 
paracentral, inferior temporal and lateral occipital regions, with normal CBF in the 
thalamus, postcentral gyrus, insula, and medial occipital areas.55 However, the degree 
of cortical thinning exceeded CBF reductions in the temporal and occipital cortices, and 
in the striatum, suggesting that structural and vascular alterations might originate from 
different underlying pathologic mechanisms.55 More studies are necessary to evaluate 
the manner of perfusion changes over the course of the disease but hypoperfusion 
seems to play a role in the pathophysiology of neuronal dysfunction in HD.   
In conclusion, although the visual system has not been the main focus in many imaging 
studies in HD to date, atrophy (i.e. volume loss and cortical thinning), reduced neural 
activity and functional connectivity, and changes in glucose metabolism of the posterior 
cerebral cortex have been reported in both early stage HD patients and premanifest 
gene carriers. This suggests that the posterior cerebral cortex might be one of the first 
cortical regions to undergo pathological and functional changes. 
3.3. Visual cognition in Huntington’s disease
Many studies investigated the progression of cognitive impairment in different HD 
disease stages.17 Here, we will focus on studies assessing cognitive deficits in HD that 
involve a visual component. Visual cognitive functioning can be divided into different 
domains of visual processing, however, the terminology that is used to define visual 
cognition widely differs among the current literature. Also, many neuropsychological 
assessments that are used to evaluate visual cognitive function often require a 
combination of several domains, such as visual attention, spatial orientation and working 
memory. Additionally, in HD patients, possible influence of a motor component on 
cognitive performances should also be considered. Below, we will discuss the reviewed 
studies using the following domains: visual perception, visuospatial processing, visual 
working memory, visuoconstruction and visuomotor function (Table 3).
In general, color, patterns, depth, motion perception, and the recognition of facial 
expressions of emotions are usually classified as visual perceptual skills. Visuospatial 
processing or visual scanning and attention are needed to visually perceive objects 
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TABLE 3  Visual cognitive domains and associated neuropsychological assessments
Domain Defi nition Assessments
Visual perception
Color perception Perception of colors and 
ability to distinguish contrast
Ishihara Color Test, Contrast 
Sensitivity Test
Visual recognition Recognition of faces and 
facial expression of emotions
Emotion Recognition Tasks
Visual organization Perceptual reorganizing 
to distinguish incomplete 
fragmented visual stimuli
Closure Speed, Visual Object 
and Space Perception 
battery, Hooper Visual 
Organization Test
Visuospatial function
Visual attention Awareness of visual stimuli Line Bisection Test, 
Cancellation Task, Visual 
Search and Attention Test, 
Embedded Figures, Map 
Search, Trail Making Test A
Visual scanning Ability to acquire information 
regarding environment and 
spatial distance (e.g. for 
reading, writing, telling time)
Counting dots, Visual 
Scanning Test, Mental 
Rotation, Street Map Task, 





Ability to retrieve 
visuospatial information from 
memory
Recurring Figures Test, 
Family Pictures (subtest of 
Wechsler Memory Scale-III), 
Trail Making Test B
Visual Recall Reproduction of a design or 
object
Visual Reproduction Task 
(immediate and delayed 
recall), Spot the change Task
Visuospatial Learning Learning and recall memory 
of visuospatial stimuli










Visuomotor Ability to maintain gaze on a 
moving target
Circle-Tracing Task (direct 
and indirect feedback), 
15-Objects task
Based on Lezak et al., 2004 56
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memory accounts for the recall of visuospatial stimuli. Visuoconstruction is defined as 
the ability to organize and manually manipulate spatial information to make a design, 
i.e. copying a complex figure or constructing three-dimensional figures from two-
dimensional units.56 Last, visuomotor function involves visual scanning and tracking of 
movement and the ability to maintain gaze on a moving target.57 
A summary of the reviewed literature regarding visual cognition is presented in Table 
4. 
3.3.1. Visual perception 
The perception of colors, contrast, and motion, the recognition of objects, facial 
expression, and emotions, and conceptual organizing skills are all classified as visual 
perception. The lateral geniculate nucleus is involved in the processing of colors 
and contrast resolution before further functional differentiation occurs in the striate 
cortex.58 Limited studies have been performed that address basic visual processing 
of contrast and motion in HD. Patients with HD showed impaired contrast sensitivity 
for moving stimuli,59 while contrast sensitivity for static stimuli seems unaffected in HD 
patients.59,60 This might indicate involvement of the (pre)-striate visual cortex early in 
the disease process.59 Still, no structural or functional neuroimaging studies have been 
performed that confirm this hypothesis. 
Conceptual organization or visual object perception has been examined in several 
studies in patients with HD, but methods differ and findings are inconsistent. One 
study assessed visuoperceptive function using the Hooper Visual Organization test in 
premanifest and manifest HD gene carriers, for which participants needed to recognize 
and name the object that is displayed on a card in fragmented form.61 Both early 
and more advanced HD patients scored significantly lower on this task compared to 
premanifest and control individuals. No differences in scores were observed between 
premanifest HD and controls. Remarkably, 70% of the premanifest individuals scored 
above 25 points (maximum of 30 points), while only 20% of the early manifest individuals 
reached this score, which illustrates the impaired task performance in manifest HD.61 
Three other studies assessed visuoperceptional skills in HD patients using the Visual 
Object and Space Perception (VOSP) battery, which measures object recognition and 
space perception separately in eight subtests with minimal involvement of motor skills 
and executive functioning.34,62,63 A cross-sectional study showed that out of all the 
subtests of the VOSP, only the performance on the object decision task was impaired 
in HD patients (39% of the HD patients performed below the fifth percentile of the 
control norm),63 while another cross-sectional study found an overall worse performance 
on the silhouettes and object decision subtasks in early HD patients compared to 
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controls.34 Brain activity of the fusiform gyrus did not predict the performance on 
visual object perceptional tests,34 which is unexpected since the fusiform gyrus is 
thought to be involved in object and facial recognition.64 A longitudinal study that 
assessed in addition to visual cognition also executive function, language, learning, 
and intelligence, reported a decline in performance for object recognition and space 
perception in HD patients after a follow-up period of 2.5 years, measured using sum 
scores for all object recognition tasks and space perception tasks.62 
In contrast, a small study in 10 HD patients reported that the identification of individual 
objects and objects adjacent to each other remained unaffected, while deficits were 
found in the simultaneous perception of multiple objects that were presented in an 
overlapping manner.65 
The perception of motion can be measured using a motion discrimination task, in 
which participants need to decide whether dots moved to the right or left in a field 
of noise. Here, findings are also inconsistent, when assessing a motion discrimination 
task in HD patients.59,60 In a pilot study of 8 HD patients and 9 premanifest HD gene 
carriers, the discrimination of motion trajectories in noise was impaired in the manifest 
HD group, but not in premanifest HD gene carriers.60 In a subsequent study with a 
larger sample (201 controls, 52 premanifest and 36 manifest HD gene carriers), no 
differences were observed in the performance on this task among different HD gene 
carrier groups and controls.59 The authors explained these different findings because 
of possible differences in the severity of HD participants that were included in the two 
studies.59 Therefore, no conclusions can be drawn from this limited evidence on the 
motion perception performance in HD patients. 
In contrast, visuoperceptual recognition of facial expressions and emotions has been 
extensively studied in HD patients. Several reviews have recently evaluated the current 
literature on emotion recognition in HD.66–68 Briefly, the ability to recognize basic 
emotions from facial expressions has consistently been found to be impaired in both 
manifest and premanifest HD, especially for negative emotions such as anger, disgust, 
and fear.67,68 Impairments in facial emotion recognition in HD seem to be associated 
with regional loss of brain tissue, altered brain activation, and changes in brain 
connectivity.68 A large study by the Predict-HD study group found that, in premanifest 
HD gene carriers, deficits in negative emotion recognition were associated with 
atrophy of the fronto-striatal network, the precuneus and occipital regions, such as the 




The dorsal temporo-occipital pathway is suggested to be involved in visuospatial 
cognition.1 Visuospatial attention involves the awareness of visual stimuli to perceive 
objects, while visuospatial scanning is necessary to acquire information regarding the 
environment, spatial distance and relationship among objects. Therefore, visuospatial 
processing is important for daily functioning, such as walking, driving, reading, and 
writing, and is often essential when measuring other cognitive domains. 
Eight studies specifically investigated visuospatial function, visual attention or visual 
scanning in HD patients.13,24,34,61,70–73 One study assessed a wide range of visuospatial 
tasks in HD patients and controls.70 Factor analyses showed that overall visuospatial 
processing capacity (measured using the performance subscales of the WAIS-R, 
Embedded Figures Test, and Mental Reorientation Test) and spatial manipulation 
(involving performance on the Mental Rotation and Street Map task) were impaired in 
HD, whereas spatial judgment (comprising of scores of the Rod-And-Frame Test and 
In-Front-Of Test) appeared unaffected.70
Another study also examined the ability to spatially rotate a mental image (i.e. a 
mental rotation task) in patients with HD and patients with Alzheimer’s disease (AD).71 
HD patients were able to mentally rotate a figure through space, but showed slowing 
in information processing speed (i.e. bradyphrenia) resulting in a worse performance, 
whereas in AD patients the accuracy, not the speed, was impaired compared to their 
respective age-matched controls 71 Other more recent studies, however, reported 
worse performance on the Mental Rotation task in both premanifest and manifest HD 
gene carriers compared to controls, with poorer performance in the more advanced 
disease stages that was not influenced by bradyphrenia.13,24 
Different neuropsychological assessments were used to measure visual scanning and 
attentional deficits in HD patients in several studies.24,34,61,72,73 The Cancelation Task and 
Line Bisection Test did not show any differences in visual attentional function between 
healthy controls, premanifest, and manifest HD gene carriers.61 In a longitudinal study, 
decline in performance on the Map Search attentional task was only observed in more 
advanced HD patients after a 12 months follow-up period.24 
The Symbol Digit Modalities Test (SDMT) and the Trail Making Test (TMT) are widely 
used assessments to measure cognitive function in HD patients.62,74,75 The SDMT is 
found to be the most sensitive cognitive task in large longitudinal studies to detect 
progressive change in HD gene carriers.62,74,75 An explanation for this might be that the 
SDMT is a demanding task that requires a high degree of visual scanning and memory, 
processing speed, object recognition, oculomotor function and motor speed. One 
study assessed the association between cognitive task performance and visual brain 
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activity changes.34 Here, early HD patients’ lower fusiform activity was associated with 
worse performance on the SDMT, which is not surprising as the SDMT also involves the 
recognition of symbols and shapes.34
Among a large group of 767 premanifest HD gene carriers, the TMT part A was 
associated with visual search and sustained attention, whereas TMT part B was 
associated with executive functioning, processing speed and working memory.72 
Premanifest HD gene carriers close to disease onset performed worse on both TMT 
part A and part B. Interestingly, only part A scores seemed to be mildly affected by 
motor disturbances.72
Only one study specifically assessed visual scanning in premanifest and manifest 
HD gene carriers using the Digit Symbol Subtest, a subscale of the Wechsler Adult 
Intelligence Scale - Revised (WAIS-R), and quantitative eye movements.73 While 
all participants used a similar visual scanning strategy, slowing and irregular visual 
scanning in both premanifest and manifest HD was related to worse performance on 
the Digit Symbol task compared to controls.73 Although this might suggest deficits in 
visual scanning in early disease stages, the influence of motor impairment on cognitive 
performance was not taken into account. 
Overall, visuospatial function in HD patients has been examined using various cognitive 
batteries, making it difficult to directly compare study findings. Some visual attentional 
tasks (such as the Mental Rotation, TMT part A and the SDMT) revealed impaired 
performance in both premanifest and manifest HD, while other tasks (such as the Line 
Bisection Test and Cancellation Task) showed no differences in task performance.
3.3.3. Visual working memory 
Visual working memory accounts for the ability to retrieve visuospatial information from 
memory, and involves learning and recall of visuospatial stimuli. Six studies assessed 
visuospatial memory function in HD patients.13,63,76–79 
Compared with other neurodegenerative disorders, such as Alzheimer’s’ disease (AD) 
and Parkinson’s disease (PD), patients with HD showed impairments in spatial working 
memory and visuospatial learning.76,77 In these studies, visuospatial working memory 
was determined as the ability to recall a sequence of squares at the right location 
on a screen76, the recognition of abstract visual stimuli76, and the recall of the right 
naming and location of sketched objects on cards.77 Patients with HD were better at 
correctly naming the objects than recalling their spatial location, whereas the opposite 
was true for the AD and PD patients.77 This was confirmed by a study in early stage 
HD patients that measured visual object and visuospatial working memory using an 
extensive battery of cognitive visual assessments.63 Here, deficits in pattern and spatial 
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recognition memory, decreased reaction times in visual search, and an impaired spatial 
working memory were found in HD patients, while visual object working memory 
showed no changes compared with healthy controls. 
To evaluate the influence of slowness of execution (bradykinesia), thinking (bradyphrenia) 
or motor speed on visual memory task performance, one study assessed accuracy and 
reaction times between different disease stages on a visual comparison task to spot the 
change of randomly selected colors between images.78 Premanifest HD gene carriers 
close to disease onset and early stage HD patients showed lower working memory 
accuracy and slower response times compared to controls. As premanifest individuals 
without motor signs also showed impairments in task performance, the findings of this 
study imply that results are influenced by a decrease in cognitive performance and 
impaired information processing, rather than reduced motor speed.78
A more recent study also reported poorer performance on the ‘Spot the change’ task 
in more advanced disease stages.13 In addition, task performance was associated with 
thickness of the lateral occipital cortex and lingual gyrus, while a non-visual motor 
task showed no associations with the visual cortex.13 This implies that the changes 
in occipital thickness are specific to visual cognition rather than general disease 
progression.13 In another study, visuospatial memory function was evaluated in HD 
patients and healthy controls using the Visual Spatial Learning Test (VSLT), which is 
a nonverbal memory test that measures immediate and delayed memory for designs 
and locations without requiring motor or language skills.79 Compared to controls, 
premanifest HD gene carriers showed, besides an impaired recall for associations 
between object and spatial location, no deficits in the memory for objects, while HD 
patients showed impairments on all measures.79
Generally, retrieving visuospatial information from memory seems to be inaccurate in 
early manifest stages and even in premanifest HD gene carriers close to disease onset, 




Visuoconstruction involves the spatial ability to reproduce complex geometric designs. 
Interpretation of visuoconstructive deficits can be difficult because tests that are used to 
measure visuoconstruction often involve other domains, such as visuospatial, executive 
and motor functioning. Only two studies investigated visuoconstructive skills in HD 
patients by assessing the ability to copy a complex figure using the Rey-Osterrieth 
Complex Figure Test.61,80 The first study explored these visuoconstructive abilities of 
HD patients with age-matched controls for HD by recording the accuracy and time 
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to copy the design.80 Here, patients with HD showed no differences in accuracy but 
needed more time to complete the test compared to their matched control group, 
which may have been due to the presence of motor disturbances.80 A second study 
examined the same part of the Rey-Osterrieth Complex Figure test, in premanifest 
and manifest HD gene carriers but measured the correct elements that were copied 
instead of evaluating the accuracy of the lines to minimize motor interference.61 In HD 
patients, total correct scores declined in more advanced disease stages. Furthermore, 
early HD patients showed mild deficits in visuoconstruction but this was not significant 
compared with premanifest HD gene carriers. 
Based on this literature, visuoconstructive skills become impaired in the more advanced 
disease stages. Still, more studies are necessary to fully determine the extent of these 
impairments and the possible influence of motor signs and bradyphrenia. 
3.3.5. Visuomotor function
Visuomotor deficits in the tracking of movements and the ability to maintain gaze on a 
moving target have been reported in HD patients.25,26,81,82
In two studies using a circle-tracing task to measure indirect and direct visual feedback, 
early HD patients were slower, less accurate and needed more time to detect errors.26,82 
This is consistent with another study using a visual tracking task that showed a higher 
error rate and longer time scores in HD patients, especially in the non-dominant hand, 
compared to controls.81 Premanifest HD gene carriers also showed less accuracy in 
completing the task compared to controls, however, no associations were found 
between visuomotor integration deficits in HD gene carriers and volumes of visual and 
motor cortices.26 This might be explained by the multifactorial demands of the circle-
tracing task that was used as an outcome measure. 
To the contrary, another study found correlations between impaired visuomotor 
performance in premanifest HD gene carriers and decreased volumes of the prefrontal 
and occipital cortices.25 In this study, visuomotor integration performance was 
measured using the time to complete the 15-objects test that contains 2 figures, each 
with overlapping drawings of 15 different items.25 This task, however, can also be used 
to assess visual perception and in addition, it remains uncertain if other signs of HD, 
such as bradyphrenia, motor and eye movement disturbances, or visuoperceptional 
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4. DISCUSSION
This review presents an overview regarding changes of the visual system in premanifest 
and manifest HD gene carriers. Although the visual cortex was not the main focus of 
many neuroimaging studies, there is increasing evidence of early neurodegeneration 
of the posterior cerebral cortex. Based on the current literature, alterations were 
primarily found in the associative visual areas, such as the lingual and fusiform gyri, 
and the lateral occipital cortex. The cuneus and primary visual cortex appear to be 
affected in more advanced disease stages. As changes of the visual association cortex 
were already detectable in the pre-symptomatic and early disease stages, this implies 
that the visual cortex might be an early marker of disease progression that can be used 
as an outcome measure in disease-modifying intervention trails. 
Clinical visual deficits or visual hallucinations are not commonly reported as typical 
features of HD. Still, studies assessing visual cognitive function in HD report impairments 
in several domains, specifically tasks involving visual object perception, facial emotion 
recognition and visuospatial processing and working memory. 
Studies assessing driving competence in HD patients also showed that visual 
processing speed, visual scanning, and visual attention are more sensitive predictors 
of performance on on-road driving assessments, compared to motor functioning.83,84
The assessment of visual cognitive impairment is therefore of clinical importance as it 
can have implications in daily functioning, such as the impact on driving performance, 
the use of electronic devices and subsequently affects participating in social activities. 
For example, the impairment to recognize negative facial emotions, such as anger, 
disgust and fear, could affect communication and social relationships.68 Also, patients 
with HD might have a higher risk of falling or experience difficulty with walking because 
of visual perceptual and visuomotor deficits. In addition, visual cognitive impairment 
can influence overall cognitive performance. 
Visual cognitive impairments have primarily been found in the manifest disease 
stage, although visuospatial working memory deficits and changes in facial emotion 
recognition are also reported in HD gene carriers prior to clinical motor onset. 
Neuropsychological studies in HD patients, however, have used heterogeneous 
cognitive batteries to examine visual cognition involving various visual skills, making 
a direct comparison between studies difficult. This was particularly found in studies 
assessing visual attention in HD, where the Map Search, TMT part A, SDMT, Stroop, 
Digit Symbol task, Line Bisection test and Cancellation task were all used to measure 
visual attention. A standardized battery of cognitive tasks focusing on visual processing 
skills might provide more information regarding the specific underlying deficits. Using 
101
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cognitive tasks with minimal motor involvement is recommended to reduce the 
possible influence of other HD related signs, such as the Visual Object and Space 
Perception battery, the Visual Spatial Learning test and the Stroop tasks. 
Visual cognitive impairment in HD gene carriers has previously been interpreted as a 
result of disturbances in the fronto-striatal network.57,63,80 However, more recent studies 
suggest that degeneration of cortical-striatal circuits that are linked to the associative 
cortical regions in the parietal lobe contribute to visual memory and visuospatial 
impairments associated with HD.77,79
We believe that the posterior cerebral cortex is one of the first cortical areas that 
undergoes changes in early stages of HD. Therefore, systematic and preferably 
longitudinal assessment of the visual cortex in HD is warranted, to improve the 
understanding of structural and functional alterations in the visual pathway in patients 
with HD. 
Linking structural changes of the visual cortex with functional cognitive decline over time 
can provide valuable information on disease progression and cortical degeneration. 
The use of a standardized battery of visual cognitive tasks might additionally provide 
more detailed information regarding impairments in specific visual domains. To reduce 
interference on task performance, we are of the opinion that visual neuropsychological 
tasks should be selected that are not influenced by motor speed, bradyphrenia or 
language skills. 
To summarize, based on the current literature, early involvement of the visual cortex in 
the neurodegenerative process in HD has been reported. Structural, metabolic, and 
functional changes are primarily found in the associative cortices, such as the cuneus, 
lingual gyrus, and fusiform gyrus. Further research is nevertheless required to provide 
more insight into the pathophysiological changes of the posterior cerebral cortex in 
HD. Clinical visual deficits or visual hallucinations are not commonly reported as typical 
features of HD. However, visual cognitive impairments are seen in several domains, 
specifically tasks involving visual object perception, facial emotion recognition and 
visuospatial processing and working memory were impaired in pre-symptomatic and 
early disease stages. Because heterogeneous cognitive batteries were used, a direct 
comparison between studies was difficult. We are of the opinion that tasks with minimal 
motor involvement are most recommended for the assessment of visual cognitive 
function in future clinical trials, such as the Visual Object and Space Perception battery, 
the Visual Spatial Learning test, and the Stroop tasks. In addition, a motor task without 
a visual component, such as the Paced Tapping task, can be included in the test battery 
as a general proxy for disease progression.75 In this way, the relationship between 
visual task performance and visual cortical changes can be measured exclusively.13,75 
102
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Investigating the association of brain structure and function with visual cognition in 
HD using a standardized visual cognitive battery and different imaging modalities can 
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ABSTRACT 
Huntington’s disease (HD) is an autosomal-dominant inherited neurodegenerative 
disorder characterized by motor disturbances, psychiatric disturbances, and cognitive 
impairment. Visual cognitive deficits and atrophy of the posterior cerebral cortex are 
additionally present in early disease stages. This study aimed to assess the extent of 
structural and functional brain alterations of the visual cortex in HD gene carriers using 
different neuroimaging modalities. 
Structural and functional magnetic resonance imaging (MRI) data were acquired from 
18 healthy controls, 21 premanifest, and 20 manifest HD gene carriers. Voxel-based 
morphometry (VBM) analysis and cortical thickness measurements were performed to 
assess structural changes in the visual cortex. Brain function was measured by assessing 
neuronal connectivity changes in response to visual stimulation and at rest in visual 
resting-state networks. Multiple linear regression analyses were performed to examine 
the relationship between visual cognitive function and structural imaging measures. 
Compared to controls, pronounced atrophy and decreased neuronal function at rest 
were present in associative visual cortices in manifest HD. The primary visual cortex 
did not show group differences in cortical thickness and in vascular activity after 
visual stimulation. Thinning of the associative visual cortex was related to worse visual 
perceptual function. Premanifest HD gene carriers did not show any differences in 
brain structure or function compared to controls. 
This study improves the knowledge on posterior brain changes in HD, as our findings 
suggest that the primary visual cortex remains preserved, both structurally and 
functionally, while atrophy of associative visual cortices is present in early HD and 




Visual processing is involved in routine daily functioning, such as walking, driving a 
car, and in social communication. In the human brain, transmission of incoming stimuli 
from the retina pass the afferent visual pathway via the optic nerve, optic tract, lateral 
geniculate nucleus in the thalamus, and optic radiation to the primary visual (striate) 
cortex in the occipital lobe and higher posterior cortical areas.1 Higher-level visual 
processing occurs in the associative extra-striate regions surrounding the primary visual 
cortex, from the secondary visual cortex to the ventral occipital-temporal pathway 
and dorsal occipital-parietal pathway.2 In Huntington’s disease (HD), an autosomal 
dominant inherited neurodegenerative disorder, progressive structural changes in the 
posterior cerebral cortex can be detected in early stages of the disease, while frontal 
and temporal regions remain less affected.3–8 The manifest stage of HD is clinically 
characterized by progressive motor disturbances such as chorea and dystonia, 
cognitive decline and psychiatric symptoms.9,10 Cognitive decline mainly involves 
progressive impairment in executive function.11 Nonetheless, neuropsychological 
studies assessing visual cognitive function in HD reported impairments in several 
visual domains, specifically tasks involving visual object perception,12,13 facial emotion 
recognition,14,15 visuospatial processing and visual working memory.7,16,17
Striatal atrophy is considered to be the origin of the characteristic choreatic motor 
signs, but it is suggested that other symptoms of HD might be related to cortical 
degeneration.4,18,19 Thinning of regions in the occipital lobe has been linked to worse 
performance on cognitive visuospatial tasks, which implies a distinct association 
between higher-level cognitive performance and occipital degeneration in HD gene 
carriers.6,7
In contrast to many structural magnetic resonance imaging (MRI) studies that showed 
neurodegenerative changes of the posterior cerebral cortex, only one study has 
assessed the functional aspects of visual brain function in HD using resting-state 
functional MRI.20 Here, functional connectivity changes were limited to the fusiform 
cortex in patients with HD, despite the presence of widespread posterior cortical 
atrophy. Still, little is known about brain function in patients with HD, and the link 
between structural cortical brain changes and functional impairments has not yet been 
fully investigated. Using different neuroimaging modalities and a visual cognitive test 
battery, this study aimed to improve the understanding of functional and structural 
alterations in the visual cortex in premanifest individuals (i.e., before the presence of 
motor symptoms) and in patients with early stage HD and investigate if there is an 
association between brain changes and visual cognitive task performance. 
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2. METHODS
2.1. Participants
A total of 59 participants (18 healthy controls, 20 premanifest HD gene carriers, and 
20 premanifest HD gene carriers) were included in this cross-sectional, observational 
study (Table 1).
Individuals were recruited from the outpatient clinic of the Neurology department at 
the Leiden University Medical Center between January 2017 and September 2017. 
HD gene carriers required a positive genetic test with a cytosine, adenine, guanine 
(CAG) repeat expansion of 36 or more on the Huntingtin gene. Partners and HD 
gene-negative relatives were recruited as healthy controls. All participants were 
between 18 and 65 years of age at the time of visit. To ensure an optimal primary 
visual acuity, individuals with an impaired primary visual ability (measured as below 
0.5; i.e., 20/40 vision) on the visual acuity test or ophthalmic disorders were excluded 
from the study. Other exclusion criteria were additional major co-morbidities not 
related to HD (including cardiovascular diseases, hypertension, diabetes mellitus and 
other neurological disorders), the inability to undergo MRI scanning (due to metallic 
implants, claustrophobia or pregnancy), or the participation in intervention trials. 
The Medical Ethical Committee of the Leiden University Medical Center approved 
this study and written informed consent according to the Declaration of Helsinki was 
obtained from all participants. 
2.2. Clinical assessments
Demographic information, CAG repeat length (for HD gene carriers only), and medical 
history was collected. Primary visual ability was measured with a visual acuity test. To 
assess the ability to perceive color differences the Ishihara Color Test was performed. 
Trained investigators assessed the degree of motor disturbances using the Unified 
Huntington’s Disease Rating Scale - Total Motor Score (UHDRS-TMS), a scale that 
measures different domains that are characteristically impaired in HD, including the 
oculomotor function, the tongue protrusion, the gait and postural stability, and the 
presence of choreatic or dystonic movements.21 Higher scores indicate increased 
motor impairment. Based on the UHDRS-TMS, HD gene carriers were divided into 
21 premanifest individuals, with a score of 5 or less, and 20 manifest individuals, 
with a score of more than 5.21 The UHDRS Total Functional Capacity (TFC) score was 
administered to assess five components of global daily functioning, including capacity 
to work, management of finances, ability to perform domestic chores, independency in 
activities of daily living (such as eating, bathing, and dressing), and care environment. 
Here, lower TFC scores indicate more impaired function. In manifest HD, the TFC score 
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is used to divide participants into disease stages, in which Stages 1 and 2 represent an 
early disease stage and Stage 5 the most advanced stage.22
The cognitive battery used in this study consisted of specific neuropsychological 
assessments with a large visual component. All cognitive tasks were administered by 
certified neuropsychological investigators and lasted approximately 30 minutes. 
The selection of cognitive assessments was based on findings from previous studies that 
focused on cognitive dysfunction in premanifest and manifest HD gene carriers.13,23–25 
The Symbol Digit Modalities Test (SDMT), Stroop Word Reading Test (SWRT), and 
Trail Making Test (TMT) were administered to assess visuospatial function, such as 
visual scanning and visual attention.24,26,27 Visual object perception was measured 
using subtests from the Visual Object and Space Perception (VOSP) battery and the 
Groningen Intelligence Test (GIT).28,29 Individual scores on each cognitive assessment 
were converted to standardized Z-scores. These Z-scores were summed and averaged 
resulting in cognitive domain scores to assess overall visuospatial and visual perceptual 
function.
2.3. Image acquisition 
All participants underwent structural and functional MRI scanning on a 3.0 Tesla MRI 
scanner (Philips Achieva, Best, the Netherlands). Both structural and functional MRI 
data were acquired using a standard 32-channel whole head coil. MRI proof glasses 
or lenses were used during scanning if participants had a visual acuity below 0.5 
(20/40 vision) without correction, to ensure optimal primary visual ability during task 
performance. Anatomical three-dimensional T1-weighted images were acquired with 
the following parameters: TE = 3.3 ms, TR = 7.2 ms, flip angle = 9°, FOV = 256 x 240 
x 176 mm and 176 slices with a slice thickness of 1 mm and no gap between slices, 
resulting in a voxel size of 1.00 x 1.00 x 1.00 mm, and scan duration of 9 minutes. 
All functional blood oxygen level-dependent (BOLD)-weighted echo-planar imaging 
whole brain volumes were obtained with the following parameters: TE = 30 ms, TR = 
3000 ms, FOV = 212 x 198 x 158 mm, flip angle = 80° and 48 slices with a slice thickness 
of 2.81 mm and slice gap of 0.5 mm, resulting in a voxel size of 3.31 x 3.31 x 2.81 mm, 




Cortical morphology was examined using volumetric and thickness outcome measures. 
Grey matter density alterations of the visual cortex in premanifest and manifest HD 
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gene carriers compared to controls were examined using voxel-based morphometry 
(VBM) analysis, which involves a voxel-wise comparison of the local concentration of 
grey matter between groups, including cortical surface area and cortical folding.30 In 
addition, to investigate subtle brain changes, the cortical thickness of specific brain 
regions in the visual cortex were measured.31
2.4.2. Voxel-based morphometry 
To assess structural voxel-wise grey matter density differences of the visual cortex 
between groups, we used a standardized VBM analysis protocol,30 using the FMRIB’s 
Software Library (FSL, version 5.0.10, Oxford, United Kingdom) tools.32,33 First, non-
brain tissue from all T1-weighted images was removed using the semi-automated brain 
extraction tool.34 Then, these brain-extracted images were segmented into different 
tissue types (i.e., grey matter, white matter, and cerebrospinal fluid). Quality control 
was performed on the brain extraction and grey matter segmentation images, and no 
data was excluded for further analyses. The grey matter images were aligned to the 2 
mm Montreal Neurological Institute (MNI)-152 standard space image, using non-linear 
registration.35,36 An averaged study-specific 4D template was subsequently created. 
Then, all native grey matter images were non-linear registered to this study specific 
template and modulated to correct for local enlargements and contractions due to 
the non-linear component of the spatial transformation.30 Finally, the modulated grey 
matter images were smoothed with an isotropic Gaussian kernel with a sigma of 3 mm, 
which corresponds to a full width at half maximum (FWHM) smoothing kernel of 7 mm. 
2.4.3. Cortical thickness
Cortical thickness of specific regions of interest was measured using cortical 
parcellation implemented in FreeSurfer version 5.3.0.37 The FreeSurfer algorithm 
automatically parcellates the cortex and assigns a neuroanatomical label to each 
location on a cortical surface model, based on probabilistic information. Four occipital 
regions (lingual gyrus, pericalcarine cortex, cuneus, and lateral occipital cortex), one 
parietal region (superior parietal cortex), and three temporal regions (temporal pole, 
fusiform gyrus, inferior temporal gyrus) defined by the Desikan-Killiany atlas were 
selected for further analyses,31 because these regions are all involved in the processing 
of visual stimuli.1 As there were no differences in cortical thickness between left and 
right hemisphere for any cortical region in our cohort, thickness was averaged across 




Alterations in brain function were assessed using task-based and resting-state fMRI. 
For the task-based fMRI, changes in BOLD signal in response to a visual stimulus were 
calculated as a proxy for cortical neuronal connectivity.38 In addition, brain function at 
rest was examined using resting-state functional connectivity analysis with pre-defined 
visual resting-state networks of interest (NOI).39 
2.4.5. Task design
The visual stimulus for the task-based fMRI scan consisted of seven blocks with an 8 Hz 
flashing black-and-white checkerboard pattern for 20 seconds, followed by 28 seconds 
of a grey screen with a red dot in the center of the screen. The visual stimuli were 
projected onto a screen, which the participant observed through a mirror attached to 
the head coil. To maintain attention and fixation to the checkerboard, each participant 
was asked to push on a button when the red dot position in the center of the screen 
changed from lighter to darker red, occurring at random intervals throughout the 
stimulus run. For the resting-state fMRI measures, participants were asked to close 
their eyes, not to fall asleep, and not to speak during the complete scanning time. 
2.4.6. Pre-processing
All functional images were pre-processed using the FEAT tool implemented in 
FSL.32 Pre-processing steps included motion correction,35 spatial smoothing using 
a Gaussian kernel of 8 mm FWHM, high-pass temporal filtering (with a cutoff of 48 
seconds for task-fMRI images, and 100 seconds for resting-state fMRI images), and 
distortion correction of B0 inhomogeneity’s. The pre-processed functional images 
were non-linear registered to individual brain-extracted T1-weighted scans, which 
were registered to MNI-152 standard space with boundary-based-registration.34,35 No 
scans were excluded after visual quality control to ensure correct registration. 
2.4.7. Vascular reactivity
Pre-processed task-based functional MRI scans were further processed to measure 
cortical vascular reactivity in response to visual stimulation. For this analysis, BOLD 
timeseries had to be extracted from the preprocessed scans. To this end, a region of 
interest (ROI) was created for each participant based on the results of an initial subject-
level analysis. During this subject-level analysis, brain regions were identified that 
reacted to the stimulus train using the general linear modeling approach implemented 
in FSL’s FEAT.32 The degree to which each voxel responded to the stimulus train was 
expressed in a Z-statistic map.
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To obtain the functional region of interest for each participant, a binary mask was 
constructed by taking the top 20% most activated voxels from this Z-statistic activation 
map. Using this mask, an average BOLD timeseries was calculated for each participant 
by averaging across all masked voxels. The resulting timeseries was cut up into blocks 
that each contained stimulus period (20 sec) and a subsequent rest period (28 sec). 
Then, the timeseries of each block were expressed as percentage BOLD change 
using the mean value of all blocks. To minimize the effect of non-physiologic noise 
on the block response, blocks with a percentage BOLD change greater than 3% were 
discarded.
Based on the method previously described by Dumas et al., 2012,38 a trapezoidal 
function was fit to the vascular reactivity response (i.e., percentage BOLD signal 
change) in the average BOLD timeseries, to describe the time-to-peak response, time-
to-baseline and amplitude of the response. The time-to-peak was calculated from the 
beginning of the block at t = 0 to onset of the trapezoid ceiling. The time-to-baseline is 
defined as the duration from the end of the stimulus at t = 20 seconds to the baseline. 
Response amplitude was defined as the distance from baseline to the peak response. 
The entire algorithm described above was implemented in R (the R foundation for 
Statistical Computing, Vienna, Austria), version 3.4.2. The full source code, along with 
additional mathematical details, has been published on GitHub (https://github.com/
jjhbw/TrapFit/).
2.4.8. Functional connectivity
After pre-processing of the functional resting state images, Independent Component 
Analysis-based Automated Removal Of Motion Artifacts was used as a data-driven 
method to identify and remove motion-related independent components from our 
resting state fMRI data.40 Then, functional connectivity analysis was performed using 
the dual regression method implemented in FSL, previously described by Filippini et 
al., 2009 and Hafkemeijer et al., 2015.41,42
For the dual regression method, we used standardized resting state NOI to measure 
functional connectivity as BOLD signal changes in the brain in relation to similar 
alterations in predefined resting state networks.39 As we focused on the visual cortex, 
we used two templates of standardized resting state networks, namely the medial 
visual network (including the calcarine sulcus, precuneus, lateral geniculate nucleus, 
and primary visual cortex) and the lateral visual network (including the occipital pole, 
lateral occipital cortex, fusiform areas, and superior parietal regions).39 To account 





Group differences in demographic and clinical outcome measures were analyzed using 
ANOVA, χ2-test, and Kruskal-Wallis test when applicable for continuous, categorical 
and skewed data respectively. Analysis of Covariance (ANCOVA), with group as factor 
and a simple contrast, was used to analyze differences in cortical thickness, task-
based fMRI response parameters and cognitive task performance in premanifest 
and manifest HD compared to controls. Age, gender, and years of education were 
included as covariates. Multiple linear regression analyses in HD gene carriers (i.e., 
premanifest and manifest HD) were performed to assess the relationship between 
neuroimaging (dependent variable) and cognitive outcome measures (independent 
variable), adjusted for age, gender, years of education, and CAG repeat length. All 
independent variables were entered in one block. Separate linear regression models 
were used for each neuroimaging measure. An alpha-level of < 0.05 was used to 
determine significance. To account for multiple comparisons in this analysis, an 
adjusted p-value was set based on the number of comparisons made for the analysis. 
Statistical analyses were performed using the Statistical Package for Social Sciences 
(SPSS for Mac, version 23, SPSS Inc.). 
For the structural VBM and resting state functional connectivity data, statistical analyses 
to detect group differences between controls, and premanifest and manifest HD were 
performed using a general linear model in FSL with age and gender as covariates. FSL-
randomise was used for voxel-wise non-permutation testing with 5,000 permutations.44 
For the VBM analysis, a binary mask of the visual cortex extracted from the MNI-152 
standard space image was used. For the functional connectivity analysis, analyses of 
variance F tests were first performed to assess if the group averages accounted for a 
significant effect in each NOI. Then, two-sample t tests were applied to obtain specific 
group differences (i.e., an increase or decrease) in functional connectivity. To account for 
the potential effects of local structural grey matter differences within and between the 
groups, individual grey matter density maps were used as additional voxel-dependent 
covariate in the statistical design. The threshold-free cluster enhancement (TFCE) 
technique was used to correct for multiple comparisons across voxels with family wise 
error,45 with a significant p-value of < 0.05 as significant threshold. Brain structures that 
showed a significant difference between groups were identified on the TFCE-statistic 
image using the Harvard-Oxford atlas and the cluster tool integrated in FSL. 
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3. RESULTS
3.1. Clinical characteristics
Demographic group characteristics are displayed in Table 1. Based on their functional 
capacity, manifest HD were in an early to moderate disease stage (4 patients in Stage 
1, 15 patients in Stage 2, and 1 patient in Stage 3).
There were no significant group differences for gender, handedness, education level, 
and use of tobacco. CAG repeat length did not differ between premanifest and 
manifest HD. Premanifest HD were younger (F[2,56] = 10.90) compared to controls (p 
= 0.028) and manifest HD (p < 0.001). Furthermore, manifest HD had a higher UHDRS-
TMS compared to controls and premanifest HD (F[2,56] = 49.41, both p < 0.001) and 
a lower UHDRS-TFC score compared to controls and premanifest HD (H[2] = 41.24, 
p < 0.001). On all visuospatial and visual perceptual tasks, manifest HD performed 
worse compared to controls. There were no significant differences in cognitive task 
performance between controls and premanifest HD. 
3.2. Structure of the visual cortex
3.2.1. Voxel-based morphometry 
Regional VBM analysis of the visual cortex was used to assess grey matter volume 
differences between groups. In manifest HD, significant cortical volume loss was 
identified bilateral in the fusiform gyrus, lingual gyrus, lateral occipital cortex and 
superior parietal cortex (Figure 1 and Table 2).  Furthermore, the left occipital pole 
and right inferior temporal cortex showed volume loss in manifest HD compared to 




TABEL 1  Demographic and clinical characteristics
Controls Premanifest HD Manifest HD
N 18 21 20






Gender (male/female) 7/11 11/10 11/9
Handedness – right (%) 15 (83.3%) 19 (90.5%) 15 (75.0%)
Education, years 17.0 ± 2.2 16.8 ± 3.2 16.4 ± 2.3
Current tobacco use 3 (16.7%) 4 (19.0%) 6 (30.0%)
CAG repeat length N/A 41.8 ± 2.2 
(38 – 45)
42.8 ± 2.4 
(40 – 48)






UHDRS – TFC 13 (11 – 13) 13 (10 – 13) 9 (6 – 13)**
Visual perception 
(compound Z-score)
0.43 ± 0.43 0.34 ± 0.48 -0.61 ± 0.91**
Visual scanning and attention
(compound Z-score)
0.26 ± 0.43 0.13 ± 0.29 -0.26 ± 0.39**
Data are mean ± SD (range) for age, CAG repeat length, years of education, and UHDRS-TMS. 
Numbers (%) are presented for handedness and tobacco use. Median (range) is given for UHDRS-
TFC. Compound standardized Z-scores on visual cognitive tasks were calculated. Scaled Z-scores 
were summed and averaged resulting in Z-scores per visual cognitive domain. Mean Z-scores ± 
SD per domain are presented. Analysis of covariance (ANCOVA) with group as simple contrast
was used to assess differences in Z-scores compared to controls, with age, gender and years of 
education as covariates. Abbreviations: N/A = Not applicable; CAG = Cytosine, Adenine, Guanine;
UHDRS-TFC = Unifi ed Huntington’s Disease Rating Scale Total Functional Capacity; UHDRS-TMS 
= Unifi ed Huntington’s Disease Rating Scale Total Motor Score.
* Signifi cant different compared to controls p < 0.05
** Signifi cant different compared to controls p < 0.001
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TABLE 2  Grey matter volume loss in the visual cortex in manifest HD
Cluster 
voxel size
Anatomical regions Side MNI coordinates 
(mm)
t value p value
x y z
870 Fusiform gyrus (BA 19/37) R 24 -72 -10 4.78 0.003
Lateral occipital cortex (BA 19) R 36 -80 -2 3.94 0.004
Lingual gyrus (BA 18) R 26 -46 0 4.11 0.014
741 Lateral occipital cortex (BA 19) L -46 -64 2 3.87 0.012
Occipital pole (BA 17) L -18 -92 -12 3.75 0.022
Fusiform gyrus (BA 19/37) L -26 -70 -6 3.32 0.038
696 Superior parietal cortex (BA 7) L -36 -46 38 4.76 0.012
606 Superior parietal cortex (BA 7) R 22 -48 56 4.85 0.007
398 Inferior temporal cortex (BA 20) R 46 -48 -6 4.35 0.019
15 Lingual gyrus (BA 18) L -26 -54 0 3.36 0.046
Voxel-wise identifi ed regions of signifi cant cortical volume loss in manifest HD compared to controls. 
All anatomical regions were identifi ed using the Harvard-Oxford Subcortical and Cortical atlases and the cluster
tool  implemented in FSL. T-statistics and corresponding p-values are presented (with a TFCE-family wise 
corrected p-value of p < 0.05). 
BA: Brodmann area, R: right hemisphere, L: left hemisphere
3.2.2. Cortical thickness
To determine subtle cortical changes in the visual cortex, the cortical thickness of 
eight regions of interest (cuneus, fusiform gyrus, inferior temporal cortex, lateral 
occipital cortex, lingual gyrus, pericalcarine cortex, superior parietal cortex, temporal 
pole) were additionally measured. Except for the pericalcarine cortex and temporal 
pole, significant cortical thinning was present in manifest HD in the cuneus, fusiform 
and lingual gyri, and inferior temporal, lateral occipital and superior parietal cortices 
compared to controls (Table 3). Premanifest HD did not show any significant differences 
in cortical thickness for all regions of interest compared to controls. 
Multiple linear regression analysis was performed to assess the relationship between 
cortical thickness and cognitive function in HD gene carriers (i.e., both premanifest 
and manifest HD). Besides the inferior temporal cortex, all regions showed significant 
associations with visual perceptual function, in which a decrease in cortical thickness 
123
6
FIGURE 1  Grey matter volume loss in the visual cortex in manifest HD
Voxel-based morphometry analysis. The significant Family-Wise-Error corrected grey matter differences 
between manifest HD and controls (p < 0.05) are presented in red-yellow, overlaid on sagittal, coronal, and 
transversal slices of Montreal-Neurological-Institute-152 standard T1-weighted images. 
Green: mask of visual cortex. Corresponding x-, y-, and z-coordinates are given. 
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6 | Structural and functional changes of the visual cortex in early HD
FIGURE 2  Blood oxygen level-dependent (BOLD) response to visual stimulation
3.3. Function of the visual cortex
3.3.1 Vascular reactivity 
Vascular brain function of the visual cortex was examined by quantifying alterations 
in BOLD signal in response to visual stimulation. Relative to baseline (i.e., prior to 
the start of the stimulus), there were no significant group differences in changes of 
the average BOLD response for the time to peak, time to baseline and amplitude 
response (Figure 2). 
Fitted average BOLD responses per group relative to baseline (0%). The grey area represents the duration of 
visual stimulation for 20 seconds.  
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Decreased functional connectivity independent of grey matter atrophy in manifest HD compared to controls 
in the medial visual network (green). Significant Family-Wise-Error corrected regions are presented in blue 
overlaid on sagittal, coronal, and transversal slices of Montreal-Neurological-Institue-152 standard T1-
weighted images. Corresponding x-, y-, and z-coordinates are given. 
FIGURE 3  Decreased functional connectivity in medial visual network in manifest HD
3.3.2. Functional connectivity 
Brain function at rest was assessed to detect disease specific functional connectivity 
network changes within the medial visual network and lateral visual network. Decreased 
functional connectivity between the bilateral lingual gyrus, occipital pole, and occipital 
fusiform gyrus and the medial visual network was present in manifest HD compared 
to controls, independent of local grey matter atrophy (Figure 3 and Table 5). No 
differences in functional connectivity with the medial visual network were observed 
between premanifest HD and controls. In addition, there were no group differences in 
lateral visual network functional connectivity. 
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TABLE 5  Decreased functional connectivity in medial visual network in manifest HD




Lingual gyrus (BA 18)
Occipital fusiform gyrus (BA 19/37)
R 12 -86 -14 4.65 0.013
Occipital pole (BA 17) R 12 -98 -6 4.27 0.016
Lingual gyrus (BA 18)
Occipital pole (BA 17)
L 0 -88 -14 4.43 0.015
Occipital fusiform gyrus (BA 19/37) L -14 -90 -16 3.39 0.035
Brain structures in the medial visual network that showed reduced functional connectivity in manifest 
HD compared to controls, independent of physiological noise, age, and gender. Structures were 
identifi ed using the Harvard-Oxford Cortical atlas and cluster tool implemented in FSL. T-statistics and 
corresponding p-values are presented (with a TFCE-family wise corrected p-value < 0.05). For each 
peak voxel x-, y-, and z-coordinates in the MNI-152 standard space image are given.




This study showed that changes in the visual cortex and visual cognitive deficits are 
present in early manifest HD gene carriers, but not in premanifest gene carriers. 
The most pronounced volume loss and cortical thinning in manifest HD was found in 
the associative visual cortices, namely the lingual and fusiform gyri, and lateral occipital 
cortex. Thinning of these cortical regions in the ventral occipital-temporal pathway 
was associated with impaired visual perceptual function (i.e., object recognition tasks), 
suggesting that the neurodegenerative processes in the cortex might play a role in the 
visual deficits found in HD. Interestingly, the primary visual cortex (i.e., pericalcarine 
region and occipital pole) did not show neurodegenerative alterations and neuronal 
activity after visual stimulation also did not differ between groups, which suggest that 
basic visual processing remains preserved in early stages of the disease. 
Our findings that cortical morphology of the primary visual cortex in early HD remained 
unaffected is in line with other studies that did not found atrophy of the primary visual 
cortex in both early and advanced disease stages.4,7,8 Still, our study is the first study 
that provides evidence of preserved basic visual processing function in early stages of 
HD using task-based fMRI that involved a black-and-white checkerboard stimulus. The 
BOLD response to visual stimulation in the primary visual cortex was not different from 
controls in both manifest and premanifest HD, which suggests that incoming stimuli 
from the optic radiation and lateral geniculate nucleus in the thalamus are properly 
received and transmitted by the primary visual cortex to higher visual cortical areas. 
In general, visual stimuli that are received by the primary visual cortex (V1) are then 
projected to the secondary visual cortex (V2), which plays a role in the color perception 
and orientation.46 Then, visual processing proceeds along the associative cortices, 
which can be divided into the ventral occipito-temporal pathway (V4) involved in color 
processing and the recognition of objects and shapes, and the dorsal occipito-parietal 
pathway (V3 and V5), involved in the processing of spatial information and movement 
perception.2,47
Visual scanning, attention, and visual object and shape recognition was measured using 
visuospatial and visual perceptual tasks respectively. Manifest HD gene carriers showed 
impairments in these domains, but only visual perceptual function was associated with 
cortical thickness. The SDMT and TMT were used to measure visuospatial function, as 
these tasks require visual scanning and attention skills 24,26. However, these tasks also 
require a high motor demand and processing speed, which are known to be impaired in 
patients with HD. This might explain that no significant relationship was found between 
visuospatial task performance and thickness of the visual cortex. 
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The secondary visual cortex is located in the cuneus and lingual gyrus, which is involved 
in color discrimination and visual working memory .46 From here, stimuli proceed 
towards the fusiform gyrus and lateral occipital cortex that are known to play a role 
in object and face recognition.48,49 This supports our findings that an impaired visual 
perceptual function in HD was associated with reduced cortical thickness in these 
regions.
Other studies reported similar findings in early manifest HD, such as a reduced nerve 
cell number in the secondary visual cortex,4 volume loss of the occipital lobe,3,20 and 
thinning of the cuneus, lingual gyrus and lateral occipital cortex that were associated 
with worse performance on cognitive tasks involving a visual component.6,7 Contrary 
to our findings, thinning and volume loss of the occipital lobe has also been observed 
in premanifest HD gene carriers.3,7,8,50 This process seems to occur in premanifest HD 
gene carriers that are within a decade or nearer to disease onset, suggesting a sudden 
increase in the rate of thinning around disease onset,7,8 but there are no longitudinal 
studies that can confirm this hypothesis. The difference with our findings might be 
explained by the fact that our cohort consisted of a heterogeneous, relatively young 
group of premanifest HD gene carriers with a median estimated time to disease onset 
of 16 years, based on the survival analysis of Langbehn et al., 2004.51 In contrast, the 
multicenter TRACK-HD and PREDICT-HD studies included large cohorts of premanifest 
HD gene carriers which were divided into close (e.g., below 9 or 10 years) and far (above 
10 to 15 years) from estimated disease onset.3,7,8 Only six premanifest participants in 
our study were within a decade or nearer to disease onset, which might explain the fact 
that we found no differences between controls and premanifest HD. 
Function of the posterior cerebral cortex has been studied less extensively in HD. 
Our study examined brain function at rest, in addition to the assessment of brain 
function during task performance. Resting state fMRI can be used to study functional 
interactions between brain regions at rest (i.e., connectivity), and as no active input is 
required during resting state fMRI, the influence of the disease on task performance 
is not of concern.52,53 Despite normal brain function after visual task stimulation, 
decreased functional connectivity at rest of the lingual and fusiform gyri, and occipital 
pole was found in manifest HD compared to controls within the medial visual network. 
One other study specifically focused on the visual cortex at rest using resting state fMRI 
in manifest HD and found only reduced connectivity in the left fusiform gyrus, despite 
widespread volume loss in the occipital cortex.20 Our findings of reduced functional 
connectivity were also independent of grey matter atrophy in these regions, which 




To improve the understanding of functional alterations in different disease stages, we 
additionally examined brain function at rest in premanifest individuals. Compared to 
controls, we found no differences in functional connectivity for both medial and visual 
networks, which is contrary to a previous study that showed reduced connectivity in the 
right parietal and bilateral visual cortices of the medial visual network in premanifest HD 
gene carriers.52 Although using several methodological approaches, these reductions 
in whole brain functional connectivity in premanifest HD were not detectable over 
time in longitudinal studies.54,55 A possible explanation for these discrepancies can be 
a selection bias, as participants with a faster rate of clinical decline might withdraw 
earlier from the study, leaving a relatively fitter premanifest group for longitudinal 
analyses.54
Still, our study provides evidence of preserved brain function of the primary visual 
cortex at rest and after visual stimulation in manifest HD, but reduced function 
in the ventral occipito-temporal pathway at rest. Structural alterations of the visual 
cortex seem, nevertheless, to be more pronounced and widespread than functional 
alterations in early manifest HD, even extending to the inferior temporal and superior 
parietal cortices. Together with previous studies that additionally found evidence of 
cortical thinning and volume loss in these regions in premanifest HD gene carriers 
that are within a decade to disease onset,3,7,8,50 this implies that structural alterations 
might precede functional alterations in HD.  Future studies with larger sample sizes 
are, however, needed to examine brain function using tasks that involve other visual 
cognitive domains, such as object or facial emotion recognition, or visuomotor 
function. 
A limitation of this study is, that due to the cross-sectional design and our heterogeneous 
group of premanifest HD gene carriers, it remains uncertain how the posterior cerebral 
cortex changes over time. It would be interesting to assess the progression of posterior 
cortical volume loss longitudinally and in addition measure the effect of volume loss 
on changes in neural connectivity. In this way, potential cortical biomarkers can be 
identified that can be used in future clinical trials. Another limitation of this study is 
the relative small sample size of our cohort, which additionally prevents examining the 
role of gender. 
In conclusion, the ventral visual pathway, specifically the lingual and fusiform gyri 
and the lateral occipital cortex, showed most pronounced structural and functional 
alterations in early manifest HD. Our study is the first to provide evidence of preserved 
basic visual function in early disease stages after visual stimulation. Clinically, visual 
perceptual function was impaired and related to reduced cortical thickness of the 
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ventral posterior brain regions. Still, changes in the visual cortex were not detectable 
in our premanifest HD group. 
Our findings suggest that clinical visual deficits in HD are linked to atrophy of the 
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ABSTRACT 
Objective: To investigate microstructure and function of the visual pathway and 
determine clinical correlates in Huntington’s disease (HD) patients. 
Methods: Diffusion tensor-imaging data was acquired of 21 premanifest, 20 manifest 
HD, and 17 healthy controls. To examine the microstructure of white matter pathways, 
mean indices of diffusion parameters were measured along the anterior and posterior 
thalamic radiation tracts using Tract-Based Spatial Statistics (TBSS). Additionally, 
electrical activity of the brain in response to visual stimuli was measured using pattern-
reversal visual-evoked potentials (VEPs). Associations with clinical measures were 
examined in HD gene carriers using univariate linear regression analyses corrected for 
age, gender, and HD group. 
Results: Microstructural alterations in manifest HD were primarily present in the optic 
radiations of posterior brain regions and to a lesser extent in the anterior brain regions. 
Reduced fractional anisotropy, and increased radial and axial diffusivity were associated 
with higher disease burden scores and increased oculomotor impairment in HD gene 
carriers. Radial diffusivity showed the strongest associations with oculomotor function 
and disease burden. Normal latencies of the pattern-reversal VEP were found in HD 
gene carriers compared to controls. Reduced amplitudes of the early components 
were present in premanifest HD and manifest HD, but were not associated with clinical 
measures. 
Conclusion: Altered microstructure of the posterior optic radiation is detectable in 
early manifest HD and is related with disease severity. Our results show that axonal 
degeneration in the occipital lobe occurs early in the disease process, while functional 




Huntington’s disease (HD) is a hereditary, neurodegenerative disorder, characterized by 
a triad of progressive motor disturbances, cognitive decline and behavioral changes.1 
The disease is caused by an abnormal expansion of the CAG (cytosine-adenosine-
guanine) repeat length in the Huntingtin gene on chromosome four.2 Atrophy of the 
striatum is the neuropathological hallmark of the disease due to extensive loss of 
striatal medium-sized spiny neurons.3 As a result, striatal atrophy is thought to be the 
origin of the typical unwanted choreiform movements that occur in patients with HD.3,4 
Neuroimaging studies have shown that striatal atrophy can be detected a decade 
before clinical disease onset in the so-called premanifest phase, and is therefore seen 
as a robust marker to track disease progression.5,6 However, besides the characteristic 
clinical signs of HD, deficits in visual cognition, such as an impaired visuospatial working 
memory or changes in facial emotion recognition have been frequently reported,7 and 
are suggested to originate from posterior cortical degeneration, since pronounced 
reductions in the absolute nerve cell number in the occipital lobe have been found in 
advanced HD patients.8–10
Moreover, in earlier disease stages, volume loss in posterior cortical brain regions is 
present,11–15 and is even associated with worse visual cognitive task performance and 
oculomotor dysfunction.11,12,15 It has therefore been proposed that besides striatal 
atrophy, cortical degeneration also contributes to the clinical phenotype of HD.15
Although there is increasing evidence of the involvement of posterior brain regions in 
the neurodegenerative process of HD, the extent of structural and functional changes 
of the in-vivo pathways to these regions remains unclear. In our study, we aimed to 
gain more insight into the neuropathological involvement of posterior brain regions in 
HD. We therefore assessed white matter diffusion properties and neurophysiological 
measurement of visual-evoked potentials to investigate structural and functional 
alterations of the visual pathway in premanifest and manifest HD gene carriers. 
2. METHODS
2.1. Participants
Fifty-eight participants (21 premanifest HD gene carriers, 20 manifest HD gene 
carriers, and 17 healthy controls) were included in this cross-sectional, observational 
study via the outpatient clinic of the Neurology department at the Leiden University 
Medical Center (LUMC) in the Netherlands. All HD gene carriers had a genetic test 
with ≥ 36 CAG repeats. Spouses and HD gene-negative relatives were recruited as 
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controls. Participants were required to have a normal or corrected-to-normal primary 
visual ability above 0.5 (20/40) on the visual acuity test and no major ophthalmic or 
neurologic co-morbidities. Participants were not included if they were unable to 
undergo MRI scanning (i.e. due to metallic implants, claustrophobia, or pregnancy). 
Patients that participated in an intervention trial were not included in this study. The 
Medical Ethical Committee of the LUMC approved this study and written informed 
consent was obtained from all participants.
Demographic data, including gender, date of birth, age at visit, and years of education, 
was obtained for all participants. Primary visual acuity and the ability to perceive 
color differences were assessed using a visual acuity test and the Ishihara Color Test 
respectively. HD gene carriers were divided into premanifest and manifest HD based 
on the presence of motor signs using the Unified Huntington’s Disease Rating Scale 
(UHDRS) total motor score.16 This scale measures the degree of motor disturbances 
in different domains, such as oculomotor function, gait and postural stability, and the 
presence of choreiform or dystonic movements. A higher score indicates more motor 
impairments. The clinically manifest phase of the disease is defined as an UHDRS – 
total motor score of more than 5, whereas HD gene carriers with a score of 5 or less 
are defined as premanifest individuals. The ocular and saccadic movement items of 
the UHDRS were summed to establish a subdomain score (range 0 – 24) of oculomotor 
function, as described previously.12,17 The disease burden score (age x [CAG repeat 
length – 35.5]) was calculated for all HD gene carriers, in which a higher score reflects 
an increased disease severity.18
2.2. DTI acquisition
Diffusion Tensor Imaging (DTI) data was acquired on a 3-Tesla whole body MRI scanning 
system (Philips Achieva, Best, the Netherlands) using a standard 32-channel head coil. 
A single shot echo-planar DTI sequence was applied with 32 gradient directions and 
a total acquisition time of approximately 8 minutes. The follow scan parameters were 
used: TR = 11.547 ms, TE = 56 ms, FOV = 220 x 220 mm2 with an acquisition matrix of 
112 x 110, 2 mm slice thickness with no gap between slices, flip angle = 90°, voxel size 
= 1.96 x 1.96 x 2.00 mm3, number of slices = 75, b-value = 1000 s/mm2, and halfscan 
factor = 0.61. 
2.3. DTI processing
Diffusion tensor imaging data were preprocessed using the FMRIB’s Diffusion Toolbox 
(FDT) that is implemented in FMRIB’s Software Library (FSL, version 5.0.10, Oxford, 
United Kingdom).19,20 First, images were corrected for distortions caused by eddy 
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currents and motion artifacts. Then, diffusion tensors were fit to the eddy-current 
corrected data resulting in fractional anisotropy (FA), radial diffusivity (RD or l⊥) and 
axial diffusivity (AD or l||) maps. RD was defined as the average of the second and 
third eigenvalues of the diffusion tensor (l2 + l3 / 2), while AD corresponded to the first 
eigenvalue (l1). 
The FA, RD, and AD maps from each participant were further analyzed using voxel-
wise tract-based spatial statistics (TBSS) analysis, part of FSL.21 Here, FA images from all 
participants were nonlinearly registered to a standard space target image (FMRIB58_
FA image) to form an averaged registered FA image. Then, a skeleton of white matter 
was generated by thresholding the averaged FA image, in which only voxels with a 
mean FA value of 0.2 or higher were included. Consequently, this mean FA skeleton 
represents the center of the white matter fibers throughout the whole brain. The 
skeleton projection was then applied to RD, and AD images, to create a separate 
skeleton for each diffusion measure. All data was visually checked for distortions or 
incorrect registration. 
The anterior and posterior thalamic radiations (including the optic radiations) tracts 
were used as a mask of the visual pathway and mean FA, RD, and AD values within this 
mask were extracted. These tracts were identified using the Johns Hopkins University 
white matter tractography atlas implemented in FSL. 
2.4. Visual-evoked potentials (VEP)
Electrical activity of the brain in response to visual stimuli was measured using a pattern-
reversal VEP (Medelec Synergy, Oxford Instruments, version 11.0) at the department of 
Clinical Neurophysiology in the LUMC.
The left and right eyes were stimulated separately in two sessions (a total of four 
sessions), and were then averaged to form one trace per eye. A high-contrast full-field 
black-and-white checkerboard was used that flashed at a frequency of 2 Hz with an 
individual square check size of 0.45 degrees of arc. Participants were seated facing the 
checkerboard screen at a viewing distance of 2 meter in a dark room and were asked to 
fixate their gaze on the center of the screen with one eye covered. The EEG signal was 
recorded using an active mid-occipital (Oz) electrode and referenced to Cz, according 
to the international 10/20 system. A total of 100 trials were recorded. Trials containing 
artifacts were manually removed before further analyses. 
Four major components (N75, P100, N140 and P200) were measured to analyze brain 
activity in the occipital cortex. For each component, the latency was calculated to 
indicate the time from stimulus onset to the component, whereas the amplitude was 
measured from peak to baseline (i.e. peak amplitude) and from peak to peak (i.e. 
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peak-to-peak amplitude), as described in the guidelines of the International Society 
for Clinical Electrophysiology of Vision (ISCEV).22
2.5. Statistics
Group differences in demographic characteristics were analyzed using analysis of 
variance (ANOVA), independent T-test or chi-square test when applicable. Group 
differences between the extracted mean FA, RD, and AD values of the white matter 
tracts of interest were analyzed using ANOVA with Sidak correction to correct for 
multiple comparisons. 
Post-hoc group differences on all diffusion outcome measures were performed using 
the general linear model (GLM) tool implemented in FSL. Age and gender were 
included as covariates in all statistical designs. FSL-randomise was used for voxel-
wise non-permutation testing with 5000 permutations.23 The Threshold-Free Cluster 
Enhancement technique was used, and family wise error was used to correct for 
multiple comparisons across voxels.24
Group differences for all VEP outcome measures were analyzed using Kruskal-Wallis 
test. If this analysis yielded significant results, post-hoc analysis was performed using 
the Mann-Whitney U test.
Separate univariate linear regression analyses were performed in HD gene carriers 
(i.e. both premanifest and manifest HD) to assess the associations between diffusion 
outcome measures and clinical assessments, and between neurophysiological outcome 
measures and clinical assessments. Only outcome measures that showed significant 
group differences compared to controls were included in the regression analyses. Age, 
gender and HD group were included as covariates and entered in one block with the 
predictor variable. The significant threshold was set at a p-value of < 0.05. Statistical 
analyses were performed using the Statistical Package for Social Sciences (SPSS for 
Mac, version 23, SPSS Inc.). 
3. RESULTS
Demographic characteristics for each group are presented in Table 1. Premanifest HD 
gene carriers were younger compared to both controls and manifest HD (F (2,55) = 
10.81, p = 0.026 and p < 0.001 respectively). Manifest HD had a higher disease burden 
score compared to premanifest HD (t (37) = 4.6, p < 0.001). In addition, manifest 
HD had more motor impairments compared to controls and premanifest HD on the 
UHDRS – total motor score (F (2,55) = 48.06, both p < 0.001) and UHDRS - oculomotor 
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score (F (2,55) = 67.00, both p < 0.001). Gender and CAG repeat length did not differ 
between groups.
To study structural integrity of the visual pathway, mean indices of diffusion parameters 
were measured along the anterior and posterior thalamic radiation tracts. Reduced FA 
(F (2,55) = 9.35, p = 0.005), increased RD (F (2,55) = 16.66, p < 0.001) and increased AD 
(F (2,55) = 8.61, p = 0.001) were found in manifest HD compared to controls (Figure 
1A). No differences in diffusion parameters were observed between premanifest HD 
and controls. 
Voxel-wise analysis showed that these reduced FA and increased RD values in manifest 
HD were primarily located posterior in the optic radiation and thalamus (Figure 1B). 
Reduced mean AD was found in the frontal lobe, particularly in the anterior limb of the 
internal capsule and thalamus. 
All diffusivity parameters showed significant associations with clinical assessments 
(Table 2). The UHDRS total motor score, UHDRS oculomotor score and disease burden 
score all showed the strongest association with radial diffusivity, meaning that higher 
clinical scores were correlated with increased radial diffusivity. 
To study functional integrity of the visual pathway, brain activity after visual stimulation 
TABLE 1  Demographic group characteristics
Controls Premanifest HD Manifest HD
N 17 21 20






Gender (m/f) 7/10 11/10 11/9




















Demographic data are showed (mean ± SD (range), except for gender (numbers)). 
Disease burden score was calculated with the formula: age x [CAG repeat length – 35.5] by 
Penney et al., 1997.
CAG = cytosine-adenosine-guanine, UHDRS = Unifi ed Huntington’s Disease Rating Scale. 
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TABLE 2  Correlations between diffusion parameters and clinical assessments in HD gene carriers 
Fractional anisotropy Axial diffusivity Radial diffusivity
R2 βstd p-value R




0.426 -0.517 0.012 0.374 0.605 0.005 0.534 0.634 0.001
UHDRS – 
Oculomotor
0.403 -0.486 0.027 0.316 0.501 0.033 0.474 0.535 0.010
Disease
burden score
0.484 -0.585 0.001 0.347 0.454 0.012 0.583 0.620 < 0.001
Separate univariate linear regression analyses were performed adjusted for age, gender and HD group (i.e. 
premanifest and manifest HD). Standardized Beta coeffi cients (βstd) represent the SD change in diffusion
parameters per every SD increase in the clinical assessments. As age is already included in the disease burden 
score (age x [CAG repeat length  – 35.5] by Penney et al., 1997), these regression analyses were performed 
without age as covariate. Signifi cant p-values < 0.05 are presented in bold.
FIGURE 1  Diffusion parameters
Diffusion parameters measured using tract-based spatial statistics (TBSS) analysis showed microstructural changes in 
manifest HD. A) Fractional anisotropy (FA), radial diffusivity (RD), and axial diffusivity (AD) values within the anterior 
and posterior thalamic radiation tracts are presented per group. Significant differences between manifest HD and 
controls are displayed, * p < 0.05 and ** p ≤ 0.001. B) Voxel-based brain regions that showed significant differences 
in diffusion parameters between manifest HD and controls. Blue: decreased diffusivity in manifest HD compared 
to controls. Red: increased diffusivity in manifest HD compared to controls. Age and gender were included as 
covariates in the statistical model. Regions are overlaid on sagittal, coronal, and transversal slices of a standard 
FMRIB FA image. A family wise error corrected threshold of p < 0.05 was used. 
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was analyzed, using mean peak latencies and amplitudes of four major pattern-reversal 
VEP components (Figure 2 and Table 3).  Four patients with HD had no recognizable 
signal due to motion artifacts and were therefore not included in the analyses. 
Significant lower peak amplitudes of the N75 and P200 components, and reduced 
N75-P100 peak-to-peak amplitude were found in manifest HD compared to controls (U 
= 206, p = 0.011; U = 37, p = 0.025; and U = 65, p = 0.010 respectively). In addition, the 
P200 component was also reduced in premanifest HD compared to controls (U = 66, p 
= 0.014). There were no significant differences between groups in mean peak latencies 
for any component. In addition, there were no significant associations between N75 
and P200 amplitudes and clinical outcome measures (Table 4).
TABLE 2  Correlations between diffusion parameters and clinical assessments in HD gene carriers 
Fractional anisotropy Axial diffusivity Radial diffusivity
R2 βstd p-value R




0.426 -0.517 0.012 0.374 0.605 0.005 0.534 0.634 0.001
UHDRS – 
Oculomotor
0.403 -0.486 0.027 0.316 0.501 0.033 0.474 0.535 0.010
Disease
burden score
0.484 -0.585 0.001 0.347 0.454 0.012 0.583 0.620 < 0.001
Separate univariate linear regression analyses were performed adjusted for age, gender and HD group (i.e. 
premanifest and manifest HD). Standardized Beta coeffi cients (βstd) represent the SD change in diffusion
parameters per every SD increase in the clinical assessments. As age is already included in the disease burden 
score (age x [CAG repeat length  – 35.5] by Penney et al., 1997), these regression analyses were performed 
without age as covariate. Signifi cant p-values < 0.05 are presented in bold.
Mean pattern reversal visual evoked potentials per group measured from electrode Oz after left and right eye 
stimulation separately. In the manifest HD group, four participants had no recognizable signal due to motions 
artifacts and were not included in further analyses. The four major components, N75, P100, N140, and P200 
are displayed, showing significant decreased N75 and P200 amplitudes in manifest HD compared to controls 
and significant decreased P200 amplitude in premanifest HD compared to controls.
FIGURE 2  Visual evoked potentials 
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This study revealed alterations in structural and functional integrity of the visual pathway 
in manifest HD compared to controls. Altered microstructure was primarily present in 
the optic radiations of posterior brain regions and to a lesser extent in the anterior 
brain regions. In addition, reduced amplitudes with normal latencies were observed 
in response to visual stimulation using pattern-reversal visual evoked potentials as a 
measure of functional integrity. 
Diffusion markers are thought to reflect the structural integrity of neural tracts in the 
brain by detecting the extent and coherence of water diffusion.25,26 Our diffusion 
tensor imaging analyses showed reduced axial diffusivity (i.e., axonal degeneration) 
in manifest HD compared to controls in the anterior limb of the internal capsule in the 
frontal lobe. In contrast, reduced fractional anisotropy (i.e., overall fiber density) and 
increased radial diffusivity (i.e. axonal myelination and diameter) were observed more 
widespread in fibers located in the thalamus and optic radiations in the occipital lobe. 
Our findings suggest that neurodegeneration of the visual pathway predominantly 
occurs in fibers that project to the posterior cerebral cortex due to loss of axonal 
fibers, which is in line with postmortem studies that observed neuronal cell loss and a 
reduction of axonal connections in the occipital lobe.8,9
Microstructural changes in tracts to the prefrontal cortex, sensorimotor cortex and 
corpus callosum were found in previous studies that assessed cortico-striatal and deep 
white matter pathways across the entire brain in patients with HD.27 Diffusivity changes 
of posterior cerebral tracts have also been found in HD, particularly located in the 
frontal white matter projections to the occipital lobe.28–30 In these studies, however, 
alterations in the occipital cortex have not been the primary focus of interest. 
Although striatal atrophy can be detected in premanifest HD a decade before the 
onset of motor symptoms,5 we did not detect microstructural white matter changes 
in our group of premanifest HD gene carriers. It is possible that axonal loss in the 
white matter tracts to the cortex only occurs in manifest disease stages and that 
microstructural changes during premanifest stages are more variable and dynamic over 
time.31 In contrast, a longitudinal study did observe changes in diffusivity over time in 
the fronto-occipital tracts in premanifest HD, most prominently in the individuals close 
to estimated disease onset.28 However, the premanifest HD group in this study already 
showed motor symptoms, suggesting that the distinction between manifest and 
premanifest was based on different criteria than our study, making direct comparisons 
difficult.  
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We additionally examined correlations between clinical functional assessments and 
diffusion outcome measures. The strongest association was found between disease 
burden score and radial diffusivity, indicating that higher disease severity is correlated 
with increased axonal fiber loss. This finding suggests that diffusion measurements 
within the visual pathway can be used as a marker of disease severity.
While diffusion markers reflect the structural integrity of white matter tracts, visual-
evoked potentials are frequently used to measure the functional integrity of the 
retinal-cortical pathway. The neural generators of the main components of the evoked 
potential wave (before 150 milliseconds) are considered to originate in the primary 
visual cortex, while late components (after 150 milliseconds) reflect activity in the 
associative occipital and parietal cortical areas.32 In our study, normal latencies of both 
main and late components were observed in HD gene carriers, which imply preserved 
pre-chiasmatic function and normal conduction velocities to the primary cortex in 
early disease stages, since prolonged latencies are generally found in demyelination 
disorders.33 We did observe reduced amplitudes for both main and late components 
(N75 and P200 respectively) in manifest HD compared to controls. Therefore, in 
addition to our findings of altered structural integrity, we provide evidence of 
changed functional integrity in the optic tracts in patients with HD as well. There are 
no previous studies that examined both visual-evoked potentials and microstructural 
brain changes of the visual pathway in HD. In line with our findings, several previous 
neurophysiological studies also reported reduced amplitudes in HD patients with 
normal latencies of the main components in response to light flashes or checkerboard 
pattern-reversal stimulation.34–37 Other pattern-reversal VEP studies, however, report 
no significant differences in both amplitudes and latencies of the main components 
in manifest HD compared to controls.38,39 Nonetheless, these studies were conducted 
before genetic testing became available and different criteria were used to define 
patients with HD. Recent neurophysiological studies focused on the late components 
to investigate higher level visual processing using more challenging visual processing 
tasks, such as a word recognition task,40 attentional categorization tasks,41,42 or a 
facial emotion expression task.37 These studies all found reduced amplitudes for late 
components.37,41,42 Since reduced main component amplitudes are frequently reported 
in manifest HD, it is hypothesized that early visual processing is already impaired, 
thus making subsequent visual processing more difficult.37 We did observe reduced 
amplitudes in main and late components in manifest HD, but future studies with a 




In our study, reduced amplitudes in premanifest HD gene carriers were additionally 
observed for the late component (P200). Only two other studies assessed the response 
to visual-evoked potentials in premanifest HD gene carriers, before the onset of 
overt motor symptoms.41,42 One study also observed reduced amplitudes of the late 
component in premanifest HD in response to a visual attentional processing task, 
while another study did not find neurophysiological impairments in early perceptual 
processing in premanifest HD.41,42 As the latter study involved more complex stimulation 
tasks, a direct comparison to our pattern-reversal VEP is not possible.
We did not observe a significant relationship between neurophysiological measures 
and clinical assessments in HD gene carriers, possibly because of the heterogeneity 
seen in the waveforms of all participants or the effects of gender and age on evoked-
potential components.43 To address the issue of heterogeneity of VEP responses, 
longitudinal studies could be performed with larger sample sizes to measure individual 
change over time as a marker for disease progression. 
This study examined the microstructure of regional white matter tracts of the visual 
pathway and the response on pattern-reversal visual-evoked potentials in premanifest 
and manifest HD gene carriers. 
In conclusion, changes in structural integrity were most prominently present in 
the thalamus and optic radiations in early manifest HD, and were associated with 
functional scores, such as disease burden and oculomotor scores, suggesting that 
microstructural changes in the optic tracts are related with clinical disease severity. 
In addition, reduced amplitudes with normal latencies were observed in response to 
visual stimulation in manifest HD patients.
Our findings show that the posterior brain regions undergo structural alterations 
in early stages of the neuropathological process in HD. These data provide more 
knowledge on the pathophysiological processes in the cerebral cortex and might aid 
in the identification of other regions than the striatum that can be used as a potential 
marker of disease severity for future clinical trials.
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Although promising disease-modifying drugs are currently under investigation, there 
are unfortunately no effective treatment options available to date to delay or prevent 
the clinical onset of Huntington’s disease (HD). Therefore, more knowledge about the 
pathophysiologic mechanisms in HD is still needed. Magnetic Resonance Imaging 
(MRI) is a non-invasive and objective approach to study the human brain. In the last 
decades, the increased use of brain imaging in HD research made it possible to better 
understand the natural course of the disease. MRI research in HD has been particularly 
focused on evaluating the onset and rate of striatal atrophy but the contribution of 
cortical changes remains less understood. 
The aim of this thesis was therefore to investigate alterations in the cerebral cortex in 
HD gene carriers and assess the relationships with clinical signs of HD. Neuroimaging, 
neurophysiological, and cognitive measurements were used to examine structure and 
function of the cerebral cortex in premanifest and early manifest HD gene carriers. In 
this chapter, the main findings described in this thesis are summarized, discussed and 
recommendations for future research are provided. 
SUMMARY 
Brain structure
Macrostructural changes of the cerebral cortex are generally examined with volumetric 
MRI using different methodological techniques. Voxel-based morphometry (VBM) 
analysis is such a neuroimaging technique that is frequently used in brain research.1,2 
VBM involves a voxel-by-voxel comparison of the local grey matter density across the 
entire brain between different groups, therefore making it a sensitive approach to 
detect disease-specific cortical changes in regional volume.1 
VBM analysis in our cohort of 79 early manifest HD gene carriers and 30 healthy 
controls showed that grey matter volume loss in HD is located in the sensorimotor 
cortex in the frontal and parietal lobes, and the associative visual cortices in the 
temporal and occipital lobes (chapter 2). In a smaller cohort of manifest HD gene 
carriers, consistent grey matter volume reductions were described in the sensorimotor 
and lateral occipital cortices (chapter 3). On the contrary, premanifest HD gene carriers 
only showed limited volume changes compared to controls in a small region involving 
the insular cortex and parietal operculum, near the sensorimotor cortex (chapter 3), 
which is consistent with previous studies.3,4 The findings from our studies suggest that 
there is an decrease in cortical volume somewhere during or close after clinical disease 
onset, however, future longitudinal analysis is warranted to investigate this hypothesis. 
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Voxel-based methods measure densities per voxel separately within a brain region. 
Opposed to this technique, network-based analysis provides information about inter-
regional changes in grey matter voxels.5 Structural covariance networks of spatially 
independent grey matter regions were identified based on the co-variation of grey 
matter using independent component analysis (chapter 3). This technique is commonly 
used in resting-state functional MRI (fMRI) studies to assess functional connectivity.6 
When used on volumetric MRI, this technique defines spatial components based on the 
co-variation of grey matter patterns among an entire cohort, which can be expressed 
in a network integrity score.6 Network integrity is described as the strength of an 
individuals’ expression in an anatomical network and indirectly provides information 
regarding network-based grey matter alterations. 
Structural covariance networks involving the precuneous, anterior cingulate, 
sensorimotor and parahippocampal cortices showed reductions in network integrity 
for both premanifest and manifest HD compared to controls (chapter 3). This indicates 
that this novel technique is sensitive to detect early grey matter changes in the cerebral 
cortex. The affected regions are generally involved in the planning, control, and 
execution of voluntary movements, visuospatial processing, and cognitive attention 
and control.7,8 Domains that were all impaired in manifest HD (chapter 3, 5, and 6). 
However, since the grey matter changes were already found in premanifest HD gene 
carriers, our results suggest that cortical changes occur prior to clinical disease onset, 
in addition to striatal atrophy.9 
Interestingly, another network comprising of the cuneus, lateral occipital cortex 
and lingual gyrus only showed decreased network integrity in manifest HD and not 
in premanifest HD (chapter 3), which indicates that there is an increase in cortical 
alterations from the premanifest phase to the manifest phase, in particular in the 
posterior cerebral cortex (chapter 5). 
Subtle local volumetric differences between groups might not be detected when 
assessing global volumes. Measuring the thickness of the cortex with an automated 
method that parcellates the gyri and sulci into many small distinct regions is a frequently 
used method to distinguish subtle group differences.10,11 
Rosas et al. were the first that used this technique in a small cohort of HD gene carriers 
to evaluate the degree of cortical thinning and reported that the earliest and most 
severely affected regions in HD are the primary motor, sensory, and visual cortical 
regions (including the superior parietal and frontal cortices).12,13 We conducted a study 
in 74 HD patients in early disease stages (HD stage 1 and 2) and observed cortical 
thinning throughout the entire brain in HD stage 2 patients, with most severe thinning 
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in the parietal and occipital lobes (chapter 4). Our findings are therefore consistent 
with previous studies reporting relative sparing of the frontal and parietal brain regions 
early in the disease.10,13,14 Still, in our study, HD patients in the most early clinical disease 
stage (HD stage 1) only showed a trend towards thinning of parietal and occipital 
cortices, while extensive striatal atrophy was observed in both disease stages, with up 
to 35% volume loss of the caudate nucleus. This implies that the rate of striatal atrophy 
stabilizes after clinical disease onset, whereas the degree of cortical atrophy increases. 
More interestingly, no associations were found between cortical thinning and striatal 
volume loss, suggesting that striatal and cortical degeneration might occur as two 
separate neurodegenerative processes (chapter 4). 
To better understand the extent of neurodegeneration in the posterior cerebral 
cortex, we conducted a cross-sectional observational study with the visual cortex 
as region of interest. Volumetric MRI was performed to examine macrostructural 
alterations of the visual cortex (chapter 6) and diffusion tensor imaging (DTI) was 
used to assess the microstructure of pathways towards the visual cortex (chapter 7). 
Microstructural characteristics of fiber tracts in the brain can generally be examined 
based on the diffusion properties of water molecules in tissues.15 It is proposed that 
changes in diffusion parameters in HD can be explained by axonal degeneration or 
demyelination,16 although the specific cellular mechanism remains unclear. 
Measurement of diffusion parameters along the anterior and posterior thalamic 
radiation tracts in manifest HD gene carriers showed signs of axonal fiber loss in the 
thalamus and optic radiation tract in the occipital lobe, and to a lesser degree in 
anterior fiber tracts in the frontal lobe (chapter 7). Remarkably, volumetric analysis of 
visual cortical regions showed reduced volumes and cortical thinning in the associative 
visual cortex, while the primary visual cortex did not show signs of atrophy (chapter 
6). This latter finding is consistent with previous studies that report early involvement 
of associative visual brain regions, such as the fusiform gyrus, lingual gyrus, lateral 
occipital cortex, and cuneus in manifest HD gene carriers (chapter 5). Premanifest HD 
gene carriers, however, did not show any macro- or microstructural alterations in the 
posterior cerebral cortex (chapter 6 and 7), again suggesting that neurodegenerative 
changes in the posterior brain regions occur after clinical disease onset. 
Brain function
The structural imaging analyses described in this thesis showed that the posterior 
cerebral cortex is affected in early manifest stages. Besides brain structure, we 
examined brain function in premanifest and manifest HD gene carriers compared to 
healthy controls (chapter 6). 
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In general, brain function can be measured using the different magnetic properties of 
oxygenated and deoxygenated blood. Activated neurons demand an increased use of 
energy leading to an increased blood flow in the surrounding microvasculature, which 
results in higher levels of oxygenated hemoglobin.17 The change in oxygenated and 
deoxygenated blood levels causes alterations in MRI signal intensity, which is referred 
to as the Blood Oxygenation Level Dependent (BOLD) signal. Therefore, this regional 
hemodynamic response indirectly reflects neuronal activity in response to a task or 
stimulus, or at rest when measuring spontaneous fluctuations in the BOLD signal 
within predefined resting-state networks.17,18 After visual stimulation using a black-and-
white checkerboard stimulus, neuronal activity of the primary visual cortex was not 
different in premanifest and manifest HD gene carriers compared to controls (chapter 
6). However, decreased functional connectivity at rest was present in the associative 
visual cortex (primarily the lingual and fusiform gyri) in manifest HD gene carriers. Our 
findings indicate preserved basic visual processing function and altered brain function 
in regions involved in higher level visual processing.
Besides the fact that we did not find structural changes of the posterior cerebral 
cortex in premanifest HD gene carriers, brain function also remained unaffected in this 
disease stage (chapter 6), supporting our suggestion that alterations (both structurally 
and functionally) in the posterior cerebral cortex only occur in the manifest disease 
stage. 
Another approach to examine brain function is measurement of pattern-reversal 
visual-evoked potentials (VEP). A VEP comprises of a high contrast black-and-white 
checkerboard that is used as visual stimulus and the neurophysiological evoked signal 
is recorded with electrodes spanning the occipital region. Amplitudes (height) and 
latencies (length) of early components (waves) are usually considered to originate in 
the primary visual cortex, while late responses are thought to reflect brain activity in the 
associative visual cortical areas.19
Normal latencies were observed in premanifest and manifest HD gene carriers, 
indicating a preserved pre-chiasmatic function and normal conduction velocities 
towards and in the primary visual cortex (chapter 7). The reduced amplitudes that were 
found in HD gene carriers could suggest that axonal loss in the visual pathways due to 
neurodegeneration causes a reduction in signal intensity. However, we did not observe 
a relationship between the evoked potential measurements and clinical assessments 
in HD gene carriers, which might be explained by the heterogeneity in waveforms that 
is commonly seen due to the effects of age and gender.20
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Clinical features
The clinical diagnosis of HD is based on the presence of motor symptoms which are 
measured using the total motor score of the Unified Huntington’s Disease Rating 
Scale.21 For this scale, motor symptoms can be divided in separate domains such as 
chorea, dystonia, gait disturbances, rigidity, and oculomotor dysfunction, with higher 
scores indicating more dysfunction.21,22 
We related the clinical motor phenotype of 79 manifest HD gene carriers to changes 
in grey matter brain regions (chapter 2). Higher chorea scores were associated with 
volume loss of the striatum and pallidum, whereas higher eye movement scores 
were related with cortical volume loss in occipital regions. The lack of relationships 
between other motor symptoms, such as dystonia and gait disturbances, and changes 
in subcortical or cortical volumes can be explained by the fact that this cohort of early 
manifest HD gene carriers scored relatively low on these items. This is not unexpected, 
since dystonia, hypokinesia and related balance problems are often seen in more 
advanced stages and our cohort consisted of early stage manifest HD gene carriers.22,23
Increased motor symptoms in HD gene carriers were also associated with reduced 
network integrity scores in the structural covariance network comprising of the striatum, 
precuneous, and anterior cingulate cortex (chapter 3), regions that are known to be 
involved in motor planning and execution.8 
Besides motor symptoms are visual processing deficits also frequently reported in 
HD.24–26 A review of the current literature showed that impairments are present in 
several visual cognitive domains, such as visual object perception, facial emotion 
recognition, visuospatial processing, and working memory, while visual hallucinations 
and ophthalmic disorders are rarely described in HD (chapter 5). Studies have 
unfortunately used heterogeneous cognitive test batteries to measure visual cognitive 
function, making direct comparisons between study findings difficult. 
In our study, we used specific cognitive tasks with a large visual component that have 
been used previously and observed impaired visual object perception and visuospatial 
function in manifest HD gene carriers (chapter 6). However, only worse performance on 
visual perceptual tasks was related with reduced cortical thickness of parieto-occipital 
brain regions. These visual perceptual tasks required minimal motor involvement and 





This thesis provides evidence for distinct changes in cortical brain structure and 
brain function in early symptomatic HD disease stages. Although striatal atrophy is 
more extensively present in HD, changes in the cerebral cortex can also be detected 
in the pre-symptomatic stage. Different methodological approaches used in our 
studies all showed a consistent pattern of cortical atrophy making volumetric MRI a 
reliable and effective tool to assess early in-vivo cortical brain changes, even in a rare 
neurodegenerative disorder such as HD. Voxel-based morphometry analyses, structural 
covariance network analysis, and cortical thickness analyses all revealed signs of 
cortical atrophy in manifest HD gene carriers located in the precuneous, sensorimotor 
cortex, secondary and associative visual cortex, and anterior cingulate cortex. In 
premanifest HD gene carriers, cortical atrophy was limited to the precuneous and 
sensorimotor cortex. It seems that striatal volume loss stabilizes after clinical disease 
onset, whereas cortical atrophy becomes more pronounced. Our findings additionally 
imply that cortical atrophy occurs simultaneous with the onset of striatal atrophy as 
an independent neurodegenerative process, since the presence of cortical thinning in 
HD gene carriers was not related with striatal volume loss, and cortical changes were 
already observed in premanifest HD gene carriers close to estimated disease onset. 
Still, cortical changes seem to be limited to the sensorimotor areas in premanifest HD, 
whereas manifest HD gene carriers showed more widespread cortical alterations, with 
the posterior cerebral cortex as main affected brain region. 
The findings of this thesis further suggest that cortical degeneration plays an important 
role in the presence of clinical features of HD, such as oculomotor dysfunction and 
visual cognitive processing deficits, while the severity of chorea, the most recognized 
clinical symptom in HD, is related to striatal volume loss. 
We additionally examined brain function in HD using functional neuroimaging and 
neuro-physiological measurements, which showed that basic visual function remains 
preserved, even in manifest disease stages. The associative visual cortex did show 
changes in brain activity at rest in manifest HD gene carriers, which is consistent with 
our findings of impaired higher level visual cognitive functioning.  The structural and 
functional neurodegenerative changes of the posterior cerebral cortex seems to 
originate in the associative visual cortices in the parietal, temporal and occipital lobes, 
with sparing of the primary visual cortex in the early manifest stages. Nevertheless, 
functional alterations of the higher-level visual cortex appear to be less pronounced 
and widespread than structural changes, which even extend to the inferior temporal 
and superior parietal cortices. Based on these findings, we can therefore conclude that 
structural cortical alterations contribute to the clinical signs of HD and likely precede 
functional brain changes in early HD.
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IMPLICATIONS AND FUTURE PERSPECTIVES 
Striatal atrophy is the hallmark of the disease and is linked to main clinical features of 
HD such as choreiform movements. Indeed, extensive volume loss was observed early 
in the disease, but the influence of cortical changes on other clinical signs that occur 
in HD should not be overlooked.
Our results demonstrate that volume loss and thinning of the cerebral cortex, especially 
the posterior brain regions, is detectable in early manifest stages and contributes to the 
presence of specific motor signs and cognitive impairments. We believe that clinical 
intervention trials could therefore benefit from using cortical volumes as outcome 
measures to assess treatment efficacy or disease progression, instead of using striatal 
volumes as outcome measure alone.
We described deficits in several visual cognitive domains, such as visual perceptual 
dysfunction and an impaired visual scanning and attention. The awareness of visual 
stimuli and processing of visual information is important because it is needed in daily 
life, for example when driving a car, during walking and in communication with others. 
Moreover, visual perceptual deficits might negatively impact complex cognitive task 
performance. While these higher-level visual processing deficits in HD are not well-
recognized clinical signs of HD, it is remarkable that early involvement of the cerebral 
cortex seems to originate in the associative visual cortices, the regions that are 
generally involved in higher-level processing.
This thesis focused on the pattern of cortical changes in HD and the relation with 
motor and cognitive symptoms. Still, it is also important to investigate the underlying 
brain changes of behavioral symptoms. There are only limited studies available that 
assessed the neuronal correlates of behavioral changes in HD,27,28 which is surprising 
since irritability, apathy, and mood disturbances are frequently reported signs in HD.29 
The presence of apathy in HD seems to be related to atrophy of the thalamus,27 while 
depressive symptoms were associated with smaller volumes of the cingulate cortex.28 
Novel disease-modifying therapeutic agents, such as huntingtin lowering drugs, are 
currently under development and could be promising for the treatment of HD. The 
study design of large multicenter longitudinal clinical trials that examine the efficacy 
of such drugs should therefore make use of structural and functional MRI for the 
assessment of both subcortical and cortical structure and function. In addition, an 
extensive cognitive test battery including visual cognitive tasks can be used to measure 
improvement of cognitive functioning. We recommend including visual cognitive tasks 
that are independent of other cognitive or motor processes, such as the Visual Object 
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and Space Perception (VOSP) tasks, in the standard cognitive battery. 
Since atrophy of the posterior cerebral cortex, and in particular the visual cortex, seems 
to occur early in the disease, we also suggest to include volumetric assessments of the 
visual cortex as outcome measure in clinical intervention trials, in addition to the more 
standard measurements of striatal volume. 
Future observational studies are continuously necessary to better understand the 
pathophysiologic mechanisms of the disease and the relationship with clinical signs. 
For a better understanding of brain function in HD, and in particular to further 
investigate impairments in higher-level visual processing, functional MRI using more 
complex visual processing tasks should be performed in future trials. In addition, it 
would be interesting to examine simultaneous recordings of visual-evoked potentials 
with functional MRI for high temporal and spatial resolution.30,31 This way, the neural 
correlates of the evoked response can be better interpreted, which provides more 
information about functional brain changes in the posterior cerebral cortex in HD. 
Especially large groups of premanifest HD gene carriers (divided based on the 
estimated time to clinical diagnosis) should be observed over time, since this group 
can have considerable benefit from disease-modifying drugs.
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De ziekte van Huntington (Huntington’s disease, HD) is een zeldzame autosomale 
dominante neurodegeneratieve aandoening. De ziekte wordt veroorzaakt door een 
abnormale CAG (cytosine-adenine-guanine) expansie in het huntingtine gen op 
chromosoom 4, coderend voor het huntingtine eiwit. Hoewel de exacte functie van het 
normale huntingine eiwit niet geheel bekend is, is het eiwit betrokken bij de embryonale 
ontwikkeling en speelt het een belangrijke rol bij axonaal transport, regulatie van 
gentranscriptie en overleven van zenuwcellen. Het afwijkende huntingtine eiwit bij 
HD aggregeert in verschillende delen van zenuwcellen en veroorzaakt progressieve 
hersenschade. 
In Nederland zijn er ongeveer 1.700 mensen met genetisch bevestigd HD en zijn er 
6.000 tot 9.000 mensen potentieel drager van de genmutatie die zich nog niet hebben 
laten testen. 
Klinisch kenmerkt de ziekte zich door een progressief beloop, zich uitend in 
bewegingsstoornissen (chorea, dystonie, rigiditeit, balansstoornissen), cognitieve 
achteruitgang (executieve functiestoornissen, geheugenstoornissen), en 
gedragsveranderingen (depressie, irritatie, apathie, en obsessief-compulsieve 
stoornissen). Hoewel symptomen tussen patiënten kunnen variëren in aard en ernst, 
en psychiatrische of cognitieve klachten al vroeg aanwezig kunnen zijn, wordt de 
ziekte gedefinieerd als klinisch manifest zodra er motorische symptomen zichtbaar 
zijn. De ziekte begint meestal rond een leeftijd van 30 tot 50 jaar met een gemiddelde 
ziekteduur van 17 tot 20 jaar. Ondanks de ontdekking van de chromosomale lokalisatie 
in 1983 en de specifieke genmutatie in 1993, is er momenteel nog geen genezing of 
remming van het ziekteproces mogelijk. De symptomatische behandeling is gericht 
op het verbeteren van de kwaliteit van leven van de patiënt en naasten en bestaat vaak 
uit medicamenteuze behandeling in combinatie met psychologische en paramedische 
ondersteuning. 
Magnetic resonance imaging (MRI) is een niet-invasieve en objectieve methode om 
in-vivo veranderingen in hersenstructuur en -functie te onderzoeken. Eerdere MRI-
studies in HD hebben aangetoond dat volume verlies in het striatum, het belangrijkste 
neuropathologische kenmerk van HD, al aantoonbaar is in de premanifeste fase, de 
fase wanneer er nog geen klinische motorische symptomen aanwezig zijn. Naast atrofie 
in het striatum zijn er ook aanwijzingen voor vroege veranderingen in de cerebrale 
cortex, maar dit is minder uitgebreid onderzocht (hoofdstuk 1). 
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Het doel van dit proefschrift was de neurodegeneratieve veranderingen in de cerebrale 
cortex in kaart te brengen in zowel de premanifeste als manifeste fase van de ziekte 
van Huntington. Met behulp van verschillende MRI-maten en neurofysiologisch 
onderzoek bieden wij meer inzicht in de structuur en functie van de hersenen in 
genmutatiedragers met HD ten opzichte van gezonde controles. Daarnaast hebben 
wij onderzocht of de mate van cerebrale atrofie in HD gerelateerd is aan stoornissen 
in de motoriek en cognitie. 
Macrostructurele veranderingen in het volume van de cortex kunnen onderzocht 
worden middels diverse methodologische technieken. Standaard volume analyses 
zijn uitgevoerd met behulp van structurele T1 MRI-scans in een cohort van 79 HD 
patiënten in een vroeg stadium van de ziekte en 30 gezonde controles (hoofdstuk 
2). Dit onderzoek toonde aan dat grijze stof veranderingen zichtbaar zijn in de 
somatosensible en motorische cortex in de frontoparietal kwabben, en in de 
associatieve visuele cortex in de temporo-occipitaal kwabben. Een toename van 
chorea was geassocieerd met een afname in volume van het striatum en pallidum, 
terwijl een toename van oogbewegingsstoornissen was gerelateerd aan afname in 
volume in corticale gebieden in de occipitale kwab. Dystonie en balansstoornissen 
waren niet gerelateerd aan volume verlies. Dit kan verklaard worden door het feit dat 
dystonie, hypokinesie en daaraan gerelateerde balansstoornissen vaker aanwezig zijn 
in meer vergevorderde stadia van de ziekte, terwijl ons cohort bestond uit patiënten 
in een vroeg ziektestadium. 
Netwerkanalyse is een nieuwe methode om volume veranderingen in de hersenen 
te bestuderen en kijkt in tegenstelling tot de standaard volume analyse niet op 
regionaal niveau, maar naar interregionale hersengebieden. Structurele netwerken zijn 
opgebouwd uit hersengebieden die overeenkomsten in structuur vertonen, waardoor 
men meer inzicht kan krijgen in ziekte-specifieke veranderingen in de hersenen. 
Netwerken bestaande uit de precuneus, cortex cingularis anterior, somatosensibele 
cortex en motorische cortex, lieten een verminderde integriteit zien in premanifest HD 
(n=30) en manifest HD (n=30) ten opzichte van gezonde controles (n=30) (hoofdstuk 
3). Verminderde netwerk integriteit van het visuele netwerk (cuneus, gyrus lingualis, 
cortex occipitalis lateralis) was alleen aanwezig in manifest HD en niet in premanifest 
HD. Dit betekent dat de overgang van de premanifest naar de manifeste fase wordt 




Globaal dagelijks functioneren wordt in HD onderzoek gemeten middels de totale 
functionele capaciteit (TFC) score. Op basis van deze score kunnen patiënten in de 
manifeste fase van de ziekte worden ingedeeld in verschillende ziektestadia, waarbij 
stadia 1 (HD1) en 2 (HD2) de vroege stadia zijn, en stadia 4 (HD4) en 5 (HD5) de meest 
gevorderde stadia. 
In onze studie met 18 gezonde controles, 31 HD1 patiënten en 43 HD2 patiënten was in 
beide ziektestadia reeds uitgebreid volume verlies in het striatum aanwezig, met name 
in de nucleus caudatus (hoofdstuk 4). In vergelijking met gezonde controles was er een 
afname in volume van de nucleus caudatus met 31.1% en 31.4% voor respectievelijk 
HD1 en HD2 patiënten. Daarnaast toonde analyse van de corticale dikte een afname 
in de gemiddelde dikte van alle hersenkwabben in HD2 patiënten, met de grootste 
reductie in corticale dikte in de pariëtale en occipitale kwabben. HD1 patiënten lieten 
echter geen veranderingen in corticale dikte zien. In de gecombineerde HD1 en HD2 
groep was er tevens geen associatie aantoonbaar tussen de mate van atrofie in het 
striatum en de cortex. Deze bevindingen suggereren dat degeneratie van het striatum 
onafhankelijk is van corticale degeneratie en dat er sprake is van twee afzonderlijke 
neurodegeneratieve processen. 
Een overzicht van de bestaande literatuur toonde aan dat volumeveranderingen in de 
posterior cerebrale cortex al vroeg in het ziekte proces ontstaan terwijl fronto-temporale 
hersengebieden relatief gespaard blijven (hoofdstuk 5). Neuropathologische studies 
hebben aangetoond dat er specifiek verlies is van neuronen in het visuele systeem 
in het posterieure deel van de hersenen. Dit wordt bevestigd door MRI-studies, die 
uitgebreide atrofie en verminderde hersenfunctie in de posterior cerebrale cortex in 
HD laten zien, met name in de cuneus, gyrus lingualis en gyrus fusiformis. 
Recente studies tonen tevens aan dat stoornissen van het visuele systeem frequent 
voorkomen in patiënten met HD, naast de veelvoorkomende symptomen zoals 
stoornissen in de motoriek, cognitieve achteruitgang en gedragsproblemen. Deze 
visuele stoornissen kunnen aanwezig zijn in verschillende ziektestadia en bestaan uit 
visuomotor en visuospatiële dysfunctie, gestoorde visuele attentie en stoornissen in 
het herkennen van visuele objecten.
Het visuele systeem in de hersenen is echter bij patiënten met HD niet eerder 
systematisch onderzocht. Daarom hebben wij een exploratieve, observationele 
studie uitgevoerd in 18 gezonde controles, 22 premanifest HD en 22 manifest HD om 
meer inzicht te krijgen in de structurele en functionele veranderingen van het visuele 
systeem. Uitkomsten van structurele en functionele MRI, neurofysiologisch onderzoek 
en visuele cognitieve neuropsychologische taken zijn verzameld en de bevindingen 
van deze studie zijn besproken in hoofdstukken 6 en 7. 
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Volume verlies en afname in corticale dikte in manifest HD was aanwezig in de 
secundaire visuele cortex en associatieve visuele cortex en niet in de primaire 
visuele cortex. Daarnaast was afname in corticale dikte in de associatieve visuele 
cortex geassocieerd met een verminderde visuele object perceptie. Structurele 
integriteit van de axonenbundels in de vezelbanen naar de visuele cortex werden 
gemeten met behulp van Diffusion Tensor Imaging (DTI). In manifest HD waren 
aangedane vezelbanen met name gelokaliseerd naar de thalamus en radiatio optica 
in de occipitaal kwab. Neurofysiologisch onderzoek middels Visual-Evoked Potentials 
(VEP) liet in premanifest en manifest HD normale geleidingssnelheden (latenties) 
maar lagere signaalintensiteiten (amplituden) zien na visuele stimulatie. DTI en VEP-
onderzoek wijst dus op tekenen van axonale schade in de banen naar de visuele cortex 
in patiënten met HD.
Een opvallende bevinding was dat in alle groepen een normale neuronale activiteit 
van de primaire visuele cortex werd gemeten na visuele stimulatie middels functionele 
MRI, terwijl er afgenomen neuronale activiteit in manifest HD werd waargenomen in de 
associatieve visuele cortex in rust. De resultaten uit deze studie wijzen derhalve op een 
normale basale visuele functie ondanks tekenen van axonale schade in de vezelbanen 
naar de visuele cortex en een gestoorde visuele aandacht en object perceptie in HD 
patiënten. 
Tot slot worden de belangrijkste bevindingen en implicaties voor toekomstige studies 
besproken in hoofdstuk 8. Samenvattend laten de studies beschreven in dit proefschrift 
zien dat er naast uitgebreide atrofie van het striatum ook corticale atrofie in vroege 
ziekte stadia kan worden aangetoond met behulp van verschillende methodologische 
technieken. Corticale atrofie lijkt met name gelokaliseerd in de somatosensibele 
en motorische cortex in de vroege (pre)klinische ziektestadia, waarna atrofie in het 
posterieure deel van de cortex meer uitgesproken wordt. Corticale degeneratie blijkt 
daarnaast ook bij te dragen aan klinische symptomen van HD, zoals oculomotor 
stoornissen en visueel cognitieve stoornissen. Systematisch onderzoek van de 
posterior cerebrale cortex toonde tevens dat neurodegeneratieve veranderingen in 
manifest HD zich met name lokaliseren in de associatieve visuele cortex waarbij de 
functie en structuur van de primair visuele cortex intact blijft. 
Naar aanleiding van onze bevindingen vinden wij dat corticaal volume gebruikt moet 
worden als uitkomstmaat in klinische HD studies (zoals observationeel en placebo-
gecontroleerd medicatie onderzoek), mede omdat de cortex in belangrijke mate 
bijdraagt aan specifieke stoornissen in de motoriek en cognitie. Naast motorische 
symptomen kunnen visuele cognitieve stoornissen van grote invloed zijn op algemeen 
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dagelijks functioneren. Visuele cognitieve achteruitgang kan mogelijk ook een negatief 
effect hebben op prestaties bij algemeen cognitief onderzoek. Daarom adviseren wij 
visueel cognitieve taken toe te voegen aan de standaard cognitieve taken die vaak 
gebruikt worden in klinisch onderzoek naar HD. 
Dit onderzoek heeft zich met name gericht op veranderingen in de cerebrale cortex en 
de invloed daarvan op stoornissen in de motoriek en cognitie in HD. De onderliggende 
hersenveranderingen van gedragsproblemen in HD is echter niet onderzocht. Gezien 
de potentieel effectieve huntingtine verlagende geneesmiddelen die momenteel 
onderzocht worden, is meer observationeel onderzoek uiterst zinvol om de complexe 
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